<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84149</article-id><article-id pub-id-type="doi">10.7554/eLife.84149</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-297735"><name><surname>Rodriguez</surname><given-names>Jonathan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6414-0526</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-297736"><name><surname>Iniguez</surname><given-names>Abdon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297737"><name><surname>Jena</surname><given-names>Nilamani</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297738"><name><surname>Tata</surname><given-names>Prasanthi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297739"><name><surname>Liu</surname><given-names>Zhong-Ying</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-6500"><name><surname>Lander</surname><given-names>Arthur D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4380-5525</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-295493"><name><surname>Lowengrub</surname><given-names>John</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1759-0900</contrib-id><email>lowengrb@math.uci.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-297740"><name><surname>Van Etten</surname><given-names>Richard A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0000-635X</contrib-id><email>vanetten@hs.uci.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Center for Complex Biological Systems, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Medicine, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Developmental and Cell Biology, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Chao Family Comprehensive Cancer Center, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Biomedical Engineering, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gyf1771</institution-id><institution>Department of Mathematics, University of California, Irvine</institution></institution-wrap><addr-line><named-content content-type="city">Irvine</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Finley</surname><given-names>Stacey D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>University of Southern California</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>Centre National de la Recherche Scientifique</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>28</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84149</elocation-id><history><date date-type="received" iso-8601-date="2022-10-12"><day>12</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-26"><day>26</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-10-14"><day>14</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.11.511822"/></event></pub-history><permissions><copyright-statement>© 2023, Rodriguez, Iniguez et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rodriguez, Iniguez et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84149-v5.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84149-figures-v5.pdf"/><abstract><p>Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturing myeloid cells driven by the product of the Philadelphia chromosome, the BCR-ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have proved effective in treating CML, but there is still a cohort of patients who do not respond to TKI therapy even in the absence of mutations in the BCR-ABL1 kinase domain that mediate drug resistance. To discover novel strategies to improve TKI therapy in CML, we developed a nonlinear mathematical model of CML hematopoiesis that incorporates feedback control and lineage branching. Cell–cell interactions were constrained using an automated model selection method together with previous observations and new in vivo data from a chimeric <italic>BCR-ABL1</italic> transgenic mouse model of CML. The resulting quantitative model captures the dynamics of normal and CML cells at various stages of the disease and exhibits variable responses to TKI treatment, consistent with those of CML patients. The model predicts that an increase in the proportion of CML stem cells in the bone marrow would decrease the tendency of the disease to respond to TKI therapy, in concordance with clinical data and confirmed experimentally in mice. The model further suggests that, under our assumed similarities between normal and leukemic cells, a key predictor of refractory response to TKI treatment is an increased maximum probability of self-renewal of normal hematopoietic stem cells. We use these insights to develop a clinical prognostic criterion to predict the efficacy of TKI treatment and design strategies to improve treatment response. The model predicts that stimulating the differentiation of leukemic stem cells while applying TKI therapy can significantly improve treatment outcomes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer</kwd><kwd>nonlinear dynamics</kwd><kwd>hematopoiesis</kwd><kwd>treatment dynamics</kwd><kwd>mathematical model</kwd><kwd>chronic myeloid leukemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U54CA217378-01A1</award-id><principal-award-recipient><name><surname>Lander</surname><given-names>Arthur D</given-names></name><name><surname>Van Etten</surname><given-names>Richard A</given-names></name><name><surname>Lowengrub</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA062203</award-id><principal-award-recipient><name><surname>Lander</surname><given-names>Arthur D</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 CA090576</award-id><principal-award-recipient><name><surname>Van Etten</surname><given-names>Richard A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1763272</award-id><principal-award-recipient><name><surname>Lander</surname><given-names>Arthur D</given-names></name><name><surname>Lowengrub</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1936833</award-id><principal-award-recipient><name><surname>Lowengrub</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1953410</award-id><principal-award-recipient><name><surname>Lowengrub</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>GRFP 16-588</award-id><principal-award-recipient><name><surname>Iniguez</surname><given-names>Abdon</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000893</institution-id><institution>Simons Foundation</institution></institution-wrap></funding-source><award-id>594598QN</award-id><principal-award-recipient><name><surname>Lander</surname><given-names>Arthur D</given-names></name><name><surname>Lowengrub</surname><given-names>John</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM136624</award-id><principal-award-recipient><name><surname>Rodriguez</surname><given-names>Jonathan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A physiological mathematical model of chronic myeloid leukemia, validated by experiments in transgenic mice and clinical data, identifies mechanisms underlying the response to tyrosine kinase inhibitor therapy, predicts biomarkers of primary resistance, and suggests new strategies to improve treatment outcomes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm of the hematopoietic system, which normally produces billions of mature myeloid and erythroid cells on a daily basis, is tightly regulated, and accommodates massive increases in the production of individual cell types in response to physiological and pathological stresses. The hematopoietic system is organized hierarchically as a collection of progressively more differentiated cells starting from a hematopoietic stem cell (HSC) located in the bone marrow (BM) and ending with postmitotic terminally differentiated myeloid and lymphoid cells (<xref ref-type="bibr" rid="bib84">Rieger and Schroeder, 2012</xref>; <xref ref-type="bibr" rid="bib59">Liggett and Sankaran, 2020</xref>).</p><p>CML is characterized by an overproduction of myeloid cells including mature granulocytes (neutrophils, basophils, and eosinophils) and their immediate precursors (metamyelocytes, myelocytes, and promyelocytes), and of myeloid progenitors (<xref ref-type="bibr" rid="bib45">Jamieson et al., 2004</xref>) including multipotential progenitors (MPPs) and committed progenitors (common myeloid progenitors [CMP], granulocyte-macrophage progenitors [GMPs], and megakaryocyte-erythroid progenitors [MEPs]). Untreated, the disease has three distinct phases (<xref ref-type="bibr" rid="bib14">Chereda and Melo, 2015</xref>). In the initial ‘chronic’ phase, the differentiation of myeloid progenitors is essentially normal, resulting in excessive levels of mature postmitotic neutrophils and their immediate precursors. In later stages of the disease (accelerated phase and blast crisis), differentiation is reduced and expansion of immature progenitors is observed. Additional clonal karyotypic abnormalities are typically only observed during the accelerated and blast crisis phases (<xref ref-type="bibr" rid="bib39">Hehlmann et al., 2020</xref>).</p><p>CML has one of the simplest cancer genomes. It is driven by a single genetic abnormality arising somatically in an HSC, the Philadelphia (Ph) chromosome, the result of a balanced translocation between chromosomes 9 and 22 that creates a fusion of the genes for <italic>BCR</italic> and <italic>ABL1</italic>. The product of the <italic>BCR-ABL1</italic> fusion gene is a dysregulated cytoplasmic protein-tyrosine kinase, BCR-ABL1. CML thus represents a natural model of dysregulated granulocytopoiesis (<xref ref-type="bibr" rid="bib81">Quintás-Cardama and Cortes, 2009</xref>).</p><p>Cell biological studies have shown that Ph<sup>+</sup> cells expressing markers of normal HSC are capable of engrafting immunodeficient mice (<xref ref-type="bibr" rid="bib92">Sirard et al., 1996</xref>; <xref ref-type="bibr" rid="bib58">Lewis et al., 1998</xref>), implying that these cells are leukemia-initiating or leukemic ‘stem’ cells (LSCs). More mature committed progenitors in CML, like normal progenitors, lack sustained self-renewal capacity and cannot stably engraft immunodeficient mice nor generate hematopoietic colonies in vitro upon serial replating (<xref ref-type="bibr" rid="bib44">Huntly et al., 2004</xref>). The proportion of LSCs in the BM is highly variable across CML patients at diagnosis and can range from a few percent to nearly 100% (<xref ref-type="bibr" rid="bib78">Petzer et al., 1996</xref>; <xref ref-type="bibr" rid="bib20">Diaz-Blanco et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Abe et al., 2008</xref>; <xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>), perhaps reflecting different periods of time patients spend in chronic phase before they are diagnosed, different rates of disease progression, or both.</p><p>There is persuasive experimental evidence of significant feedback regulation of different cell compartments in the dynamics of myeloid cell production in both normal and CML hematopoiesis, including signaling between the normal and CML cells (<xref ref-type="bibr" rid="bib46">Jiang et al., 1999</xref>; <xref ref-type="bibr" rid="bib19">Devireddy et al., 2005</xref>; <xref ref-type="bibr" rid="bib103">Vicente-Dueñas et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Naka et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>; <xref ref-type="bibr" rid="bib116">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Krause et al., 2013</xref>; <xref ref-type="bibr" rid="bib104">Walenda et al., 2014</xref>; <xref ref-type="bibr" rid="bib107">Welner et al., 2015</xref>). For instance, experiments in a mouse model of CML provided evidence that IL-6, produced by leukemic neutrophils, blocked MPP differentiation toward a lymphoid fate, implying feedback from the myeloid lineage onto MPPs (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>). Surprisingly, our knowledge of the details of feedback regulation in hematopoiesis is still incomplete, especially for granulopoiesis, where even late-stage feedback interactions are poorly understood. For example, two cytokines, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), can pharmacologically increase neutrophil production, but mice lacking both cytokines maintain baseline neutrophil levels and can still increase neutrophil production in response to infection (<xref ref-type="bibr" rid="bib7">Basu et al., 2000</xref>). In many cases, it is not known which cell types are providing and receiving the feedback, what signals are used, and what aspects of proliferative cell behavior they influence (i.e., proliferation rates, renewal probability, or progeny fate choice).</p><p>In spite of this knowledge deficit, CML can be treated quite effectively using selective small-molecule tyrosine kinase inhibitors (TKIs) of the <italic>BCR-ABL1</italic> kinase. TKIs such as imatinib, dasatinib, and nilotinib, which inhibit proliferation and increase apoptosis of Ph<sup>+</sup> cells, have dramatically lowered CML death rates (<xref ref-type="bibr" rid="bib33">Gambacorti-Passerini et al., 2011</xref>). The response to TKI therapy in CML is monitored primarily by determining the level of <italic>BCR-ABL1</italic> mRNA transcripts in peripheral blood, normalized to a control RNA and expressed as a percentage on an International Scale (<xref ref-type="bibr" rid="bib3">Arora and Press, 2017</xref>). <italic>BCR-ABL1</italic> transcript levels, an approximation of the proportion of circulating malignant cells at any given time, generally decrease exponentially in patients responding to TKI therapy resulting in at least two distinct slopes when plotted semi-logarithmically—an initial rapid decline attributed to TKI-induced killing of more mature myeloid cells, and a subsequent slower decline postulated to represent lower death rates of more primitive leukemic stem/progenitor cells (<xref ref-type="bibr" rid="bib70">Michor et al., 2005</xref>). Clinical resistance to TKI therapy in CML is a significant problem and is classified as acquired resistance (increasing <italic>BCR-ABL1</italic> transcript levels following a substantial decrease) or primary resistance (lack of an adequate initial response). Many patients with acquired resistance have developed mutations in the BCR-ABL1 kinase domain that mediate pharmacological resistance to the TKI (<xref ref-type="bibr" rid="bib28">Ernst and Hochhaus, 2012</xref>). By contrast, 10–15% of newly diagnosed CML patients fail to achieve an ‘early molecular response,’ defined as the level of <italic>BCR-ABL1</italic> transcripts being less than 10% at 3 mo (<xref ref-type="bibr" rid="bib37">Hanfstein et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Marin et al., 2012</xref>). Clinical data indicate that switching TKIs may not benefit these patients (<xref ref-type="bibr" rid="bib112">Yeung et al., 2012</xref>; <xref ref-type="bibr" rid="bib113">Yeung et al., 2015</xref>), suggesting that this group is destined to do poorly regardless of the specific inhibitor used. <italic>BCR-ABL1</italic> mutations are generally not present in this group of patients (<xref ref-type="bibr" rid="bib115">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="bib79">Pietarinen et al., 2016</xref>), and thus the mechanism(s) underlying this primary resistance is unclear. We hypothesized that these variable patient responses to TKI therapy arise from nonlinearity introduced by non-cell-autonomous interactions between normal and CML cells. To test this hypothesis, we developed a novel mathematical model of CML hematopoiesis and TKI treatment that incorporates lineage branching and interactions between normal and CML cells through feedback and feedforward regulation.</p><p>Mathematical modeling of leukemia has a long history aimed at understanding disease progression and improving treatment response using single and combination targeted therapies and immunotherapy (<xref ref-type="bibr" rid="bib108">Whichard et al., 2010</xref>; <xref ref-type="bibr" rid="bib80">Pujo-Menjouet, 2015</xref>; <xref ref-type="bibr" rid="bib10">Brunetti et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Kuznetsov et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Roeder and Glauche, 2021</xref>). Further, recent efforts have been made to integrate mathematical modeling in clinical decision-making to design personalized therapies (<xref ref-type="bibr" rid="bib41">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Engelhardt and Michor, 2021</xref>). Many models of leukemia have utilized simplified lineage architectures and minimal feedback (<xref ref-type="bibr" rid="bib86">Roeder et al., 2006</xref>; <xref ref-type="bibr" rid="bib51">Komarova and Wodarz, 2007</xref>; <xref ref-type="bibr" rid="bib43">Horn et al., 2008</xref>; <xref ref-type="bibr" rid="bib32">Foo et al., 2009</xref>; <xref ref-type="bibr" rid="bib36">Hähnel et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Pedersen et al., 2021</xref>). While these models can be made to fit the multiphasic disease response data of CML to TKI treatment, the simplicity of the models can make these fitted parameters of limited clinical value. More physiologically accurate, nonlinear models that account for cell–cell signaling and lineage branching are expected to improve clinical relevance. Mathematical models that incorporate feedback signaling have been developed in normal (<xref ref-type="bibr" rid="bib26">Engel et al., 2004</xref>; <xref ref-type="bibr" rid="bib67">Marciniak-Czochra et al., 2009</xref>; <xref ref-type="bibr" rid="bib64">Mahadik et al., 2019</xref>, <xref ref-type="bibr" rid="bib71">Mon Père et al., 2021</xref>) and diseased (<xref ref-type="bibr" rid="bib109">Wodarz, 2008</xref>; <xref ref-type="bibr" rid="bib88">Sachs et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Krinner et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Stiehl et al., 2014</xref>; <xref ref-type="bibr" rid="bib97">Stiehl et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Crowell et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Woywod et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Jiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Stiehl et al., 2018</xref>; <xref ref-type="bibr" rid="bib114">Zenati et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib91">Sharp et al., 2020</xref>) hematopoiesis. Because of the vast number of possible ways in which feedback models of normal hematopoiesis and leukemia can be configured, mathematical models tend to greatly simplify the lineage architectures and the feedback interactions among the cell types. For example, <xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref> developed a hierarchical ordinary differential equation (ODE) model of normal hematopoiesis containing multiple cell types and branch points (16 cell types and 4 branch points) in the lineage tree. Limiting the feedback loops to involve only local, negative regulation (e.g., regulation by self and immediate progenitor/progeny in the lineage tree) results in about 10<sup>6</sup> models, which enabled the use of a stochastic optimization algorithm to obtain parameters consistent with homeostasis and a requirement for a rapid return to equilibrium following system perturbations.</p><p>In the context of leukemia, the model architectures are typically much simpler. Generally, models of leukemia introduce a parallel mutant lineage with the same structure as that used to model the normal hematopoietic cells but with different parameters. For example, Wodarz developed an unbranched lineage ODE model of normal and leukemia stem and differentiated cells in which feedback from the differentiated cells controlled whether the stem cells divided symmetrically or asymmetrically, and demonstrated this provides a mechanism for blast crisis in CML to occur without additional mutations (<xref ref-type="bibr" rid="bib109">Wodarz, 2008</xref>). Krinner et al. incorporated positive and negative feedback regulation of differentiation and proliferation in an unbranched lineage model that combined a discrete agent-based model for the stem cell compartment with an ODE system for the progenitor and differentiated cells to provide a detailed view of the stem cell dynamics and to test the effect of therapies (<xref ref-type="bibr" rid="bib54">Krinner et al., 2013</xref>). <xref ref-type="bibr" rid="bib97">Stiehl et al., 2015</xref> developed an unbranched lineage ODE model of normal and leukemic cells in which only negative feedback regulation of stem and progenitor cell self-renewal fractions was considered, and this was further limited to arise only from factors produced by the postmitotic, mature normal and leukemic cells. Later work extended this approach to investigate clonal selection and therapy resistance (<xref ref-type="bibr" rid="bib96">Stiehl et al., 2014</xref>), the role of cytokines on leukemia progression (<xref ref-type="bibr" rid="bib98">Stiehl et al., 2018</xref>), combination treatment strategies (<xref ref-type="bibr" rid="bib6">Banck and Görlich, 2019</xref>), and niche competition (<xref ref-type="bibr" rid="bib99">Stiehl et al., 2020</xref>). Clonal competition was also considered in an ODE feedback model of CML (<xref ref-type="bibr" rid="bib110">Woywod et al., 2017</xref>) and a stochastic model with feedback (<xref ref-type="bibr" rid="bib22">Dinh et al., 2021</xref>). Simpler unbranched lineage models of normal and leukemic cells in which only the normal cells respond to feedback but normal and leukemic cells compete for space in the BM have been used to investigate regimes of coexistence of normal and leukemic cells (<xref ref-type="bibr" rid="bib18">Crowell et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Jiao et al., 2018</xref>) and design combination therapies using optimal control algorithms (<xref ref-type="bibr" rid="bib91">Sharp et al., 2020</xref>).</p><p>Here, we develop a nonlinear ODE model of normal and CML hematopoiesis using a general approach that integrates an automated method, design space analysis (DSA; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>), with data gleaned from previously published experiments, and from two new in vivo experiments presented here that separately decrement the number of stem cells and terminally differentiated myeloid cells in the BM of mice. This approach enables us to systematically select among plausible model architectures and signaling interactions without a priori knowledge of which cells are providing and receiving signaling stimuli. We start with a model for normal hematopoiesis that accounts for stem, multipotent progenitor cells, and two types of terminally differentiated cells representing the myeloid and lymphoid lineage branches. This approach allows us to reduce the potential model space from about 60,000 models to a single model class and reveals the existence of feedforward and feedback mechanisms. We then extend the model to incorporate CML hematopoiesis by introducing a parallel lineage of CML cells with the same model architecture but with different parameters. The model captures the dynamics of CML at various stages of the disease and exhibits variable response to TKI treatment consistent with that observed in clinical data. The model suggests biomarkers of primary resistance, identifies the underlying mechanisms governing the response to TKI therapy, and suggests new treatment strategies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Model of normal hematopoiesis</title><p>The primary challenge in developing mathematical models of normal and CML hematopoiesis is sorting through the combinatorial explosion of models that occurs when cell–cell signaling interactions are taken into account. Consider the model hematopoietic system shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, which accounts for hematopoietic stem (<bold>HSC; S</bold>), multipotent progenitor (<bold>MPP; P</bold>), and two types of postmitotic, terminally differentiated cells—myeloid (<bold>TD</bold><sub><bold>m</bold></sub>) and lymphoid (<bold>TD</bold><sub><bold>l</bold></sub>). The HSC self-renew with fraction (e.g., probability) <italic>p</italic><sub><italic>0</italic></sub> or differentiate with fraction 1-<italic>p</italic><sub><italic>0</italic></sub>. That is, the fraction of HSC that remain as HSC after division is <italic>p</italic><sub><italic>0</italic></sub>. The MPPs self-renew with fraction <italic>p</italic><sub><italic>1</italic></sub> and differentiate into either lymphoid or myeloid cells with fractions <italic>q</italic><sub><italic>1</italic></sub> and 1-<italic>p</italic><sub><italic>1</italic></sub>-<italic>q</italic><sub><italic>1</italic></sub>, respectively. The HSC and MPPs divide with rates <italic>η</italic><sub><italic>1</italic></sub> and <italic>η</italic><sub><italic>2</italic></sub> and the myeloid and lymphoid cells die at rates <italic>d</italic><sub><italic>m</italic></sub> and <italic>d</italic><sub><italic>l</italic></sub>, respectively. The ODEs that govern the dynamics of the cells are given in ‘Methods.’ Assuming that there is either positive or negative regulation of the self-renewal and differentiation probabilities and division rates of any cell type from any other cell type results in 59,049 models, counting each combination of regulated signaling as a separate model.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Branched lineage model of normal hematopoiesis with feedback regulation.</title><p>(<bold>A</bold>) Branched lineage model consisting of hematopoietic stem cells (HSC; S), multipotent progenitor cells (MPP; P), and postmitotic, terminally differentiated myeloid (TD<sub>m</sub>) and lymphoid (TD<sub>l</sub>) cells. Modulation of the HSC and MPP self-renewal fractions (p<sub>0</sub> and p<sub>1</sub>), division rates (η<sub>1</sub> and η<sub>2</sub>), and fate switching probability (q<sub>1</sub>) through feedback can arise from any cell type. The different line styles correspond to regulation by a particular cell type (dashed for S, solid for P, dot-dashed for TD<sub>l</sub>, and dotted for TD<sub>m</sub>). (<bold>B</bold>) Using Design Space Analysis, four candidate model classes are identified that differ in how HSCs are regulated. (<bold>C</bold>) Using biological data from the literature as discussed in the text, we reduced the model space by hypothesizing that factors secreted by terminally differentiated myeloid cells direct the fate of MPPs (e.g., IL-6) and those by MPPs suppress HSC self-renewal (e.g., CCL3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig1-v5.tif"/></fig><p>To select the most physiologically accurate models, we first filtered the models using an automated approach (DSA) developed by Savageau and co-workers (<xref ref-type="bibr" rid="bib89">Savageau et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>; <xref ref-type="bibr" rid="bib62">Lomnitz and Savageau, 2016</xref>) that enables models to be distinguished based on their range of qualitatively distinct behaviors, without relying on knowledge of specific values of the parameters. This method relies on identifying boundaries in parameter space that separate qualitative behaviors of a particular model, which is much more efficient than searching for model behaviors directly. The boundaries can be approximated from a sequence of inequalities that identify regions where one term on the right-hand side of each ODE (e.g., the rate of change) dominates all others in the sources (positive terms) and another dominates the sinks (negative terms). This is known as a dominant subsystem (S-system) of the model. The number of S-systems in each model depends on the number of combinations of positive and negative terms in the rates of change. If the equilibria of the S-systems, which are determined analytically, are not self-consistent (e.g., consistent with the assumed dominance of terms reflected in the inequalities) or the equilibria are not stable, then the S-system is rejected. If all the S-systems of a particular model are rejected, then that model is removed from further consideration. Models with at least one self-consistent and stable S-system are viable candidates for further analysis. DSA can be easily automated to make the analysis of very large numbers of equations feasible. Details are provided in ‘Methods’ and ‘Appendix 1’ (Section 1). The result of this procedure is the elimination of all but the four model classes shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, which require negative regulation of the stem cell self-renewal fraction but differ by where this regulation arises. The models within the classes share at least one S-system and have common qualitative behaviors. The differences between models in a class lie in whether or not there is positive, negative, or no regulation on the rest of the parameters from any of the cell types. This reduces the number of possible models to 26,244.</p><p>Previous work has implicated several feedback mechanisms active in both normal and malignant hematopoiesis. Interleukin-6 (IL-6) is produced by differentiated myeloid cells and acts to bias MPPs toward a myeloid fate (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>; <xref ref-type="bibr" rid="bib107">Welner et al., 2015</xref>). Such negative feedback circuits, known as fate control, have been shown to provide an effective strategy for robust control of cell proliferation and reduction of oscillations in branched lineages (<xref ref-type="bibr" rid="bib11">Buzi et al., 2015</xref>). The chemokine CCL3 (also known as macrophage inhibitory protein α [MIP-1α]), produced in BM by basophilic myeloid progenitors (<xref ref-type="bibr" rid="bib5">Baba et al., 2016</xref>), acts to inhibit the proliferation and self-renewal of normal HSC (<xref ref-type="bibr" rid="bib9">Broxmeyer et al., 1989</xref>; <xref ref-type="bibr" rid="bib93">Staversky et al., 2018</xref>), but CML HSC are relatively resistant to its action (<xref ref-type="bibr" rid="bib25">Eaves et al., 1993</xref>, <xref ref-type="bibr" rid="bib4">Baba et al., 2013</xref>). In hypothesizing these regulatory networks, we arrived at a single model class as shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. In this class, there are 729 model candidates, which differ only in how the HSC and MPP cell division rates and the MPP self-renewal fraction are regulated. These above results suggest that IL-6 is a candidate feedback factor expressed in the myeloid compartment (TD<sub>m</sub>) with the ability to negatively regulate the fraction q<sub>1</sub> of MPPs that differentiate into lymphoid cells. CCL3 is a candidate factor mediating negative feedback from the MPP population onto HSC self-renewal. To further constrain the remaining models, we performed cell biological experiments in mice to glean information about cell–cell interactions by separately perturbing the stem cell and myeloid cell compartments.</p></sec><sec id="s2-2"><title>Depletion of HSC increases HSC and MPP proliferation</title><p>As described in ‘Methods,’ healthy C57BL6/J (B6) mice were treated with low-dose (50 cGy) ionizing radiation, previously shown to be selectively toxic to HSC in the BM (<xref ref-type="bibr" rid="bib95">Stewart et al., 1998</xref>). The BM stem/progenitor compartment was analyzed by flow cytometry in untreated mice, and on days 1, 3, and 7 post-irradiation, using the gating strategy in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. These time points and the number of mice analyzed at each time point were informed by a Bayesian hierarchical framework for optimal experimental design of mathematical models of hematopoiesis (<xref ref-type="bibr" rid="bib60">Lomeli et al., 2021</xref>). In particular, the Bayesian framework suggests combining early time points (soon after radiation was applied) with late time points because the early time points provide more information about division rates, while the late time points provide more information about the feedback parameters. One day after treatment, we observed an acute approximately twofold decrease in the relative size of the HSC compartment in the irradiated mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), accompanied by approximately threefold increase in proliferation rates for both HSC and MPPs (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). There was no significant change in MPP population, however, and the system returned to equilibrium by day 7. These results suggest that the HSC population exerts negative feedback on their own division rate (η<sub>1</sub>) and inhibits the division of MPPs through a negative feedforward loop on η<sub>2</sub>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Fluorescence-activated cell sorting (FACS) analysis of mouse Lin–Sca-1+c-Kit+ (LSK) bone marrow stem/progenitor cells and the proposed branched lineage hematopoiesis model.</title><p>(<bold>A</bold>) Gating schema for phenotyping hematopoietic stem cells (HSC, defined as LSK CD34–CD48–) and multipotential progenitors (MPP, defined as LSK CD34+ CD48+), and BrdU incorporation in their respective compartments. (<bold>B</bold>) Distributions of HSC (blue), MPP (orange), and other (purple) compartments on days 1, 3, and 7 in the bone marrow (BM) of control (CTRL) B6 mice and mice that received 50 cGy radiation. (<bold>C</bold>) Frequency of HSC and MPP proliferation in CTRL (gray bars) and irradiated (blue bars) mice measured by BrdU incorporation on days 1, 3, and 7. Data are shown as mean ± SEM. *p&lt;0.05. (<bold>D</bold>) Representative histograms depicting the frequency of myeloid cells as measured by CD11b expression in mice 24 hr after intravenous administration of isotype control (iso) or RB68C5 (50 μg) antibody. (<bold>E</bold>) Left panel: bar graph showing the frequency of CD11b+ cells in BM of mice that were treated with isotype control antibody (Iso; orange bar, n = 3 ) or RB68C5 antibody (50 μg; blue bars, n = 3). Right panel: HSC (blue), MPP (orange), and other cell type (purple) frequencies from mice that received isotype or RB6-8C5 antibody. Data are shown as mean ± SEM. *p&lt;0.05. (<bold>F</bold>) Proposed feedforward-feedback model of hematopoiesis with associated feedback strengths denoted with γ<sub>1</sub>–γ<sub>5</sub>. The negative feedback loops shown in blue correspond to those suggested by previous experimental data (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>; <xref ref-type="bibr" rid="bib93">Staversky et al., 2018</xref>), while the negative feedback and feedforward loops in red are supported by our cell depletion experiments in (<bold>A–E</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig2-v5.tif"/></fig></sec><sec id="s2-3"><title>Depletion of mature myeloid cells increases the MPP population</title><p>B6 mice were treated with the anti-granulocyte antibody RB68C5 (50 μg), and their BM was analyzed 1 d after treatment (see ‘Methods’). This treatment resulted in an ~20% decrease in mature BM myeloid cells, as measured by CD11b expression (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>), and was accompanied by a concomitant increase in the size of the phenotypic MPP compartment (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and a decrease in the HSC compartment (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). These results suggest that there is a negative feedback loop from the myeloid cells onto the MPP self-renewal fraction p<sub>1</sub>.</p><p>Taking all these results into consideration, we arrive at the feedback-feedforward model shown in <xref ref-type="fig" rid="fig2">Figure 2F</xref>. The negative feedback loops shown in blue correspond to those suggested by previous experimental data, while the negative feedback and feedforward loops in red are suggested by the cell depletion experiments presented here. See ‘Methods’ for a detailed description of the corresponding ODEs. Although these validation data were derived from mice, we hypothesize that similar cell–cell signaling occurs in humans.</p></sec><sec id="s2-4"><title>Parameter estimation for feedback-feedforward model of hematopoiesis</title><p>To determine biologically relevant parameters for the feedback-feedforward model in <xref ref-type="fig" rid="fig2">Figure 2F</xref>, a grid-search algorithm was employed. The full ODE model is given in ‘Methods’ and Appendix 1 (Section 2). The 12 model parameters (proliferation and death rates, self-renewal and branching fractions, feedback/feedforward gains) were sampled using a random uniform distribution for each parameter. See ‘Methods,’ Appendix 1 (Section 3), and <xref ref-type="table" rid="app1table2 app1table3">Appendix 1—tables 2 and 3</xref> for details and a full parameter list. Once parameter values were chosen, the model was simulated for long times. If a parameter set resulted in steady state values consistent with the range of values previously reported for a dynamic human hematopoiesis model (<xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref>), that parameter set was accepted. Out of ~10<sup>6</sup> possible parameter combinations, a total of 1493 parameter sets were accepted (<xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>). We further restricted the candidate parameter sets by considering only those with sufficiently large feedforward gains on the MPP division rate (γ<sub>5</sub> &gt; 0.01) in order to focus on the novel feedforward dynamics. This reduced the number of eligible parameter sets to 563, and their distributions are shown in <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>. Each of these parameter sets can be thought of as representing the ‘normal’ condition of a virtual patient by having different individual parameters, for example, due to genetic, epigenetic or environment factors, that nevertheless result in a ‘normal’ homeostatic hematopoietic system. The different parameter sets thus model a range of variability across individual CML patients. The values of the parameters used are given in Appendix 1, Section 3.</p></sec><sec id="s2-5"><title>Sensitivity analyses of hematopoiesis model</title><p>DSA can be used to determine qualitative model behaviors and how sensitive the model is to perturbations of key parameters. Here, we focused on the feedback gains γ<sub>1</sub> and γ<sub>3</sub> on the HSC and MPP self-renewal probabilities, respectively (see Appendix 1, Section 1.3 for details, and for sensitivity analyses for other parameters, see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). As indicated in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, DSA identifies four regions (design space) in the γ<sub>1</sub> and γ<sub>3</sub> plane which the dynamics are governed by different S-systems. Using a parameter set in each design space region (indicated by white dots) as a base value, we performed a parameter sweep in which we vary γ<sub>1</sub> and γ<sub>3</sub> in a range within 0.9–1.1 times the magnitude of their original values. In <xref ref-type="fig" rid="fig3">Figure 3B</xref>, the evolution of each of the cell populations is shown, starting from an initial condition in which there are only a small number of HSC. The different graphs correspond to the parameter sets (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>) in the four regions of the design space although the dynamics are shown for the full ODE solutions. The solid curves denote results from the original (white dot) parameter set, and the shading denotes the range of behaviors when the parameters are varied. The black and blue curves correspond to the HSC and MPPs, respectively, while the dark-green and light-green correspond to the terminally differentiated myeloid and lymphoid cells. While the system tends to equilibrium for all parameter combinations, the approach to equilibrium is different. The dynamics in regions i and ii are monotonic while those in regions iii and iv are not (e.g., the equilibria in regions i and ii are stable nodes, while those in regions iii and iv are stable spirals). Further, the larger the γ<sub>1</sub>, the faster the approach toward equilibrium. The cell numbers and proportions in each design space region are different as well. In regions i and ii, the HSC dominate while in regions iii and iv the differentiated myeloid cells dominate the population. Further, the number of cells in regions i and iii is larger than those in regions ii and iv. The equilibrium cell populations in region iii correspond more closely to the physiological populations identified by <xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref>. <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> depicts the effective parameters in region iii as it develops toward the physiological steady state.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Qualitative behavior of feedforward-feedback model and parameter sensitivity.</title><p>(<bold>A</bold>) The colored regions (i–iv) represent areas of design space in which there are distinct qualitative behaviors as a function of the feedback gains γ<sub>1</sub> and γ<sub>3</sub> of the hematopoietic stem cell (HSC) and multipotential progenitor (MPP) self-renewal fractions, respectively. White dots denote specific parameter combinations. (<bold>B</bold>) The dynamics for each cell compartment within each of the four design space regions (i–iv). Solid lines represent ordinary differential equation (ODE) solutions using the specific parameter combinations (black dots in <bold>A</bold>) while the lightly colored regions represent the range of ODE solutions resulting from perturbations in γ<sub>1</sub> and γ<sub>3</sub> in a range within 0.9–1.1 times their original values. The blue and black curves correspond to the HSC and MPPs, respectively, the green and turquoise curves correspond to the myeloid and lymphoid cells. (<bold>C</bold>) The return to equilibrium following partial depletion of mature myeloid cells (10%, 50%, 90%) using the parameter combination (white dot) in region iii.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig3-v5.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The dynamics from the steady state with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value from <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig3-figsupp1-v5.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effective parameters for proliferation, self-renewal, and branching as the solutions to the model for the normal hematopoietic system approach steady state.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig3-figsupp2-v5.tif"/></fig></fig-group><p>We next investigated the sensitivity of the model to perturbations about the equilibrium cell population. In <xref ref-type="fig" rid="fig3">Figure 3C</xref>, we present the results obtained by reducing the number of terminally differentiated myeloid cells from their equilibrium value by 10% (dot-dashed), 50% (dashed), and 90% (solid) and with parameters from design space region iii (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>). By initially depleting the myeloid cells, which is similar to the experiment in <xref ref-type="fig" rid="fig2">Figure 2D and E</xref>, the hematopoietic system is shifted away from its steady state. While the presence of the negative feedback loops introduces small magnitude oscillations of the HSC, MPPs, and lymphoid cells, the myeloid cell dynamics are monotonic and the system robustly returns to its steady state over times that are consistent with those established in previous experiments (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>) for similar perturbation studies.</p></sec><sec id="s2-6"><title>Extension of the hematopoiesis model to CML</title><p>Following previous modeling studies, we modeled CML by introducing a parallel lineage of mutant leukemic cells (denoted by the superscript L) but with the behavior of that lineage coupled at many points to the behavior of non-mutant cells, and vice versa. In particular, the model for normal and CML cells shares the same lineage structure and feedback architecture with both normal and mutant cell types providing a source of regulating factors, and although all the leukemic parameters (<xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>) could be different from their normal counterparts (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>), we begin by assuming the only difference between the two lineages is a decrease in the feedback strength for leukemic HSC (<bold>HSC<sup>L</sup>; S<sup>L</sup></bold>), as indicated by <italic>p</italic><sub><italic>0</italic></sub><sup><italic>L</italic></sup> in the schematic in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. This makes the leukemic cells less responsive to negative feedback and enables leukemic cells to gain a competitive advantage for growth. One candidate mediator of this negative feedback is CCL3, previously shown to inhibit self-renewal and division of normal HSC but HSC<sup>L</sup> are less sensitive to its inhibitory regulation (<xref ref-type="bibr" rid="bib25">Eaves et al., 1993</xref>, <xref ref-type="bibr" rid="bib24">Dürig et al., 1999</xref>, <xref ref-type="bibr" rid="bib5">Baba et al., 2016</xref>; <xref ref-type="bibr" rid="bib93">Staversky et al., 2018</xref>). An example of CML hematopoiesis is shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, where it is seen that, after the introduction of a few HSC<sup>L</sup> at equilibrium of the normal hematopoietic system, the CML cells (dashed curves) repopulate the BM at the expense of normal cells (solid curves). Because of negative feedback, the system will eventually reach a new equilibrium consisting solely of leukemic cells. See <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref> for the leukemic parameter values, and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s5">5</xref> for parameter sensitivity studies of systems containing both normal and CML cells.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Extension of the model of hematopoiesis to chronic myeloid leukemia (CML).</title><p>(<bold>A</bold>) Schematic of two branched lineages consisting of normal and CML cell compartments. The two lineages share the same feedback architecture. The difference between the two lineages is the leukemic hematopoietic stem cell (HSC) self-renewal is less affected by negative feedback, denoted by p<sub>0</sub><sup>L</sup> (see text). (<bold>B</bold>) Dynamics of hematopoiesis upon introduction of CML cells. We begin with having normal hematopoiesis at equilibrium. At time 0, 10<sup>4</sup> leukemic stem cells (HSC<sup>L</sup>, S<sup>L</sup>) cells are introduced to the system and subsequently expand over time at the expense of the normal cells, which decrease. (<bold>C</bold>) Sensitivity analyses of the outcomes of CML hematopoiesis with values corresponding to the proportion of parameter sets where less than 50% of terminal cells are leukemic. (<bold>D</bold>) The fitness of the leukemic stem cells relative to the normal stem cells, as measured by the ratio of their characteristic self-renewal fractions (<inline-formula><mml:math id="inf1"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) determines whether CML will progress and leukemic cells will take over the system after CML stem cells are introduced.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-v5.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp1-v5.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp2-v5.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp3-v5.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp4-v5.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each parameter, as labeled, ranging from 90% to 110% of the original parameter value in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>.</title><p>The solid line represents the median of the perturbations, while the shaded region represents 95% of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp5-v5.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Variations in the other leukemic parameters and their associated gamma for all eligible parameter sets.</title><p>Plots display data using the same criteria as <xref ref-type="fig" rid="fig4">Figure 4C</xref>, but results show nearly complete insensitivity to changes in either value for the other leukemic parameters.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig4-figsupp6-v5.tif"/></fig></fig-group><p>We then perturbed each of the leukemic parameters within 10% of the values in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref> and found that only the leukemic stem cell self-renewal parameters—the maximal HSC<sup>L</sup> self-renewal fraction <inline-formula><mml:math id="inf3"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and the feedback gain <inline-formula><mml:math id="inf4"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> on the HSC<sup>L</sup> self-renewal fraction—have the potential to significantly influence the results. The results are insensitive to changes in the other leukemic cell parameters (see Appendix 1, Section 9, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2</xref>–<xref ref-type="fig" rid="fig6s4">4</xref>). These results are characteristic of even larger changes in the base parameters.</p><p>In this and subsequent parameter investigations, we constrained <inline-formula><mml:math id="inf5"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> to be less than or equal to <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , the maximal self-renewal fraction of the normal HSC, motivated by the paucity of evidence that <inline-formula><mml:math id="inf7"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is larger than <inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , coupled with experimental data suggesting that <inline-formula><mml:math id="inf9"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is less than or equal to <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . For example, CML long-term culture initiating cells (LTC-IC; thought to be phenotypically similar to stem cells) decrease significantly in in vitro cultures while the number of normal LTC-IC is unchanged, consistent with a relative decrease in self-renewal probability of the CML cells (<xref ref-type="bibr" rid="bib102">Udomsakdi et al., 1992</xref>). In vivo, HSC self-renewal can be assessed directly through transplantation studies. In this regard, CML HSC engraft immunodeficient mice variably and inefficiently compared to normal human HSC (<xref ref-type="bibr" rid="bib105">Wang et al., 1998</xref>) while HSC from <italic>BCR-ABL1</italic> transgenic mice exhibit an engraftment defect upon secondary transplantation into syngeneic recipients (<xref ref-type="bibr" rid="bib90">Schemionek et al., 2010</xref>). Both results are suggestive of a relative decrease in self-renewal capacity of <italic>BCR-ABL1</italic>+ stem cells.</p><p>Next, we performed a sweep through leukemic stem cell self-renewal parameters <inline-formula><mml:math id="inf11"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf12"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> for each of the eligible parameter sets for normal hematopoiesis (see below). We found that for the terminally differentiated cell proportion to be at least 50% leukemic (darker regions), there are biological constraints upon the combination of <inline-formula><mml:math id="inf13"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf14"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). As the heat map shows, in order for CML to dominate hematopoiesis (e.g., terminally differentiated cell proportion &gt;50% leukemic), the CML stem cells should have <inline-formula><mml:math id="inf15"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> sufficiently close to <inline-formula><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf17"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> should be sufficiently small. As the ratio <inline-formula><mml:math id="inf18"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf19"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> decreases from 1, the system requires smaller feedback gains <inline-formula><mml:math id="inf20"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> to compensate and allow for CML to develop. Further, there are threshold values of the parameters required for CML hematopoiesis to prevail. Namely, the system is dominated by normal cells (CML cells do not ‘take over’) when <inline-formula><mml:math id="inf21"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf22"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is sufficiently large or when <inline-formula><mml:math id="inf23"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is sufficiently small.</p><p>To further examine these biological constraints, we calculated characteristic effective self-renewal fractions for normal and leukemic stem cells, defined as <inline-formula><mml:math id="inf24"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mover accent="true"><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf25"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mover accent="true"><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:math></inline-formula>, where <inline-formula><mml:math id="inf26"><mml:mover accent="true"><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> , a characteristic value for the size of the MPP population based on MPP steady state values (<xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref>). The relative fitness of the CML cells defined by the ratio of characteristic values of the HSC<sup>L</sup> and HSC self-renewal fractions: <inline-formula><mml:math id="inf27"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf28"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> . Here, all eligible parameter sets representing the states of the normal system are considered and the leukemic parameters <inline-formula><mml:math id="inf29"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf30"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf31"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> are varied from 0.6 to 1.0 and 0.1–0.6, respectively. In <xref ref-type="fig" rid="fig4">Figure 4D</xref>, we examined the relative fitness of leukemic cells through the distribution of the ratio of characteristic values colored by leukemic cells outcompeting normal (orange) and normal cells maintaining majority (blue). As expected, the larger the relative fitness, the more likely that CML will take over the system and dominate hematopoiesis. For further analysis of the leukemic parameter combinations for CML hematopoiesis and under treatment, see <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2</xref>–<xref ref-type="fig" rid="fig6s4">4</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, Appendix 1, Sections 9–11, and <xref ref-type="fig" rid="app1fig11">Appendix 1—figures 11</xref>–<xref ref-type="fig" rid="app1fig17">17</xref> for details.</p></sec><sec id="s2-7"><title>Validation of the CML model</title><p>To test whether our mathematical model recapitulates known features of CML biology, we simulated a published transplant experiment in a transgenic mouse model of CML that recapitulates the main features of human CML (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>). In this experiment, either HSC<sup>L</sup> or leukemic MPPs (MPP<sup>L</sup>) were implanted into sublethally irradiated mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Transplantation of HSC<sup>L</sup> enables engraftment and myeloid cell production that leads to CML. On the other hand, transplanting MPP<sup>L</sup>s does not allow for long-term engraftment but results in a larger fraction of donor-derived lymphoid cells after 35 d (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This study presented evidence that IL-6 produced by differentiated myeloid cells reprograms these MPP<sup>L</sup> progenitors toward a myeloid fate (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>). As described in ‘Methods’ and Appendix 1, Section 4, we modeled this experiment by reducing the number of cells in equilibrium to mimic the effects of sublethal radiation. We explored a range of possible reductions of HSC<sup>L</sup>, MPP<sup>L</sup>, and differentiated myeloid and lymphoid cells and tracked the outcomes when 4000 HSC<sup>L</sup> or MPP<sup>L</sup> were introduced after the decrements from equilibrium. We then discarded those parameter sets that did not yield results consistent with a simple majority of myeloid cells for HSC<sup>L</sup> transplant and a simple majority of lymphoid cells for MPP<sup>L</sup> transplant (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>). In particular, 85 parameter sets were discarded, leaving a total of 478 parameter sets remaining. Characteristic results are presented in <xref ref-type="fig" rid="fig5">Figure 5C and D</xref> when the reductions for HSC<sup>L</sup>, MPP<sup>L</sup>, and terminally differentiated cells were 55, 35, and 10%, respectively, from their equilibrium values. See <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> for results using other decrements, the removed parameter set criteria (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), and <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref> for the final parameter distributions. When HSC<sup>L</sup> are transplanted (solid curves), the donor-derived MPP<sup>L</sup> (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, left) rapidly increased as did the terminally differentiated myeloid and lymphoid cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, right). Consistent with the experiments, there is a larger fraction of donor-derived myeloid cells than lymphoid cells after 30 d (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). In contrast, when MPP<sup>L</sup> are introduced (dashed curves), their population decreases (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, right) because the MPP<sup>L</sup> do not stably engraft. Concomitantly, there is burst of donor-derived myeloid and lymphoid cells at early times (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, right) as the transplanted MPP<sup>L</sup> differentiate.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Validation of model through simulated transplant.</title><p>Results of a transplant experiment from <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>. Schematic (<bold>A</bold>) depicting the experimental pipeline and results (<bold>B</bold>), adapted from Figure 2A-C in <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>. When HSC<sup>L</sup> are transplanted into sublethally irradiated mice, chronic myeloid leukemia (CML)-like leukemia is induced and the myeloid cells expand. When leukemic multipotent progenitor cells (MPP<sup>L</sup>, P<sup>L</sup>) are transplanted, they do not stably engraft and transiently produce a larger fraction of differentiated lymphoid cells. (<bold>C</bold>) Simulated time evolutions of donor-derived HSC<sup>L</sup>, MPP<sup>L</sup>, and terminally differentiated lymphoid (TD<sub>l</sub>), and myeloid (TD<sub>m</sub>) cells when HSC<sup>L</sup> (solid) or MPP<sup>L</sup> (dashed) cells are transplanted. (<bold>D</bold>) Bar chart showing model predictions of the percentages of donor-derived myeloid and lymphoid cells after 35 d when HSC<sup>L</sup> or MPP<sup>L</sup> are transplanted, which is consistent with the experimental data in (<bold>B;</bold> see text).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig5-v5.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Heat map depicting the outcomes of transplant experiments in the presence of decrements of 50–70% HSC<sup>L</sup> and 30–50% MPP<sup>L</sup> from their equilibrium values (see text for details).</title><p>The heat map quantifies the number of parameter sets that are consistent with the experimental observations (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>) that there is a simple majority of myeloid or lymphoid cells after 35 d when HSC<sup>L</sup> or MPP<sup>L</sup> are transplanted, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig5-figsupp1-v5.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>The dynamics of each parameter set that does not match the experimentally observed behavior of the transplant experiments from <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>.</title><p>These parameter sets are removed from the pool of eligible parameter sets if in the worst-case scenario for each parameter set they are not consistent with the criteria outlined in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig5-figsupp2-v5.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Distributions of the remaining 478 parameters after removal determined through the depletion sweep.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig5-figsupp3-v5.tif"/></fig></fig-group><p>The early time dynamics of the myeloid and lymphoid cells depend on the specific values of the MPP<sup>L</sup> self-renewal (p<sub>1</sub>) and fate control (q<sub>1</sub>) fractions, whose values in turn depend on the number of myeloid cells through negative feedback regulation. In particular, if <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, then more myeloid than lymphoid cells will be produced at early times, as in <xref ref-type="fig" rid="fig5">Figure 5C</xref> (right), whereas more lymphoid cells will be produced if <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> . In both cases, because the MPP<sup>L</sup>s do not stably engraft and instead differentiate into lymphoid and myeloid cells, we observe that there is a larger fraction of donor-derived lymphoid cells after 30 d (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), consistent with the experiments. This occurs because there is a decreasing flux of differentiating cells since there is no stable engraftment and the lymphoid cells are longer-lived (smaller death rate) than the shorter-lived myeloid cells, which have a larger death rate.</p></sec><sec id="s2-8"><title>Leukemic stem cell load influences TKI therapy outcomes</title><p>We next explored the effects of TKI therapy on CML in the model. While the overall size of the phenotypic HSC compartment is not increased in CML patients (<xref ref-type="bibr" rid="bib45">Jamieson et al., 2004</xref>), the proportion of HSC<sup>L</sup> in the BM can vary widely across newly diagnosed CML patients from a few percent to nearly 100% (<xref ref-type="bibr" rid="bib78">Petzer et al., 1996</xref>; <xref ref-type="bibr" rid="bib20">Diaz-Blanco et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Abe et al., 2008</xref>; <xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>). We therefore investigated how the HSC<sup>L</sup> load in the BM affects therapy outcomes. We used one eligible parameter set (see <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>), out of all 478 parameter sets all of which are capable of characterizing the normal state of our simplified model of the hematopoietic system and one choice of leukemic parameters (see <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>) in which the only difference between normal and leukemic cells is that the HSC<sup>L</sup> are one half as sensitive to negative feedback regulation compared to the normal HSC (<inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>). The initial condition was obtained by simulating the development of CML, analogous to that shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, prior to initiating therapy. TKI treatment was initiated at three different times to achieve varying leukemic stem cell load (6, 18, and 36 mo) and was simulated by introducing a death rate of HSC<sup>L</sup> and MPP<sup>L</sup> proportional to their proliferation rates, with the HSC<sup>L</sup> proliferation rate lower than that of normal HSC (<xref ref-type="bibr" rid="bib49">Jørgensen et al., 2006</xref>). While some studies have shown that primitive CML stem/progenitor cells are relatively resistant to killing by TKIs in vitro (<xref ref-type="bibr" rid="bib35">Graham et al., 2002</xref>; <xref ref-type="bibr" rid="bib16">Corbin et al., 2011</xref>), clinical studies suggest that long-term TKI therapy can decrement the CML stem cell compartment, at least in some patients (<xref ref-type="bibr" rid="bib30">Etienne et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2019</xref>), consistent with mathematical modeling of patient <italic>BCR-ABL1</italic> transcript data (<xref ref-type="bibr" rid="bib100">Tang et al., 2011</xref>). This supports the concept that TKIs possess a measure of leukemia stem cell killing ability, and we therefore included this effect in our model. The TKI treatment parameters were the same across the three cases. See ‘Methods’ and Appendix 1 for details and <xref ref-type="table" rid="app1table4 app1table5">Appendix 1—tables 4 and 5</xref> for parameter values. Thus, these cases can be thought of as representing the response of one virtual patient to TKI therapy implemented at different times after disease initiation.</p><p>At an early treatment time with lower (&lt;90%) initial HSC<sup>L</sup> fractions (HSC<sup>L</sup>, <xref ref-type="fig" rid="fig6">Figure 6A</xref>), the numbers of MPP<sup>L</sup> (blue-dashed), leukemic terminally differentiated lymphoid (light-green-dashed), and myeloid (dark-green-dashed) decrease rapidly at the early stages of treatment and are accompanied by a rapid increase in HSC<sup>L</sup> due to the loss of negative feedback from the MPP<sup>L</sup>. This loss of negative feedback from the MPP<sup>L</sup> also results in a rapid increase in the number of normal HSC (black solid curves) that subsequently drives an increase in the normal MPPs (blue solid). The increased number of HSC and HSC<sup>L</sup> decreases their division rates due to the autocrine negative regulatory loop as well as the division rates of the MPPs and MPP<sup>L</sup> through feedforward negative regulation. This decreases the flux into the terminally differentiated cell compartments (both normal and leukemic), thereby decreasing their numbers at early times. At later times, both the HSC<sup>L</sup> and MPP<sup>L</sup> gradually decrease in response to TKI-induced cell death, which drives an accompanying decrease in the leukemic differentiated cells. A small, transient increase in MPP<sup>L</sup> is observed before the gradual decline. This is driven primarily by the increase in flux into the MPP<sup>L</sup> compartment by differentiating HSC<sup>L</sup>, although there is also a small contribution from the feedforward regulation of the MPP<sup>L</sup> division rate, which lowers the effectiveness of TKI therapy on the MPP<sup>L</sup>. Both of these effects are reduced as the HSC<sup>L</sup> numbers are decreased by TKI therapy. This in turn increases the effectiveness of TKI therapy in killing leukemic cells at later times and enables the normal cells (solid curves) to rebound toward their pre-leukemic equilibrium values.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The response of chronic myeloid leukemia (CML) to tyrosine kinase inhibitor (TKI) therapy.</title><p>(<bold>A–C</bold>) Simulated cell dynamics of normal and leukemic cells in response to TKI therapy that is started at different time points in CML development (<bold>A</bold>, early times; <bold>B</bold>, intermediate times; <bold>C</bold>, late times). See text. (<bold>D</bold>) Simulated molecular response curves corresponding to the application of TKIs for each of simulations in (<bold>A–C</bold>). The simulated molecular response from (<bold>A</bold>) (blue) compares well with clinical data (symbols) measuring treatment responses to two different TKIs (imatinib, dasatinib) averaged across a cohort of patients (<xref ref-type="bibr" rid="bib34">Glauche et al., 2018</xref>). The simulated molecular responses from (<bold>B</bold>) and (<bold>C</bold>) (orange solid and dashed curves) are indicative of primary resistance. (<bold>E–G</bold>) Experiments in chimeric mice (see text) that show that the size of the leukemic stem cell clone correlates with decreased response to TKI therapy. Peripheral blood (PB) leukocyte counts (<bold>E</bold>), percentage of PB granulocytes (<bold>F</bold>), and PB <italic>BCR-ABL1</italic><sup>+</sup> (leukemic) granulocyte chimerism (<bold>G</bold>) are shown in cohorts of mice treated with dasatinib. Blue symbols are chimeras bearing &gt;90% <italic>BCR-ABL1</italic><sup>+</sup> HSC<sup>L</sup>, red-orange symbols are chimeras bearing 46–75% <italic>BCR-ABL1</italic><sup>+</sup> HSC<sup>L</sup>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig6-v5.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Effective parameters for proliferation, self-renewal, and branching after leukemic stem cells are added to the normal system at steady state, and after tyrosine kinase inhibitor (TKI) therapy begins for the cases shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> in the main text.</title><p>The vertical gray line depicts the start of treatment (time <inline-formula><mml:math id="inf35"><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>). Black represents treatment at early times (shortly after chronic myeloid leukemia [CML] develops), blue denotes treatment at intermediate times, and green denotes treatment a long time after CML develops.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig6-figsupp1-v5.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each leukemic parameter, as labeled, ranging from 90% to 110% of the original parameter value (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref> for normal cells, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref> for leukemic cells), except for <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mi>L</mml:mi></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, which is never varied above the <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> value.</title><p>The solid line represents the unperturbed state, while the shaded region represents the entire range of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig6-figsupp2-v5.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each leukemic parameter, as labeled, ranging from 90% to 110% of the original parameter value (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref> for normal cells, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref> for leukemic cells).</title><p>The solid line represents the unperturbed state, while the shaded region represents the entire range of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig6-figsupp3-v5.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>The dynamics from steady state upon introduction of leukemic stem cells with perturbations of each leukemic parameter, as labeled, ranging from 90% to 110% of the original parameter value (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref> for normal cells, <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref> for leukemic cells).</title><p>The solid line represents the unperturbed state, while the shaded region represents the entire range of the perturbation dynamics.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig6-figsupp4-v5.tif"/></fig></fig-group><p>At intermediate treatment time with larger (90–99%) HSC<sup>L</sup> fractions (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), the responses of the leukemic and normal cells to TKI treatment at early times are qualitatively similar to those observed in the previous case although the effects are more pronounced. The increase in HSC<sup>L</sup> is much larger than the previous case because there are fewer normal cells to compete with in the BM. This significantly decreases the HSC/HSC<sup>L</sup> and MPP/MPP<sup>L</sup> division rates through the negative feedback/feedforward regulation and correspondingly the rates of TKI-induced cell death. Accordingly, at later times the MPP<sup>L</sup> population rebounds, driven by the flux of differentiating HSC<sup>L</sup>, and eventually the system reaches a state in which both normal and leukemic cells coexist. The stem cell compartment is dominated by HSC<sup>L</sup> which are largely quiescent, while the multipotent progenitor and terminally differentiated cell compartments have a higher fraction of normal cells. This is consistent with experimental results from mouse models (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>) and our own unpublished data. In this scenario, <italic>BCR-ABL1</italic> transcript levels in the peripheral blood are ~1–9%, but the patient would not respond further to TKI treatment and hence would not reach MR3; this has been observed clinically including one of the patients in our study (see below). The small flux of differentiating normal and leukemic stem and progenitor cells, combined with the negative feedback loops on the self-renewal and branching fractions, supports nearly steady populations of differentiated cells.</p><p>When given years to develop and a late time to treatment, the HSC<sup>L</sup> fraction is nearly 100% (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), and there are so few normal stem cells that the leukemic cells easily maintain nearly 100% of each cellular compartment even in the presence of TKI therapy. Aside from a short-lived, transient decrease in MPP<sup>L</sup> (and differentiated leukemic cell) numbers, the leukemic cells are largely unresponsive to TKI therapy because the feedback/feedforward negative regulation of stem and progenitor cell division rates makes these rates so low that the TKIs are largely ineffective in killing the leukemic stem and progenitor cells. As in the previous case, the negative feedback regulation and the small fluxes of differentiating leukemic stem and progenitor cells enables the system to approach a steady state containing only leukemic cells.</p><p>In <xref ref-type="fig" rid="fig6">Figure 6D</xref>, we plot the simulated <italic>BCR-ABL1</italic> transcript levels over time for the three scenarios. As described in ‘Methods,’ the transcripts are modeled using a relative ratio of leukemic and normal terminally differentiated myeloid and lymphoid cell numbers. The solid blue curve corresponds to CML using the treatment time from <xref ref-type="fig" rid="fig6">Figure 6A</xref>, which responds to TKI therapy. Just as in the clinical data (symbols), the response to TKI therapy produces a biphasic exponential decrease in <italic>BCR-ABL1</italic> transcripts, which decreases below 10<sup>–1</sup>, representing a so-called major molecular response (MMR or MR3), which represents a major goal of therapy in CML as the risk of relapse and leukemia-related death is virtually nonexistent once this milestone is achieved (<xref ref-type="bibr" rid="bib40">Hochhaus et al., 2017</xref>). Consistent with previous interpretations, the rapid initial decrease in <italic>BCR-ABL1</italic> transcripts is due to TKI-induced cell death of MPP<sup>L</sup> and the increase in normal HSC and MPPs, which induce corresponding changes in the myeloid and lymphoid cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The long-term, slower depletion of leukemic cells and the stable normal cell populations result in the second phase of the biphasic response. The simulated results compare well with clinical data from the DAISISON study of imatinib versus dasatinib in patients with newly diagnosed CML (<xref ref-type="bibr" rid="bib17">Cortes et al., 2016</xref>) where the data corresponds to mean <italic>BCR-ABL1</italic> transcripts, with standard deviations, adapted from <xref ref-type="bibr" rid="bib34">Glauche et al., 2018</xref> for patients who received imatinib (blue) or dasatinib (red).</p><p>The two other curves in <xref ref-type="fig" rid="fig6">Figure 6D</xref> correspond to the treatment times from <xref ref-type="fig" rid="fig6">Figure 6B</xref> (solid orange) and C (dashed orange). In these cases, the <italic>BCR-ABL1</italic> transcripts do not decrease below the MR3 threshold, indicating that neither of these virtual patients responds adequately to TKI therapy. There is a partial response in patient from <xref ref-type="fig" rid="fig6">Figure 6B</xref> as the transcripts initially decrease due to TKI-mediated death of MPP<sup>L</sup>, but this effect soon saturates because the leukemic stem cells are able to drive the regrowth and persistence of leukemic progenitor and differentiated cells. For the virtual patient with parameters from <xref ref-type="fig" rid="fig6">Figure 6C</xref>, there is essentially no change in the <italic>BCR-ABL1</italic> transcripts when therapy is applied. These behaviors are consistent with those observed in CML patients with primary resistance to TKI therapy (<xref ref-type="bibr" rid="bib115">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="bib112">Yeung et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Pietarinen et al., 2016</xref>).</p></sec><sec id="s2-9"><title>HSC<sup>L</sup> load influences the response to TKI therapy in a mouse CML model</title><p>The fundamental difference between these three virtual patients is the number of leukemic stem cells at the start of therapy, which occurs because treatment is initiated at different times following the development of CML (early—6 mo after CML initiation ~93% initial HSC<sup>L</sup> fraction, intermediate—18 mo after CML initiation ~99% initial HSC<sup>L</sup> fraction, late—36 mo after CML initiation ~99.99% initial HSC<sup>L</sup> fraction). Our results suggest that the higher the HSC<sup>L</sup> fraction at the start of therapy, the less effective the therapy. This follows from the feedback/feedforward regulation where increased numbers of HSC and HSC<sup>L</sup> decrease their own proliferation rates as well as those of the MPPs and MPP<sup>L</sup> (see <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> and <xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref> for further explorations of feedback/feedforward regulation of parameters). This reduces the effectiveness of TKI therapy as evidence suggests TKIs preferentially target dividing leukemic cells (<xref ref-type="bibr" rid="bib35">Graham et al., 2002</xref>; <xref ref-type="bibr" rid="bib16">Corbin et al., 2011</xref>) and suggests a mechanism why some patients are destined to do poorly with TKI therapy.</p><p>To test this hypothesis, we created BM chimeric mice containing both normal and leukemic (<italic>BCR-ABL1</italic><sup>+</sup>) HSC by transplantation of BM from conditional <italic>BCR-ABL1</italic> transgenic mice (<xref ref-type="bibr" rid="bib52">Koschmieder et al., 2005</xref>) into unirradiated congenic recipient mice. Following stable engraftment, <italic>BCR-ABL1</italic> expression is induced in transgenic HSCs by withdrawal of doxycycline (see ‘Methods’). These chimeras represent a novel and physiologically accurate in vivo model of early CML development that reflects interactions between normal and CML cells in a BM microenvironment unperturbed by radiation (<xref ref-type="bibr" rid="bib85">Rodriguez et al., 2022</xref>). Two cohorts of chimeric mice bearing either a high HSC<sup>L</sup> burden (94 ± 1.5% of the HSC population) or an intermediate HSC<sup>L</sup> burden (58 ± 12%) were treated with dasatinib (25 mg/kg daily by oral gavage). Both cohorts showed a hematological response to TKI therapy, with decreased peripheral blood leukocyte counts (<xref ref-type="fig" rid="fig6">Figure 6E</xref>) and a decreased percentage of circulating granulocytes (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). By contrast and consistent with the predictions of the quantitative model, while mice bearing smaller populations of HSC<sup>L</sup> showed a decrease in the percentage of circulating <italic>BCR-ABL1</italic><sup>+</sup> granulocytes in response to TKI therapy, mice with the highest HSC<sup>L</sup> burden showed virtually no decrease in circulating leukemic cells (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Because the level of circulating granulocytes reflects the proportion of BM HSC (<xref ref-type="bibr" rid="bib111">Wright et al., 2001</xref>; data not shown), these results demonstrate that TKI therapy is unable to decrement the HSC<sup>L</sup> compartment in mice with predominantly <italic>BCR-ABL1</italic><sup>+</sup> HSC at the start of treatment.</p></sec><sec id="s2-10"><title>HSC self-renewal as an additional determinant of TKI response</title><p>While analyses of clinical data also show that patients with lower leukemic stem cell burden are more likely to respond to TKI treatment (<xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>), some patients with a high percentages of leukemic stem cells at the start of treatment are nonetheless still capable of responding to TKI therapy (e.g., see Figure 3 in <xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>). This suggests that leukemic stem cell burden alone does not predict the molecular response to TKIs. To investigate this further, we tested the response to TKI treatment for each of our 478 parameter sets. In <xref ref-type="fig" rid="fig7">Figure 7A</xref>, we present the results using only one choice of leukemic parameters (see <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). Other choices of leukemic parameters give similar results (see <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>). The model outcomes bear a striking resemblance to the clinical data of <xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>. The leukemic stem cell fraction does influence TKI response, but treatment outcomes are seen to vary among virtual patients within the same initial leukemic stem cell load. We then asked what characteristics (e.g., parameter sets) distinguish whether a virtual patient achieves a MR3 response within 50 mo. We also varied the HSC<sup>L</sup> parameters, taking into account several studies suggesting that CML stem cells are at least 5–10 times less sensitive to CCL3-mediated inhibition of self-renewal (<xref ref-type="bibr" rid="bib25">Eaves et al., 1993</xref>, <xref ref-type="bibr" rid="bib12">Chasty et al., 1995</xref>; <xref ref-type="bibr" rid="bib106">Wark et al., 1998</xref>; <xref ref-type="bibr" rid="bib24">Dürig et al., 1999</xref>); for example, <inline-formula><mml:math id="inf38"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> should be less than 0.2. Further, since 10–15% of patients do not respond to TKI treatment even in the absence of <italic>BCR-ABL1</italic> mutations (<xref ref-type="bibr" rid="bib37">Hanfstein et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Marin et al., 2012</xref>), we estimate <inline-formula><mml:math id="inf39"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> / <inline-formula><mml:math id="inf40"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mn>0.8</mml:mn></mml:math></inline-formula> from <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref> to roughly match this proportion of nonresponding patients. Taken together, this suggests that the effective leukemic stem cell fitness would be <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≈</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. We thus varied the HSC<sup>L</sup> parameters accordingly. In <xref ref-type="fig" rid="fig7">Figure 7B</xref>, we plot the results for <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> as a bivariate histogram for <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf44"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> with proportion of response (blue) and nonresponse (orange) for every parameter set. Surprisingly, we found that although the fitness <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> impacts response, the parameter that clearly distinguished responders from nonresponders was the maximal self-renewal fraction <italic>p</italic><sub><italic>0,max</italic></sub> for normal stem cells, shown in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (marginal y-axis). See <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> for the distributions as a function of the other parameters using the single leukemic parameter set from <xref ref-type="fig" rid="fig7">Figure 7A</xref> (see <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>), and <xref ref-type="fig" rid="app1fig15">Appendix 1—figures 15</xref>–<xref ref-type="fig" rid="app1fig16">16</xref> in Appendix 1, Section 10 for different bivariate distributions corresponding to different choices of the minimum fitness <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> . In particular, larger values of <italic>p</italic><sub><italic>0,max</italic></sub> and <italic>γ</italic><sub><italic>1</italic></sub> are correlated with a decreased response to TKI therapy after leukemia develops. Although these parameters are associated with normal HSC, the self-renewal fraction <italic>p</italic><sub><italic>0</italic></sub><sup><italic>L</italic></sup> of HSC<sup>L</sup> and feedback strength <inline-formula><mml:math id="inf47"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> depends on these parameters since we assumed the fitness of the CML stem cells <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> is larger than a minimum threshold. Therefore, increasing the self-renewal fraction of the normal stem cells has the effect of also increasing the fitness of the CML stem cells.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Leukemic stem cell load alone does not predict response to tyrosine kinase inhibitor (TKI) therapy.</title><p>(<bold>A</bold>) Scatter plot of the distribution of simulated <italic>BCR-ABL1</italic> transcripts at 18 mo after start of treatment as a function of the HSC<sup>L</sup> proportion at the start of TKI therapy for each of the 478 parameter sets. The time to reach MR3 (<italic>BCR-ABL1</italic> transcripts less than 0.1%) is indicated by the color. (<bold>B</bold>) The proportion of parameter sets that achieve MR3 within 50 mo (responders, blue) and those that do not (nonresponders, orange) shown as a joint distribution of the parameters <inline-formula><mml:math id="inf49"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> using the minimum fitness threshold <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>L</mml:mi></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, which reveals the maximal self-renewal fraction of the normal HSC, <inline-formula><mml:math id="inf52"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (y-axis marginal distribution), distinguishes response across parameter combinations. (<bold>C</bold>) Dynamics of the effective leukemic stem cell self-renewal fraction for the parameter set used in <xref ref-type="fig" rid="fig6">Figure 6A–D</xref> (blue) and an arbitrary representative non-responsive parameter set (orange) during chronic myeloid leukemia (CML) development and before initiation of therapy (t &lt; 0), and after application of TKI therapy (t &gt; 0). (<bold>D</bold>) Early time dynamics (e.g., t = 0–3 mo; left of the vertical line) of the transcript levels reveal that it is difficult to distinguish responders (blue) from nonresponders (orange). At later times (e.g., t = 3–6 mo; right of the vertical line), the two populations are easier to distinguish. (<bold>E</bold>) Receiver operating curves (ROC) obtained from the 478 parameter sets using our new prognostic criterion based on the relative changes in transcript levels (solid) and the transcript halving time (dashed) for the first 3 mo (blue) and the second 3 mo (orange) after therapy. The prognostic thresholds (symbols) are identified by optimizing true and false positives rates. Early molecular response (EMR) at 3 mo (10% transcript levels) and 6 mo (1% transcript levels) are shown by the blue square and orange diamond, respectively. Inset: expanded view of the ‘elbow’ region of the ROC curves to display differences between the prognostic tests. Accuracy is improved using the 3–6 mo time window, and our new prognostic criterion outperforms the EMR and halving time prognostics in this time window. (<bold>F</bold>) The accuracy of the prognostic criteria applied to CML patient data (n = 7) treated using the same TKI dosing for the 6-month period after therapy is started. The results are consistent with the synthetic data in (<bold>E</bold>). (<bold>G</bold>) The prognostic criteria applied to patient data (n = 7) in which therapy could be changed but those changes were maintained for 6 mo (see text). Although the data are limited, the results are consistent with those in (<bold>E</bold>) and (<bold>F</bold>) suggesting increased accuracy using the 3–6-month window, and that the prognostic criterion based on relative change may yield more accurate predictions than EMR and halving time in the 3–6-month time frame.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig7-v5.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Parameter distributions by response to tyrosine kinase inhibitor (TKI) treatment using synthetic data.</title><p>Blue denotes a parameter set achieves MR3 within 50 mo (responder), and yellow denotes a parameter set that does not (non-responder).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig7-figsupp1-v5.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Comparison of the proportion of cases that successfully respond to therapy as a function of the ratio of characteristic values of leukemic and normal stem cells: <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</title><p>The relative fitness is the critical determinant of whether chronic myeloid leukemia (CML) cells respond to tyrosine kinase inhibitor (TKI) treatment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig7-figsupp2-v5.tif"/></fig></fig-group><p>To understand further the differences between response and nonresponse to TKI therapy, we took the parameter set from <xref ref-type="fig" rid="fig6">Figure 6A</xref> as a representative patient for response and selected an arbitrary nonresponsive parameter set (<xref ref-type="table" rid="app1table6">Appendix 1—table 6</xref>) to be a representative patient for nonresponse. In <xref ref-type="fig" rid="fig7">Figure 7C</xref>, we show that the effective <italic>p</italic><sub><italic>0</italic></sub><sup><italic>L</italic></sup> (the fraction of HSC<sup>L</sup> self-renewal after feedback) for nonresponders (orange) is larger after TKI therapy is applied than for responders (blue). In particular, as TKI treatment kills the leukemic progenitors, this increases the effective self-renewal fraction for both normal and leukemic stem cells because of the release of negative feedback. When the maximum self-renewal p<sub>0,max</sub> is larger, the leukemic stem cells experience an acute increase in self-renewal, resulting in their dominance over normal stem cells that then leads to a decreased response to TKIs.</p><p>Clinical data provide support for this mechanism of resistance. Patients with clonal hematopoiesis, in which there is a dominant clone driving hematopoiesis, exhibit predominantly normal hematopoiesis but frequently have mutations in the genes, such as <italic>TET2</italic>, <italic>DNMT3A</italic>, and <italic>ASXL1</italic>, that are known to increase stem cell self-renewal (<xref ref-type="bibr" rid="bib94">Steensma, 2018</xref>). Clinical data shows that CML patients whose blood cells have mutations in <italic>TET2</italic> and <italic>ASXL1</italic>, some of which may exist prior to development of CML, frequently exhibit a poor response to TKI therapy (<xref ref-type="bibr" rid="bib50">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Marum et al., 2017</xref>). Taken together, these data suggest that patients with higher stem cell self-renewal fare worse when their CML is treated using TKIs than patients with lower stem cell self-renewal.</p></sec><sec id="s2-11"><title>Predicting long-term response to TKI treatment</title><p>Several measures of the response of CML patients to TKI therapy have been developed, based on <italic>BCR-ABL1</italic> transcript levels in peripheral blood. Here we test a new, model-driven criterion for predicting patient response and compare the results with several other criteria currently used in the clinic. A major focus has been on the predictive value of the decline in transcripts over the first 3 mo of treatment, principally the so-called ‘early molecular response’ or EMR (defined as <italic>BCR-ABL1</italic> transcripts &lt;10% at 3 mo and &lt;1% at 6 mo), where patients with &gt;10% transcripts had significantly lower probability of achieving cytogenetic remission and decreased overall survival (<xref ref-type="bibr" rid="bib37">Hanfstein et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Marin et al., 2012</xref>). Subsequently, there was an effort to improve the predictive power by focusing on the velocity of reduction in transcripts (<xref ref-type="bibr" rid="bib8">Branford et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Hanfstein et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Pennisi et al., 2019</xref>). Because the best predictor of patient response to TKIs, the self-renewal fraction of normal stem cells, is very difficult to measure clinically, we searched for an alternative criterion that could accurately predict patient response and could still be measured using the data collected in standard practice. Therefore, we focused on alternative time frames and calculation methods for assessing <italic>BCR-ABL1</italic> transcript levels (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). It is important to be able to predict the long-term TKI response early after starting treatment in order to enable changes in therapy. However, since both responders (blue) and nonresponders (orange) may show significant decreases in the transcript levels in the first months of treatment, it was difficult to distinguish between the two at relatively early time points. By contrast, responses in the 3–6-month time frame make it easier to identify the different behaviors of responders and nonresponders (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><p>By calculating the relative changes of the transcript levels from 3 to 6 mo, we developed a prognostic formula: <inline-formula><mml:math id="inf54"><mml:mi>P</mml:mi><mml:mi>F</mml:mi><mml:mo>(</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mn>6</mml:mn><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>L</mml:mi><mml:mn>1</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>L</mml:mi><mml:mn>1</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>L</mml:mi><mml:mn>1</mml:mn><mml:mo>(</mml:mo><mml:mn>6</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula>. We found that optimizing for sensitivity (TPR, the true positive rate) and specificity (1-FPR, with FPR being the false positive rate) resulted in a prognostic threshold of <inline-formula><mml:math id="inf55"><mml:mi>P</mml:mi><mml:mi>F</mml:mi><mml:mo>≈</mml:mo><mml:mo>-</mml:mo><mml:mn>3.2</mml:mn><mml:mo>,</mml:mo></mml:math></inline-formula> with sensitivity of <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.91</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and specificity of <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.91</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, orange curves) compared to the optimal sensitivity and specificity of the velocity-based prognostic (<inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.89</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.88</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> respectively) and <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.77</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>≈</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> for EMR 1% with our parameter sets. This demonstrates that this prognostic tool had higher sensitivity and specificity than previously developed predictive criteria in separating responders (<inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mo>−</mml:mo><mml:mn>3.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) from nonresponders (<inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mo>−</mml:mo><mml:mn>3.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>), where response is defined as achievement of MR3 within a clinically relevant timeframe of 18 mo. We also tested the various prognostics at the 0–3-month interval as is the current clinical practice, but that resulted in lower predictive power (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, blue curves). These results highlight the importance of including the 3–6-month TKI response in predicting the long-term outcome of treatment, instead of considering only the first 3 mo. See <xref ref-type="fig" rid="app1fig7">Appendix 1—figures 7 and 17</xref> in Sections 8 and 12, respectively, for further discussion, comparison of additional prognostic criteria, and the effect of leukemic parameters.</p><p>We then applied our prognostic criterion to anonymized CML patient data (see ‘Methods’) to determine clinical significance and utility. The prognostic tests shown in <xref ref-type="fig" rid="fig7">Figure 7E</xref> were calculated for both the first 3 mo and the subsequent 3–6-month period after the start of therapy, for the patients who were treated with the same TKI and dosage for the full 6 mo. All the prognostic tests achieved a more accurate prediction of patient outcome using the 3–6-month data compared to the same test applied to the first 3 mo (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). To expand clinical utility, the prognostics were calculated for cases where TKI therapy was changed (due either to toxicity or an inadequate response) but then maintained for a subsequent 6-month period, which were added to the data from <xref ref-type="fig" rid="fig7">Figure 7F</xref>. The aggregated data (<xref ref-type="fig" rid="fig7">Figure 7G</xref>) reaffirms the improved accuracy in prediction using the 3–6-month transcript data compared to that from 0 to 3 mo. Over the first 3 mo, all the prognostic criteria performed similarly. Although the number of patients was small, the results suggest that our prognostic criteria may perform better than the EMR and velocity-based prognostics that are in current clinical use. For comparisons between the prognostic criteria and time frames with patient data, see Appendix 1, Section 7, <xref ref-type="fig" rid="app1fig8">Appendix 1—figures 8</xref>–<xref ref-type="fig" rid="app1fig10">10</xref>.</p></sec><sec id="s2-12"><title>Improving response to therapy: Combining TKIs with interventions that promote differentiation</title><p>Our model suggests that combination therapy to modulate the stem cell self-renewal rate, in addition to directly targeting the leukemic HSC and MPPs with TKI therapy, might counteract TKI treatment resistance mediated by high stem cell self-renewal. Such pro-differentiation therapy could be accomplished through either direct stimulation of differentiation or through suppression of self-renewal. In our modeling experiments, we explored the impact of this approach through the suppression of self-renewal (see ‘Methods’ for details). To begin the exploration of the combined TKI-differentiation therapy, we performed this combination therapy on each of our 478 parameter sets, which represents a population of CML patients with person-to-person variability. We then recorded which parameter sets achieved MR3 within 50 mo for each strength of the differentiation therapy (<italic>Δ</italic>), where <italic>Δ</italic> is a dimensionless constant greater than 0 that constantly suppresses stem cell self-renewal (both normal and CML) in the setting of combination therapy (see ‘Methods’ and Appendix 1, <xref ref-type="disp-formula" rid="equ43 equ44">Equations 40 and 41</xref>). Using these data, <xref ref-type="fig" rid="fig8">Figure 8A</xref> depicts the proportion of parameter sets achieving MR3 given a strength of differentiation therapy of <italic>Δ</italic>. As differentiation therapy strength increases from zero, the proportion of parameter sets that achieve MR3 increases before leveling off between <italic>Δ</italic> = 0.2–0.3, with maximum efficacy occurring at a strength of differentiation <italic>Δ</italic> of about 0.24. The efficacy of combination therapy then begins to decline rapidly, and with too great a strength of differentiation treatment, the combination therapy becomes inferior to TKI therapy alone.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Combining tyrosine kinase inhibitor (TKI) therapy with differentiation promoters enhances response to treatment.</title><p>(<bold>A</bold>) The proportion of the 478 parameter sets that achieve MR3 under combined TKI and differentiation therapy depends nonmonotonically on the strength Δ of the differentiation therapy, with the peak response (86.8%) occurring at <italic>Δ</italic> = 0.24. (<bold>B</bold>) The maximum stem cell self-renewal fraction for a single <inline-formula><mml:math id="inf64"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mi> </mml:mi></mml:math></inline-formula> in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (marginal y) with hatching indicating the effects of the combination of TKI and differentiation therapy with <italic>Δ</italic> = 0.24. Blue hatching indicates nonresponders (who did not achieve MR3) that become responders (achieve MR3) while orange hatching indicates responders that become nonresponders upon combined treatment. Differentiation promoters allow nonresponders to TKI therapy with large self-renewal fractions to reach MR3. The opposite outcome, loss of MR3 in a TKI responder, primarily occurs only at the smallest self-renewal fractions. (<bold>C</bold>) Time evolution of <italic>BCR-ABL1</italic> transcripts during combination therapy, with <italic>Δ</italic> = 0.24 (black) and <italic>Δ</italic> = 0.5 (blue), using the parameter set from <xref ref-type="fig" rid="fig5">Figure 5B</xref> that does not achieve MR3 using TKI monotherapy (red). (<bold>D, E</bold>) The time derivatives of the number of normal (<bold>D</bold>) and leukemic (<bold>E</bold>) stem cells during combination therapy. The differentiation promoter attenuates the rapid increases in the rates of change at early times after therapy starts in both normal and leukemic cells, but the attenuation is much larger in the leukemic cells. This results in the growth of normal cells, while leukemic cells experience restricted growth or outright depletion depending upon the differentiation therapy strength. (<bold>F</bold>) Simplified diagram representing the key interactions between the cells and the impact on outcomes of TKI and combination therapy. Green: chronic myeloid leukemia (CML) hematopoiesis depicting the loss of normal stem cells and progenitors and the increase in leukemic stem cells and progenitors. Red fill: TKI treatment failure. The TKI-induced death of leukemic progenitors relieves negative feedback and increases stem cell self-renewal, resulting in increases in both normal and leukemic stem cells, and eventually their progeny (panel 2). The increases are larger for the leukemic cells because their self-renewal fraction is bigger. Increases in the leukemic progenitor compartment (panel 3) drive down the self-renewal fraction of normal stem cells proportionally more than for the leukemic stem cells. The increases in HSC<sup>L</sup> also drive down proliferation rates, which makes the leukemic cells less responsive to TKI treatment. Altogether, this makes the leukemic cells more fit than the normal cells and results in therapy failure. Blue fill: treatment by combined TKI and pro-differentiation therapy reduces stem cell self-renewal relative to TKI monotherapies, equalizes the normal and leukemic self-renewal fractions, which limits leukemic stem cell growth and limits decreases in proliferation rates, making the HSC<sup>L</sup> and MPP<sup>L</sup> more susceptible to TKI-induced death (panel 2). This allows repopulation of the bone marrow by normal stem cells and progenitors to occur (panel 3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig8-v5.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Changes in the parameter distributions from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> when combined differentiation and tyrosine kinase inhibitor (TKI) therapy is administered.</title><p>Blue denotes a parameter set achieves MR3 within 50 mo, and orange denotes parameter sets that do not. Orange hatching denotes a parameter set that achieves MR3 within 50 mo with TKI monotherapy, but does not achieve MR3 within 50 mo under combination therapy. Blue hatching denotes a parameter set that does achieve MR3 within 50 mo with combination therapy but does not with TKI therapy alone.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig8-figsupp1-v5.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Variations in <inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> for all parameter sets with combination therapy show improvement of response with combination therapy compared to <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref> (bottom right).</title><p>Plots display data using the same criteria as <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref> (bottom right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-fig8-figsupp2-v5.tif"/></fig></fig-group><p>To investigate how combination therapy effectively targets resistance, and the mechanism of the decreased efficacy of combination therapy in achieving MR3 when <italic>Δ</italic> is large, we returned to examining parameter distributions. <xref ref-type="fig" rid="fig8">Figure 8B</xref> depicts the same distribution of <italic>p</italic><sub><italic>0,max</italic></sub> as in <xref ref-type="fig" rid="fig7">Figure 7B</xref>, but overlaid with a second histogram (hatched regions) to denote the effect of the differentiation therapy at the point of maximum efficacy (see <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> for all the parameter distributions). The two types of hatching reveal important factors that determine under which conditions combination therapy improves or impairs response. The orange hatching represents transition from response to nonresponse by combination therapy; this occurs in individuals with the lowest <italic>p</italic><sub><italic>0,max</italic></sub>. In these cases where stem cell self-renewal is already close to the ideal effective self-renewal fraction of 0.5, differentiation therapy pushes too many normal cells into differentiation, causing the normal cell populations to deplete themselves and decreasing the efficacy as <italic>Δ</italic> increases beyond 0.24. In contrast, the blue hatching shows the desired scenario of nonresponding individuals with high <italic>p</italic><sub><italic>0,max</italic></sub> becoming responders and achieving MR3 within 50 mo due to the combination therapy.</p><p>To understand further the mechanisms underlying the efficacy of combination therapy, we explored treatment dynamics (changes in <italic>BCR-ABL1</italic> transcript levels) and the rates of change of both normal and leukemic stem cell populations for the nonresponsive individual from <xref ref-type="fig" rid="fig7">Figure 7D</xref>. By applying two different strengths of differentiation therapy (<italic>Δ</italic> = 0.24 and 0.5) in combination with TKI therapy, for this individual both strengths are able to achieve MR3 at ~18 mo (<xref ref-type="fig" rid="fig8">Figure 8C</xref>) in contrast to TKI monotherapy, which resulted in a failure to reach MR3 (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, orange). <xref ref-type="fig" rid="fig8">Figure 8D and E</xref> show how the rates of change in the size of the normal and leukemic stem cell compartments vary with respect to time for the three different Δ values. For TKI therapy alone (<italic>Δ</italic> = 0), rates of growth of both the normal and leukemic stem cell populations show an increase as a result of the loss of negative feedback due to TKI-induced killing of MPP<sup>L</sup>, but the leukemic stem cells experience a much greater numerical increase and outcompete normal cells, resulting in a system that exhibits resistance to the TKI therapy. Under conditions of maximum efficacy (<italic>Δ</italic> = 0.24), the normal stem cell population rate of change still increases rapidly but to a maximum level below that for TKI monotherapy before decreasing more rapidly to zero as the system re-equilibrates. In contrast, under the same conditions the rate of change of the leukemic stem cell population is greatly reduced and becomes negative after normal stem cells begin to outcompete the leukemic stem cells. Under conditions of stronger differentiation therapy (<italic>Δ</italic> = 0.5), although the accumulation rate of the normal stem cells is substantially reduced, the growth rate of the HSC<sup>L</sup> is immediately negative. This enables the normal HSC to easily outcompete the leukemic cells and restore the system to the normal state. Effectively, for large values of HSC self-renewal and corresponding feedback gains, the differentiation promoter acts to bring the self-renewal fraction of the normal HSC closer to that of the HSC<sup>L</sup>, which then enables the TKI therapy to disadvantage the leukemic cells, and allow for repopulation and dominance by normal cells. For the effect of combination therapy on different combinations of leukemic parameters, see <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref> and Appendix 1, Section 11 for further analysis.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this work, we developed a nonlinear mathematical model of normal and CML hematopoiesis that incorporated feedback control, lineage branching, and signaling between normal and CML cells. Using ODEs, we modeled the dynamics of the stem, multipotent progenitor, and terminally differentiated cell populations. To filter through the combinatorial explosion of models that occurs when cell–cell signaling interactions are taken into account, we focused first on normal hematopoiesis. We used DSA (<xref ref-type="bibr" rid="bib89">Savageau et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>; <xref ref-type="bibr" rid="bib61">Lomnitz and Savageau, 2013</xref>; <xref ref-type="bibr" rid="bib62">Lomnitz and Savageau, 2016</xref>), an approach that enables models to be distinguished based on their range of qualitatively distinct behaviors without relying on knowledge of specific values of the parameters, to perform an automated search for regions of stability in thousands of proposed models and efficiently eliminate unphysiological, unstable models. When combined with previous observations and new in vivo data to further constrain cell–cell interactions, we arrived at a new feedback-feedforward model (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>Using cell perturbation experiments in mice, we validated several features of the model, including feedback from differentiated myeloid cells on MPP self-renewal, and feedforward regulation by stem cells on proliferation of stem and MPP compartments. We postulate that these regulatory loops may also regulate human blood cell production. While there are some known differences between mouse and human hematopoiesis (<xref ref-type="bibr" rid="bib74">Parekh and Crooks, 2013</xref>), many signaling pathways are conserved between species. For example, the role of IL-6 in regulating lymphoid differentiation (e.g., γ<sub>4</sub> in <xref ref-type="fig" rid="fig2">Figure 2F</xref>) has been validated in mice (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>) and human samples (<xref ref-type="bibr" rid="bib107">Welner et al., 2015</xref>), while CCL3 mediates negative feedback from progenitors onto stem cell self-renewal (e.g., γ<sub>1</sub> in <xref ref-type="fig" rid="fig2">Figure 2F</xref>) in both mice (<xref ref-type="bibr" rid="bib93">Staversky et al., 2018</xref>) and humans (<xref ref-type="bibr" rid="bib9">Broxmeyer et al., 1989</xref>). TGF-β, produced by HSC, differentiated myeloid cells, and BM stroma, is a candidate factor regulating negative feedback of HSC onto their own division rate and that of the MPPs (<xref ref-type="bibr" rid="bib118">Zhao et al., 2014b</xref>; <xref ref-type="bibr" rid="bib73">Naka and Hirao, 2017</xref>), while IL-6 may inhibit MPP self-renewal and increase myeloid differentiation (<xref ref-type="bibr" rid="bib117">Zhao et al., 2014a</xref>), at least under stress conditions. The role of these candidate hematopoietic regulators could be tested directly in our mouse model via a genetic approach. Moving forward, it will be important to validate results from mouse model systems in human studies whenever possible.</p><p>We used a grid-search algorithm to determine a set of approximately 500 biologically relevant parameter sets for our new model. While we could have used other approaches such as the Latin hypercube algorithm to sample our multidimensional parameter space (<xref ref-type="bibr" rid="bib82">Read et al., 2018</xref>), we chose to perform a gridsearch because of the ease of implementation and the fact that our goal was not to exhaustively search the full parameter space, but rather to obtain a set of biologically relevant parameter values consistent with normal hematopoietic homeostasis. In particular, using each parameter set in the model yields steady states that are consistent with normal ranges of hematopoietic cells. These parameter sets model a population of individuals with normal cell counts but person-to-person variability of parameters due, for example, to genetic, epigenetic and/or environmental differences.</p><p>We then extended the model to incorporate CML hematopoiesis by introducing a mutant lineage with the same structure as the normal system. We incorporated one of the central features of CML pathophysiology, that the leukemic stem cell clone, hypothesized to arise from a single HSC that acquires a Ph chromosome, has a competitive advantage over normal HSC and with time comes to dominate the stem cell compartment (<xref ref-type="bibr" rid="bib21">Dingli et al., 2010</xref>; <xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Holyoake and Vetrie, 2017</xref>; <xref ref-type="bibr" rid="bib65">Majeti et al., 2022</xref>). This competitive advantage could be a consequence of positive feedback (autocrine or paracrine) on the HSC<sup>L</sup> population or negative feedback with different strengths for normal and leukemic stem cells. Candidate mediators of such positive and negative feedback include interleukin-3 (<xref ref-type="bibr" rid="bib46">Jiang et al., 1999</xref>) and CCL3 (<xref ref-type="bibr" rid="bib5">Baba et al., 2016</xref>), respectively. Our current model incorporated differential negative feedback of MPPs on HSC (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) with the HSC<sup>L</sup> being less sensitive to the negative feedback than are the normal HSC, which is consistent with CCL3 (<xref ref-type="bibr" rid="bib25">Eaves et al., 1993</xref>, <xref ref-type="bibr" rid="bib4">Baba et al., 2013</xref>). This one difference provided leukemic cells with a competitive advantage for growth, and in the absence of treatment, the leukemic cells will take over the BM at the expense of normal cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Upon exploration of the leukemic parameter space, we found that only the leukemic cell parameters for the leukemic stem cells (HSC<sup>L</sup>)—the maximal HSC<sup>L</sup> self-renewal fraction <inline-formula><mml:math id="inf67"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> , the feedback gain <inline-formula><mml:math id="inf68"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> on the HSC<sup>L</sup> self-renewal fraction, and the TKI-induced HSC<sup>L</sup> death rate <inline-formula><mml:math id="inf69"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>—have the potential to significantly influence the results. The results are insensitive to changes in the other leukemic cell parameters (see <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2</xref>–<xref ref-type="fig" rid="fig6s4">4</xref>, and <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref>).</p><p>When combined with TKI therapy, the feedback/feedforward model exhibited variable responses to TKI treatment, consistent with those observed in CML patients. That is, although our 500 parameter sets were consistent with normal hematopoietic cell counts, the responses to TKI treatment were highly variable, with some sets responding to treatment while others did not. The model predicted that a contributor to primary TKI resistance is the overall proportion of HSC that are leukemic, consistent with experimental data in mice (<xref ref-type="fig" rid="fig6">Figure 6G</xref>) as well as patient data (<xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>). However, leukemic stem cell burden alone does not predict the molecular response to TKIs, as observed both clinically (<xref ref-type="bibr" rid="bib101">Thielen et al., 2016</xref>) and in our data (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), since some patients with high HSC<sup>L</sup> fractions in their BM nonetheless still respond to TKIs.</p><p>The model suggested that a key predictor of reduced response to TKI treatment is an increased tendency of normal hematopoietic stem cells to self-renew, which in turn influences self-renewal of the leukemic stem cells since they were estimated to be sufficiently fit with respect to the normal stem cells. This is also consistent with clinical data that suggest that CML patients whose normal and leukemic cells share mutations in genes such as <italic>TET2</italic> and <italic>ASXL1</italic>, which are known to increase stem cell self-renewal (<xref ref-type="bibr" rid="bib94">Steensma, 2018</xref>), tend to have inferior outcomes under TKI therapy (<xref ref-type="bibr" rid="bib50">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Marum et al., 2017</xref>). This is illustrated in <xref ref-type="fig" rid="fig8">Figure 8F</xref> (red panel), where the high initial HSC<sup>L</sup> population and the subsequent decline of progenitor cells reveals the effect that high stem cell self-renewal has on driving TKI resistance. In our model, the presence of a <italic>TET2</italic> or <italic>ASXL1</italic> mutation in both normal and leukemic stem cells that led to a proportional increase in self-renewal in both populations would tend to cause resistance to TKI therapy, provided that the HSC<sup>L</sup> are sufficiently fit in the presence of the mutations, which we would expect. The self-renewal-driven resistance we describe herein challenges the prevailing paradigm that TKI resistance is proliferation-driven and a consequence of HSC<sup>L</sup> quiescence (<xref ref-type="bibr" rid="bib35">Graham et al., 2002</xref>; <xref ref-type="bibr" rid="bib16">Corbin et al., 2011</xref>).</p><p>Because stem cell self-renewal is hard to quantify experimentally, we developed a clinical prognostic criterion to predict TKI response based on the relative changes in the <italic>BCR-ABL1</italic> transcripts over a 3-month period. Using the synthetic data from our normal and leukemic parameter sets, we found that using changes in transcripts from 3 to 6 mo was very effective in predicting the long-term outcome of treatment (e.g., reaching MR3 within 18 mo). In contrast, using transcript data from 0 to 3 mo resulted in less accurate predictions. This observation also holds for prognostic criteria based on EMR and transcript halving time, which are currently used in the clinic. We then tested the prognostic criteria on data obtained from small number of anonymized CML patients and found the same conclusions hold. Our results suggest that the relative change prognostic criterion more accurately predicts patient response than EMR and the halving time, although more data are needed to confirm this. Our cohort of patients was small due to the variable nature of patient treatment and inconsistent data collection, for example, patients were frequently switched from one TKI to another or one dosage to another (sometimes multiple times), and the patients’ <italic>BCR-ABL1</italic> transcript levels were not always consistently recorded. However, we believe that this pilot study demonstrates the feasibility of our approach. Moving forward, we aim to apply our approach to larger datasets and hope to convince others to do the same.</p><p>Two strategies can be postulated to overcome TKI resistance. One approach could be to decrease stem cell self-renewal either by inhibiting self-renewal directly (e.g., by augmenting TET2 function using ascorbate; <xref ref-type="bibr" rid="bib2">Agathocleous et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Cimmino et al., 2017</xref>) or by promoting differentiation (e.g., using retinoids; <xref ref-type="bibr" rid="bib23">Drumea et al., 2008</xref>). By applying combined TKI and pro-differentiation therapy, the self-renewal fractions of the normal and leukemic stem cells can be decreased and brought closer together, which ultimately disadvantages the leukemic cells because of TKI-induced cell death (<xref ref-type="fig" rid="fig8">Figure 8F</xref>, blue panel). An alternative or complementary approach would be to increase stem cell proliferation via pro-proliferative stimuli such as IFN-alpha (<xref ref-type="bibr" rid="bib29">Essers et al., 2009</xref>) to increase efficacy of TKIs in killing HSC<sup>L</sup>.</p><p>It is apparent that the feedback/feedforward interactions incorporated in our model, which are necessarily somewhat restricted, may be further constrained by spatial characteristics of the BM microenvironment. Nonetheless, our model still displays consistent and biologically relevant behaviors, and although further refinement of the model behaviors is possible, based upon our findings the key behaviors (feedback mechanisms and importance of stem cell self-renewal) would be expected to remain much the same. To explore experimentally observed phenomena not captured by our current model such as treatment-free remission, where a low level of HSC<sup>L</sup> persists in the absence of TKI pressure without myeloid cell expansion, improvement of the model is necessary. For example, it may be necessary to incorporate features of the BM microenvironment such as stem cell–niche interactions (<xref ref-type="bibr" rid="bib63">MacLean et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Lai et al., 2022</xref>) and interactions with immune cells (<xref ref-type="bibr" rid="bib36">Hähnel et al., 2020</xref>). The inclusion of a quiescent stem cell state and additional cellular compartments (such as committed progenitors) coupled with appropriately constrained cell–cell signaling would also make the model more physiologically accurate.</p><p>In summary, the feedback/feedforward model we have presented here, while a simplified version of normal and CML hematopoiesis, makes novel and testable predictions regarding the origins of non-genetic primary resistance, which patients will respond to TKI treatment and suggests a combination therapy that can overcome primary resistance. Although preliminary evidence was presented to support model predictions, future work should focus on designing targeted experiments and collecting patient outcomes to generate data to more thoroughly test the model.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Mathematical model of hematopoiesis</title><p>The classical depiction of hematopoiesis is a hierarchy of cell types starting with the hematopoietic stem cell at the top, followed by progenitors and ultimately ending with mature cells located in the peripheral blood. Therefore, we model hematopoiesis using a lineage ODE model (<xref ref-type="bibr" rid="bib86">Roeder et al., 2006</xref>; <xref ref-type="bibr" rid="bib51">Komarova and Wodarz, 2007</xref>; <xref ref-type="bibr" rid="bib43">Horn et al., 2008</xref>; <xref ref-type="bibr" rid="bib32">Foo et al., 2009</xref>; <xref ref-type="bibr" rid="bib57">Lander et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Marciniak-Czochra et al., 2009</xref>; <xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Buzi et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Hähnel et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Pedersen et al., 2021</xref>) to describe cellular growth dynamics. The modeling allows us to follow the similar hierarchical structure by creating an order of differentiation. Our branched lineage model of hematopoiesis is simplified and only models HSCs, progenitor cells (MPPs), and two types of terminally differentiated cells (myeloid and lymphoid cells). The model can easily include additional cell types, such as committed progenitor cell types, which will provide an additional level of detail. The model consists of two dividing cell types consisting of S (HSC) and P (MPP) cells with a division rate associated to the cells (η<sub>1</sub> and η<sub>2,</sub> respectively). The S cells have the ability to self-renew with fractions (p<sub>0</sub>) or differentiate (1 p<sub>0</sub>). The P cells have the ability to self-renew with fraction (p<sub>1</sub>) or differentiate into either TD<sub>l</sub> (lymphoid) or TD<sub>m</sub> (myeloid) cells (q<sub>1</sub> or 1-p<sub>1</sub>-q<sub>1,</sub> respectively). Both S and P cells do not die within the model. The terminal cells form the majority of the hematopoietic system and consist of TD<sub>l</sub> and TD<sub>m</sub> cells. TD<sub>m</sub> and TD<sub>l</sub> cells are postmitotic and die at rates d<sub>m</sub> and d<sub>l</sub>, respectively. The following equations (<xref ref-type="disp-formula" rid="equ2 equ3 equ4 equ5">Equations 1–4</xref>) describe the dynamics of the system:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msubsup><mml:mi>x</mml:mi><mml:mi>S</mml:mi><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>x</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msubsup><mml:mi>x</mml:mi><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>x</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>x</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Further expanded forms of the equations are shown in Appendix 1, <xref ref-type="disp-formula" rid="equ29 equ30 equ31 equ32">Equations 26–29</xref>, with the addition of feedback regulation for each of the parameters.</p></sec><sec id="s4-2"><title>Design space analysis</title><p>We use an automated method developed by Savageau and collaborators (<xref ref-type="bibr" rid="bib89">Savageau et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>; <xref ref-type="bibr" rid="bib61">Lomnitz and Savageau, 2013</xref>; <xref ref-type="bibr" rid="bib62">Lomnitz and Savageau, 2016</xref>) that separates models by distinct qualitative behaviors at steady state. The strategy is to deconstruct the model of interest at steady state to focus on cases where one production term and one loss term dominate, which gives a dominant subsystem (S-System). This implies that particular inequalities hold in order to ensure the production and loss terms chosen are larger than the others. The inequalities are evaluated at the S-system’s steady state to assess self-consistency. If the inequalities are satisfied, the system is self-consistent and the regions where equality holds form boundaries that pertain to a particular qualitative behavior associated with the system. The interior region (where strict inequality holds) is termed a domain in design space. If all the S-systems associated with a model do not have any equilibria that are self-consistent or equilibria that are stable, then the model is rejected. The benefits of this method are that it does not require prior knowledge about parameter values, and it can enumerate the different types of qualitative dynamics a certain system may have. By eliminating subsets of parameters for which the equilibrium is unstable, this approach will automatically select models that are robust to parameter variation due to stability. When we applied this method to the ODE system in <xref ref-type="fig" rid="fig2">Figure 2F</xref> (Appendix 1, <xref ref-type="disp-formula" rid="equ29 equ30 equ31 equ32">Equations 26–29</xref>), we found that only the four model classes shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref> were accepted. See Appendix 1, Section 1, for further details.</p></sec><sec id="s4-3"><title>Parameter estimation</title><p>To approximate biologically relevant parameters for the model a grid-search algorithm was employed. Parameters were sampled using a random uniform distribution for each parameter (see Appendix 1, Section 3.1). Once parameter values were chosen, the model was simulated to steady state. If a parameter set resulted in steady-state values consistent with the order of magnitude in <xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref>, the parameter set was accepted, otherwise it was rejected. Specifically, these inequalities had to be satisfied 10<sup>4</sup> &lt; HSC &lt; MPPs with MPPs fixed at 10<sup>5</sup> and MPPs &lt; TD<sub>l</sub> &lt; T<sub>Dm</sub>. For 10<sup>6</sup> iterations, a sample of 1493 parameter sets were accepted. The distribution for these parameter sets is shown in <xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>. To further explore the effect of the feedforward interaction, these parameter sets were reduced to the 563 sets with γ<sub>5</sub> &gt; 0.01. The distribution for these sets is shown in <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>. The parameter sets used in <xref ref-type="fig" rid="fig3">Figures 3</xref>—<xref ref-type="fig" rid="fig7">7</xref> are provided in <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>.</p></sec><sec id="s4-4"><title>Modeling CML development</title><p>To model CML development in the presence of normal hematopoietic cells, we introduce a new leukemic cell type for each compartment. Each compartment is then composed of both normal and leukemic subcompartments, which exhibit feedback together as a single compartment. We assume the only difference between the two cell lineages is the feedback strength for leukemic HSC self-renewal. This small difference gives the leukemic lineage a competitive advantage for growth, consistent with the ability for leukemic HSC to initiate CML (<xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Holyoake and Vetrie, 2017</xref>) and the differential response of the normal and leukemic cells to CCL3 (<xref ref-type="bibr" rid="bib25">Eaves et al., 1993</xref>, <xref ref-type="bibr" rid="bib4">Baba et al., 2013</xref>), which negatively regulates stem cell self-renewal. The full equations used in the model are shown in Appendix 1, <xref ref-type="disp-formula" rid="equ33 equ34 equ35 equ36 equ37 equ38 equ39 equ40">Equations 30–37</xref>.</p></sec><sec id="s4-5"><title>Modeling transplant experiments</title><p>The model was tested by simulating the transplant experiments (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>) of <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref> where HSC<sup>L</sup> or MPP<sup>L</sup> were implanted into sublethally irradiated mice and terminal cell counts were measured after 35 d. We used two parallel lineages of leukemic cells with identical parameters to mirror the two leukemic cell populations of the experiment. To mimic the effects of sublethal radiation, we reduced the cell populations from their equilibrium values by variable amounts. The HSC<sup>L</sup> depletions varied between 50 and 70% and the MPP<sup>L</sup> depletions varied between 30 and 50% while both terminal cells were depleted by 10%. After depletion, an additional 4000 cells of either stem or progenitor types were transplanted in accordance with the experiment. We then discarded the 85 parameter sets that were not consistent with the results from <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>, leaving 478 eligible parameter sets. The results shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> used depletions of 55% for HSC<sup>L</sup>, 35% for MPP<sup>L</sup>s. See Appendix 1, Section 4 and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s3">3</xref> for results using other decrements, the discarded parameter sets, and the final parameter distributions.</p></sec><sec id="s4-6"><title>Modeling TKI therapy</title><p>To account for the treatment by TKIs, additional proliferation-dependent death terms are added to the equations for leukemic stem cells and leukemic progenitor cells shown in Appendix 1, <xref ref-type="disp-formula" rid="equ41 equ42">Equations 38 and 39</xref> (parameter values are given in <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>). These represent the ability of TKIs to induce cell death in the leukemic cells. Both cell types have unique death rates, to reflect TKIs having different efficacy in killing stem cells and progenitors. The death rates were selected using a single parameter set to ensure a reasonable biphasic curve for <italic>BCR-ABL1</italic> transcript levels compared to patient transcript levels from <xref ref-type="bibr" rid="bib34">Glauche et al., 2018</xref>. The same death rates were then used across every parameter set to ensure consistency. In addition to these changes upon initiation of TKI therapy, the leukemic stem cell division rate is reduced. This reduction models the ability of TKIs to drive leukemic stem cells to quiescence (<xref ref-type="bibr" rid="bib49">Jørgensen et al., 2006</xref>).</p><p>To approximate the <italic>BCR-ABL1</italic> transcript levels, we used a method based upon (<xref ref-type="bibr" rid="bib70">Michor et al., 2005</xref>). We use the cell counts of both normal and leukemic terminal cells for both myeloid and lymphoid lineages. The terminal cells are used as in our model they are the closest to peripheral blood in which transcript levels are measured clinically. This results in the following measure for <italic>BCR-ABL1</italic> transcript levels: <inline-formula><mml:math id="inf70"><mml:mfrac><mml:mrow><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mo>-</mml:mo><mml:mi>A</mml:mi><mml:mi>B</mml:mi><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msubsup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msubsup><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></inline-formula> .</p></sec><sec id="s4-7"><title>Modeling combined TKI and differentiation therapy</title><p>Combination therapy consists of simultaneously employing TKI therapy, described in ‘Methods’ and Appendix 1, Sections 2–3, and the addition of a new differentiation therapy. To model differentiation therapy, we altered the form of p<sub>0</sub> by including a new constant repressive force that affects both normal and leukemic self-renewal, resulting in <inline-formula><mml:math id="inf71"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> and <inline-formula><mml:math id="inf72"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>, where <inline-formula><mml:math id="inf73"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf74"><mml:mi mathvariant="normal">Δ</mml:mi></mml:math></inline-formula> is the differentiation therapy strength. We then performed combination therapy using our existing parameters, swept through differentiation therapy strengths and recorded which parameter sets achieved MR3 within 50 mo. We then determined that a differentiation therapy strength of D = 0.24 resulted in the highest proportion of parameter sets that achieved MR3 response. The full equations for combined TKI and differentiation therapy are shown in Appendix 1, <xref ref-type="disp-formula" rid="equ43 equ44">Equations 40 and 41</xref>.</p></sec><sec id="s4-8"><title>CML patient data</title><p>Data from newly diagnosed CML patients (n = 21) treated with TKI therapy at UCI Health were obtained under an honest broker mechanism from the electronic health record under Exemption 4 for human subjects research.</p></sec><sec id="s4-9"><title>Mice</title><p>C57BL/6J female mice (Jackson Laboratories), 6–12 wk of age were used for irradiation and myeloid depletion experiments. Conditional <italic>BCR-ABL1</italic> double transgenic mice (<xref ref-type="bibr" rid="bib52">Koschmieder et al., 2005</xref>) were obtained from Dr. Emmanuel Passegue (Columbia University). All protocols in mice were approved by the Institutional Animal Use and Care Committee of University of California, Irvine.</p></sec><sec id="s4-10"><title>Irradiation of mice</title><p>To achieve selective depletion of HSCs, a 50 cGy dose of irradiation from X-ray source (Precision X-rad 320) was applied. Control mice did not receive irradiation. The distribution of time points at which observations were made (days 1, 3, and 7 post-irradiation), and the number of mouse replicates to use at each time point (between 2 and 7, totaling 13 mice), were informed by our Bayesian hierarchical framework for optimal experimental design (<xref ref-type="bibr" rid="bib60">Lomeli et al., 2021</xref>).</p></sec><sec id="s4-11"><title>Myeloid cell depletion</title><p>RB6-8C5, an anti-Gr1 antibody (catalog # BE0075, BioXCell) or isotype control (catalog # BE0090, BioXCell) was injected intravenously, 50 µg per mouse, and mice sacrificed 24 hr later.</p></sec><sec id="s4-12"><title>BrdU injections</title><p>In irradiation experiments, mice were pulsed with BrdU by IP injection of 200 µl of 10 mg/ml BrdU in DPBS. BrdU flow kit (552598) from BD Biosciences was used for detection of BrdU labeling in hematopoietic cells by flow cytometry.</p></sec><sec id="s4-13"><title>Flow cytometry analysis of cell populations</title><p>BM cells from femur and tibia of control and dosed mice were isolated by flushing bones. Following lysis of red blood cells (RBC lysis buffer, eBiosciences), leukocytes were stained with CD34 antibody for 1 hr and subsequently incubated with a cocktail of biotinylated antibodies directed against lineage markers (CD3, Gr-1, B220, Ter119) and stem/progenitor markers (c-Kit, Sca-1, CD48) for 30 min. Streptavidin (SA)-conjugated fluorochrome was utilized to detect biotinylated antibodies. Following fixation, permeabilization, and DNase digestion, anti-BrdU antibody was used to assess BrdU incorporation. Events were acquired on FACS Arial II and analyzed with Flowjo v.10 software.</p></sec><sec id="s4-14"><title>Antibodies</title><p>Monoclonal antibodies for flow cytometry were biotinylated mouse lineage panel (559971, BD Biosciences), PE-CF594 Streptavidin (562318, BD Biosciences), anti-mouse CD48 (561242, BD Biosciences), anti-mouse CD34 eFluor450 (48-0341-82, eBiosciences), anti-mouse Sca-1-PE (108108, BioLegend), anti-mouse c-Kit-APC (17-1171-82, eBiosciences), and FITC BrdU flow kit (559619, BD Biosciences).</p></sec><sec id="s4-15"><title>Generation and TKI treatment of chimeric <italic>BCR-ABL1</italic> mice</title><p>The full details of the CML mouse model will be published elsewhere (Jena et al., in preparation). Briefly, BM cells from conditional <italic>BCR-ABL1</italic> double transgenic mice (CD45.2<sup>+</sup>) (Koschmieder, Gottgens et al. 2005) (40 million cells) were transplanted intravenously into unirradiated C57BL/6J recipients (CD45.1<sup>+</sup>CD45.2<sup>+</sup>) maintained on doxycycline to suppress <italic>BCR-ABL1</italic> expression. Two months post-transplant, doxycycline was removed to allow induction of CML-like leukemia. Chimerism was assessed by percentage of CD45.1<sup>–</sup> CD45.2<sup>+</sup> granulocytes in peripheral blood. To generate chimeric mice with high (&gt;90%) leukemic stem cell burden, the donor and recipient pair was reversed, with double transgenic mice transplanted with normal B6 BM. In mice with established CML-like leukemia (peripheral blood leukocytes &gt; 20,000/μl and &gt;40% circulating granulocytes), TKI treatment was initiated with dasatinib (25 mg/kg daily by oral gavage).</p></sec><sec id="s4-16"><title>Data availabality</title><p>Code used to generate the figures, determine the S-Systems and files containing parameter sets are found at the following GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/jonatdr/CML_Treatment">https://github.com/jonatdr/CML_Treatment</ext-link> (copy archived at <xref ref-type="bibr" rid="bib48">Jonatdr, 2023</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Software, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Supervision, Project administration</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol (AUP-19-159) of the University of California, Irvine.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84149-mdarchecklist1-v5.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Modelling code and parameter set data are available in a Github repository. Patient data is unavailable publicly as it could be used to potentially identify the patients. Deidentified raw patient transcript data will be made available to qualified researchers (academic or industry) upon request to Dr. Van Etten at vanetten@hs.uci.edu.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Iniguez</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Grid-search</data-title><source>GItHub</source><pub-id pub-id-type="accession" xlink:href="https://github.com/jonatdr/CML_Treatment/tree/main/Grid-search">Grid-search</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank the reviewers for their careful analysis of the manuscript and their suggestions, which significantly improved it. ADL, JSL, and RAV acknowledge the National Institutes of Health for partial support through grant nos. 1U54CA217378-01A1 for a National Center in Cancer Systems Biology at UC Irvine and P30CA062203 for the Chao Family Comprehensive Cancer Center at UC Irvine. In addition, ADL and JSL acknowledge support from DMS-1763272 and the Simons Foundation (594598QN) for an NSF-Simons Center for Multiscale Cell Fate Research, RAV acknowledges support from R01 CA090576. JSL also acknowledges NSF grants DMS-1936833 and DMS-1953410. JR and AI each acknowledge support from NSF graduate research fellowships.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>A</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name><name><surname>Hayakawa</surname><given-names>F</given-names></name><name><surname>Kitamura</surname><given-names>K</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Katsumi</surname><given-names>A</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Jamieson</surname><given-names>CHM</given-names></name><name><surname>Wang</surname><given-names>JYJ</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Retention but significant reduction of Bcr-Abl transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy</article-title><source>International Journal of Hematology</source><volume>88</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s12185-008-0221-1</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agathocleous</surname><given-names>M</given-names></name><name><surname>Meacham</surname><given-names>CE</given-names></name><name><surname>Burgess</surname><given-names>RJ</given-names></name><name><surname>Piskounova</surname><given-names>E</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Crane</surname><given-names>GM</given-names></name><name><surname>Cowin</surname><given-names>BL</given-names></name><name><surname>Bruner</surname><given-names>E</given-names></name><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Spangrude</surname><given-names>GJ</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ascorbate regulates haematopoietic stem cell function and leukaemogenesis</article-title><source>Nature</source><volume>549</volume><fpage>476</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1038/nature23876</pub-id><pub-id pub-id-type="pmid">28825709</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Press</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Measurement of BCR-Abl1 transcripts on the International scale in the United States: Current status and best practices</article-title><source>Leukemia &amp; Lymphoma</source><volume>58</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1080/10428194.2016.1190974</pub-id><pub-id pub-id-type="pmid">27412040</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Naka</surname><given-names>K</given-names></name><name><surname>Morishita</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>N</given-names></name><name><surname>Hirao</surname><given-names>A</given-names></name><name><surname>Mukaida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>2661</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.1084/jem.20130112</pub-id><pub-id pub-id-type="pmid">24166712</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Tanabe</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>S</given-names></name><name><surname>Yamanishi</surname><given-names>Y</given-names></name><name><surname>Morishita</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>N</given-names></name><name><surname>Karasuyama</surname><given-names>H</given-names></name><name><surname>Hirao</surname><given-names>A</given-names></name><name><surname>Mukaida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice</article-title><source>Blood</source><volume>127</volume><fpage>2607</fpage><lpage>2617</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-10-673087</pub-id><pub-id pub-id-type="pmid">27006388</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banck</surname><given-names>JC</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>In-Silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment</article-title><source>BMC Systems Biology</source><volume>13</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s12918-019-0684-0</pub-id><pub-id pub-id-type="pmid">30704476</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Hodgson</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>HH</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Quilici</surname><given-names>C</given-names></name><name><surname>Dunn</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>&quot;Emergency&quot; granulopoiesis in G-CSF-deficient mice in response to <italic>Candida albicans</italic> infection</article-title><source>Blood</source><volume>95</volume><fpage>3725</fpage><lpage>3733</lpage><pub-id pub-id-type="pmid">10845903</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Yeung</surname><given-names>DT</given-names></name><name><surname>Parker</surname><given-names>WT</given-names></name><name><surname>Roberts</surname><given-names>ND</given-names></name><name><surname>Purins</surname><given-names>L</given-names></name><name><surname>Braley</surname><given-names>JA</given-names></name><name><surname>Altamura</surname><given-names>HK</given-names></name><name><surname>Yeoman</surname><given-names>AL</given-names></name><name><surname>Georgievski</surname><given-names>J</given-names></name><name><surname>Jamison</surname><given-names>BA</given-names></name><name><surname>Phillis</surname><given-names>S</given-names></name><name><surname>Donaldson</surname><given-names>Z</given-names></name><name><surname>Leong</surname><given-names>M</given-names></name><name><surname>Fletcher</surname><given-names>L</given-names></name><name><surname>Seymour</surname><given-names>JF</given-names></name><name><surname>Grigg</surname><given-names>AP</given-names></name><name><surname>Ross</surname><given-names>DM</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prognosis for patients with CML and &gt; 10 % BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</article-title><source>Blood</source><volume>124</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-03-566323</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Sherry</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Carow</surname><given-names>C</given-names></name><name><surname>Wolpe</surname><given-names>SD</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells</article-title><source>The Journal of Experimental Medicine</source><volume>170</volume><fpage>1583</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1084/jem.170.5.1583</pub-id><pub-id pub-id-type="pmid">2478652</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunetti</surname><given-names>M</given-names></name><name><surname>Mackey</surname><given-names>MC</given-names></name><name><surname>Craig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Understanding normal and pathological hematopoietic stem cell biology using mathematical modelling</article-title><source>Current Stem Cell Reports</source><volume>7</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s40778-021-00191-9</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzi</surname><given-names>G</given-names></name><name><surname>Lander</surname><given-names>AD</given-names></name><name><surname>Khammash</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell lineage branching as a strategy for proliferative control</article-title><source>BMC Biology</source><volume>13</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-015-0122-8</pub-id><pub-id pub-id-type="pmid">25857410</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasty</surname><given-names>RC</given-names></name><name><surname>Lucas</surname><given-names>GS</given-names></name><name><surname>Owen-Lynch</surname><given-names>PJ</given-names></name><name><surname>Pierce</surname><given-names>A</given-names></name><name><surname>Whetton</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia</article-title><source>Blood</source><volume>86</volume><fpage>4270</fpage><lpage>4277</lpage><pub-id pub-id-type="pmid">7492787</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KK</given-names></name><name><surname>Du</surname><given-names>TF</given-names></name><name><surname>Xiong</surname><given-names>PS</given-names></name><name><surname>Fan</surname><given-names>GH</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>372</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00372</pub-id><pub-id pub-id-type="pmid">31139566</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chereda</surname><given-names>B</given-names></name><name><surname>Melo</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Natural course and biology of CML</article-title><source>Annals of Hematology</source><volume>94 Suppl 2</volume><fpage>S107</fpage><lpage>S121</lpage><pub-id pub-id-type="doi">10.1007/s00277-015-2325-z</pub-id><pub-id pub-id-type="pmid">25814077</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimmino</surname><given-names>L</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yoshimi</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>GH</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>V</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Witkowski</surname><given-names>MT</given-names></name><name><surname>Mitchell-Flack</surname><given-names>M</given-names></name><name><surname>Grillo</surname><given-names>I</given-names></name><name><surname>Bakogianni</surname><given-names>S</given-names></name><name><surname>Ndiaye-Lobry</surname><given-names>D</given-names></name><name><surname>Martín</surname><given-names>MT</given-names></name><name><surname>Guillamot</surname><given-names>M</given-names></name><name><surname>Banh</surname><given-names>RS</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Dickins</surname><given-names>RA</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Tsirigos</surname><given-names>A</given-names></name><name><surname>Neel</surname><given-names>BG</given-names></name><name><surname>Aifantis</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Restoration of TET2 function blocks aberrant self-renewal and leukemia progression</article-title><source>Cell</source><volume>170</volume><fpage>1079</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.032</pub-id><pub-id pub-id-type="pmid">28823558</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbin</surname><given-names>AS</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Loriaux</surname><given-names>M</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of Bcr-Abl activity</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>396</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1172/JCI35721</pub-id><pub-id pub-id-type="pmid">21157039</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Boqué</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Chuah</surname><given-names>C</given-names></name><name><surname>Casanova</surname><given-names>L</given-names></name><name><surname>Bradley-Garelik</surname><given-names>B</given-names></name><name><surname>Manos</surname><given-names>G</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>2333</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.8899</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowell</surname><given-names>HL</given-names></name><name><surname>MacLean</surname><given-names>AL</given-names></name><name><surname>Stumpf</surname><given-names>MPH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Feedback mechanisms control coexistence in a stem cell model of acute myeloid leukaemia</article-title><source>Journal of Theoretical Biology</source><volume>401</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2016.04.002</pub-id><pub-id pub-id-type="pmid">27130539</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devireddy</surname><given-names>LR</given-names></name><name><surname>Gazin</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake</article-title><source>Cell</source><volume>123</volume><fpage>1293</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.10.027</pub-id><pub-id pub-id-type="pmid">16377569</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Blanco</surname><given-names>E</given-names></name><name><surname>Bruns</surname><given-names>I</given-names></name><name><surname>Neumann</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>JC</given-names></name><name><surname>Graef</surname><given-names>T</given-names></name><name><surname>Rosskopf</surname><given-names>M</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Pechtel</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Baer</surname><given-names>A</given-names></name><name><surname>Rohr</surname><given-names>U-P</given-names></name><name><surname>Kobbe</surname><given-names>G</given-names></name><name><surname>von Haeseler</surname><given-names>A</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><name><surname>Haas</surname><given-names>R</given-names></name><name><surname>Kronenwett</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Molecular signature of CD34 (+) hematopoietic stem and progenitor cells of patients with CML in chronic phase</article-title><source>Leukemia</source><volume>21</volume><fpage>494</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404549</pub-id><pub-id pub-id-type="pmid">17252012</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingli</surname><given-names>D</given-names></name><name><surname>Traulsen</surname><given-names>A</given-names></name><name><surname>Lenaerts</surname><given-names>T</given-names></name><name><surname>Pacheco</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Evolutionary dynamics of chronic myeloid leukemia</article-title><source>Genes &amp; Cancer</source><volume>1</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1177/1947601910371122</pub-id><pub-id pub-id-type="pmid">21779452</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>KN</given-names></name><name><surname>Jaksik</surname><given-names>R</given-names></name><name><surname>Corey</surname><given-names>SJ</given-names></name><name><surname>Kimmel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data</article-title><source>Computational and Systems Oncology</source><volume>1</volume><elocation-id>e1026</elocation-id><pub-id pub-id-type="doi">10.1002/cso2.1026</pub-id><pub-id pub-id-type="pmid">34541576</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drumea</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Rosmarin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Retinoic acid signaling in myelopoiesis</article-title><source>Current Opinion in Hematology</source><volume>15</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1097/MOH.0b013e3282f20a9c</pub-id><pub-id pub-id-type="pmid">18043244</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dürig</surname><given-names>J</given-names></name><name><surname>Testa</surname><given-names>NG</given-names></name><name><surname>Lord</surname><given-names>BI</given-names></name><name><surname>Kasper</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Telford</surname><given-names>N</given-names></name><name><surname>Dexter</surname><given-names>TM</given-names></name><name><surname>Heyworth</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Characterisation of the differential response of normal and CML haemopoietic progenitor cells to macrophage inflammatory protein-1alpha</article-title><source>Leukemia</source><volume>13</volume><fpage>2012</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401610</pub-id><pub-id pub-id-type="pmid">10602423</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Cashman</surname><given-names>JD</given-names></name><name><surname>Wolpe</surname><given-names>SD</given-names></name><name><surname>Eaves</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells</article-title><source>PNAS</source><volume>90</volume><fpage>12015</fpage><lpage>12019</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.24.12015</pub-id><pub-id pub-id-type="pmid">8265663</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>C</given-names></name><name><surname>Scholz</surname><given-names>M</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy</article-title><source>Blood</source><volume>104</volume><fpage>2323</fpage><lpage>2331</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0306</pub-id><pub-id pub-id-type="pmid">15226178</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>D</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A quantitative paradigm for decision-making in precision oncology</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.01.006</pub-id><pub-id pub-id-type="pmid">33637444</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression</article-title><source>Seminars in Oncology</source><volume>39</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2011.11.002</pub-id><pub-id pub-id-type="pmid">22289492</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essers</surname><given-names>MAG</given-names></name><name><surname>Offner</surname><given-names>S</given-names></name><name><surname>Blanco-Bose</surname><given-names>WE</given-names></name><name><surname>Waibler</surname><given-names>Z</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Duchosal</surname><given-names>MA</given-names></name><name><surname>Trumpp</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>IFNalpha activates dormant haematopoietic stem cells in vivo</article-title><source>Nature</source><volume>458</volume><fpage>904</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1038/nature07815</pub-id><pub-id pub-id-type="pmid">19212321</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etienne</surname><given-names>G</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Rea</surname><given-names>D</given-names></name><name><surname>Rigal-Huguet</surname><given-names>F</given-names></name><name><surname>Nicolini</surname><given-names>F</given-names></name><name><surname>Charbonnier</surname><given-names>A</given-names></name><name><surname>Guerci-Bresler</surname><given-names>A</given-names></name><name><surname>Legros</surname><given-names>L</given-names></name><name><surname>Varet</surname><given-names>B</given-names></name><name><surname>Gardembas</surname><given-names>M</given-names></name><name><surname>Dubruille</surname><given-names>V</given-names></name><name><surname>Tulliez</surname><given-names>M</given-names></name><name><surname>Noel</surname><given-names>M-P</given-names></name><name><surname>Ianotto</surname><given-names>J-C</given-names></name><name><surname>Villemagne</surname><given-names>B</given-names></name><name><surname>Carré</surname><given-names>M</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Mahon</surname><given-names>F-X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Long-Term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia</article-title><source>Journal of Clinical Oncology</source><volume>35</volume><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.68.2914</pub-id><pub-id pub-id-type="pmid">28095277</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasani</surname><given-names>RA</given-names></name><name><surname>Savageau</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Automated construction and analysis of the design space for biochemical systems</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2601</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq479</pub-id><pub-id pub-id-type="pmid">20823298</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>J</given-names></name><name><surname>Drummond</surname><given-names>MW</given-names></name><name><surname>Clarkson</surname><given-names>B</given-names></name><name><surname>Holyoake</surname><given-names>T</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib</article-title><source>PLOS Computational Biology</source><volume>5</volume><elocation-id>e1000503</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000503</pub-id><pub-id pub-id-type="pmid">19749982</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambacorti-Passerini</surname><given-names>C</given-names></name><name><surname>Antolini</surname><given-names>L</given-names></name><name><surname>Mahon</surname><given-names>F-X</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Fava</surname><given-names>C</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Della Casa</surname><given-names>CM</given-names></name><name><surname>Morra</surname><given-names>E</given-names></name><name><surname>Abruzzese</surname><given-names>E</given-names></name><name><surname>D’Emilio</surname><given-names>A</given-names></name><name><surname>Stagno</surname><given-names>F</given-names></name><name><surname>le Coutre</surname><given-names>P</given-names></name><name><surname>Hurtado-Monroy</surname><given-names>R</given-names></name><name><surname>Santini</surname><given-names>V</given-names></name><name><surname>Martino</surname><given-names>B</given-names></name><name><surname>Pane</surname><given-names>F</given-names></name><name><surname>Piccin</surname><given-names>A</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><name><surname>Durosinmi</surname><given-names>MA</given-names></name><name><surname>Leeksma</surname><given-names>O</given-names></name><name><surname>Pogliani</surname><given-names>EM</given-names></name><name><surname>Puttini</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>E</given-names></name><name><surname>Reiffers</surname><given-names>J</given-names></name><name><surname>Piazza</surname><given-names>R</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name><name><surname>Kim</surname><given-names>D-W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib</article-title><source>Journal of the National Cancer Institute</source><volume>103</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr060</pub-id><pub-id pub-id-type="pmid">21422402</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glauche</surname><given-names>I</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Baldow</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>P</given-names></name><name><surname>Rothe</surname><given-names>T</given-names></name><name><surname>Liebscher</surname><given-names>H</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Roeder</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Quantitative prediction of long-term molecular response in TKI-treated CML-lessons from an imatinib versus dasatinib comparison</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>12330</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-29923-4</pub-id><pub-id pub-id-type="pmid">30120281</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>SM</given-names></name><name><surname>Jørgensen</surname><given-names>HG</given-names></name><name><surname>Allan</surname><given-names>E</given-names></name><name><surname>Pearson</surname><given-names>C</given-names></name><name><surname>Alcorn</surname><given-names>MJ</given-names></name><name><surname>Richmond</surname><given-names>L</given-names></name><name><surname>Holyoake</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro</article-title><source>Blood</source><volume>99</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1182/blood.v99.1.319</pub-id><pub-id pub-id-type="pmid">11756187</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hähnel</surname><given-names>T</given-names></name><name><surname>Baldow</surname><given-names>C</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Mustjoki</surname><given-names>S</given-names></name><name><surname>Jilg</surname><given-names>S</given-names></name><name><surname>Jost</surname><given-names>PJ</given-names></name><name><surname>Dulucq</surname><given-names>S</given-names></name><name><surname>Mahon</surname><given-names>FX</given-names></name><name><surname>Roeder</surname><given-names>I</given-names></name><name><surname>Fassoni</surname><given-names>AC</given-names></name><name><surname>Glauche</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Model-Based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with CML</article-title><source>Cancer Research</source><volume>80</volume><fpage>2394</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2175</pub-id><pub-id pub-id-type="pmid">32041835</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanfstein</surname><given-names>B</given-names></name><name><surname>Müller</surname><given-names>MC</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Erben</surname><given-names>P</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Fabarius</surname><given-names>A</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Göhring</surname><given-names>G</given-names></name><name><surname>Proetel</surname><given-names>U</given-names></name><name><surname>Kolb</surname><given-names>H-J</given-names></name><name><surname>Krause</surname><given-names>SW</given-names></name><name><surname>Hofmann</surname><given-names>W-K</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Dengler</surname><given-names>J</given-names></name><name><surname>Hänel</surname><given-names>M</given-names></name><name><surname>Falge</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Kneba</surname><given-names>M</given-names></name><name><surname>Stegelmann</surname><given-names>F</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name><name><surname>Waller</surname><given-names>CF</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Saußele</surname><given-names>S</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><collab>SAKK</collab><collab>German CML Study Group</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)</article-title><source>Leukemia</source><volume>26</volume><fpage>2096</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.85</pub-id><pub-id pub-id-type="pmid">22446502</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanfstein</surname><given-names>B</given-names></name><name><surname>Shlyakhto</surname><given-names>V</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Dietz</surname><given-names>C</given-names></name><name><surname>Erben</surname><given-names>P</given-names></name><name><surname>Fabarius</surname><given-names>A</given-names></name><name><surname>Proetel</surname><given-names>U</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>SW</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Hänel</surname><given-names>M</given-names></name><name><surname>Dengler</surname><given-names>J</given-names></name><name><surname>Falge</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Kneba</surname><given-names>M</given-names></name><name><surname>Stegelmann</surname><given-names>F</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name><name><surname>Waller</surname><given-names>CF</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Hofmann</surname><given-names>W-K</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MC</given-names></name><collab>SAKK and the German CML Study Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Velocity of early Bcr-Abl transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib</article-title><source>Leukemia</source><volume>28</volume><fpage>1988</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1038/leu.2014.153</pub-id><pub-id pub-id-type="pmid">24798484</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Voskanyan</surname><given-names>A</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Kalmanti</surname><given-names>L</given-names></name><name><surname>Rinaldetti</surname><given-names>S</given-names></name><name><surname>Kohlbrenner</surname><given-names>K</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Fabarius</surname><given-names>A</given-names></name><name><surname>Seifarth</surname><given-names>W</given-names></name><name><surname>Spieß</surname><given-names>B</given-names></name><name><surname>Wuchter</surname><given-names>P</given-names></name><name><surname>Krause</surname><given-names>S</given-names></name><name><surname>Kolb</surname><given-names>H-J</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Hossfeld</surname><given-names>DK</given-names></name><name><surname>Nerl</surname><given-names>C</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Burchert</surname><given-names>A</given-names></name><name><surname>Brümmendorf</surname><given-names>TH</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Saußele</surname><given-names>S</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><collab>SAKK and the German CML Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>High-risk additional Chromosomal abnormalities at low blast counts Herald death by CML</article-title><source>Leukemia</source><volume>34</volume><fpage>2074</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-01039-7</pub-id><pub-id pub-id-type="pmid">32913312</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Fujihara</surname><given-names>S</given-names></name><name><surname>Ortmann</surname><given-names>C-E</given-names></name><name><surname>Menssen</surname><given-names>HD</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>O’Brien</surname><given-names>SG</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><collab>IRIS Investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Long-Term outcomes of imatinib treatment for chronic myeloid leukemia</article-title><source>The New England Journal of Medicine</source><volume>376</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1609324</pub-id><pub-id pub-id-type="pmid">28273028</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>K</given-names></name><name><surname>Cazemier</surname><given-names>K</given-names></name><name><surname>Baldow</surname><given-names>C</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Kheifetz</surname><given-names>Y</given-names></name><name><surname>Schirm</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>M</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Volgmann</surname><given-names>C</given-names></name><name><surname>Thiede</surname><given-names>C</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Bornhäuser</surname><given-names>M</given-names></name><name><surname>Suttorp</surname><given-names>M</given-names></name><name><surname>Scholz</surname><given-names>M</given-names></name><name><surname>Glauche</surname><given-names>I</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Roeder</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology</article-title><source>BMC Medical Informatics and Decision Making</source><volume>20</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/s12911-020-1039-x</pub-id><pub-id pub-id-type="pmid">32041606</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holyoake</surname><given-names>TL</given-names></name><name><surname>Vetrie</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The chronic myeloid leukemia stem cell: stemming the tide of persistence</article-title><source>Blood</source><volume>129</volume><fpage>1595</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-696013</pub-id><pub-id pub-id-type="pmid">28159740</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>M</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Roeder</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mathematical modeling of genesis and treatment of chronic myeloid leukemia</article-title><source>Cells Tissues Organs</source><volume>188</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1159/000118786</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huntly</surname><given-names>BJP</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Deguchi</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Duclos</surname><given-names>N</given-names></name><name><surname>Rowan</surname><given-names>R</given-names></name><name><surname>Amaral</surname><given-names>S</given-names></name><name><surname>Curley</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>IR</given-names></name><name><surname>Akashi</surname><given-names>K</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors</article-title><source>Cancer Cell</source><volume>6</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.10.015</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>CHM</given-names></name><name><surname>Ailles</surname><given-names>LE</given-names></name><name><surname>Dylla</surname><given-names>SJ</given-names></name><name><surname>Muijtjens</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Zehnder</surname><given-names>JL</given-names></name><name><surname>Gotlib</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Keating</surname><given-names>A</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Granulocyte-Macrophage progenitors as candidate leukemic stem cells in blast-crisis CML</article-title><source>The New England Journal of Medicine</source><volume>351</volume><fpage>657</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040258</pub-id><pub-id pub-id-type="pmid">15306667</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name><name><surname>Holyoake</surname><given-names>T</given-names></name><name><surname>Eaves</surname><given-names>A</given-names></name><name><surname>Eaves</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia</article-title><source>PNAS</source><volume>96</volume><fpage>12804</fpage><lpage>12809</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.22.12804</pub-id><pub-id pub-id-type="pmid">10536003</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Feedback regulation in a stem cell model with acute myeloid leukaemia</article-title><source>BMC Systems Biology</source><volume>12</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/s12918-018-0561-2</pub-id><pub-id pub-id-type="pmid">29745850</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Jonatdr</collab></person-group><year iso-8601-date="2023">2023</year><data-title>Cml_Treatment</data-title><version designator="swh:1:rev:91df5a6dd841d97a2dbca6bc42a976749cfe52e3">swh:1:rev:91df5a6dd841d97a2dbca6bc42a976749cfe52e3</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:da99de56554580a4b5587d9e436d18a766b54666;origin=https://github.com/jonatdr/CML_Treatment;visit=swh:1:snp:3a06846de4b04be3e2803bcf1a288be5d98d3b30;anchor=swh:1:rev:91df5a6dd841d97a2dbca6bc42a976749cfe52e3">https://archive.softwareheritage.org/swh:1:dir:da99de56554580a4b5587d9e436d18a766b54666;origin=https://github.com/jonatdr/CML_Treatment;visit=swh:1:snp:3a06846de4b04be3e2803bcf1a288be5d98d3b30;anchor=swh:1:rev:91df5a6dd841d97a2dbca6bc42a976749cfe52e3</ext-link></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>HG</given-names></name><name><surname>Copland</surname><given-names>M</given-names></name><name><surname>Allan</surname><given-names>EK</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Eaves</surname><given-names>A</given-names></name><name><surname>Eaves</surname><given-names>C</given-names></name><name><surname>Holyoake</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate</article-title><source>Clinical Cancer Research</source><volume>12</volume><fpage>626</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0429</pub-id><pub-id pub-id-type="pmid">16428509</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Tyndel</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>J-S</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>Y-K</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lipton</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>DDH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy</article-title><source>Blood</source><volume>129</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-04-708560</pub-id><pub-id pub-id-type="pmid">27733357</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komarova</surname><given-names>NL</given-names></name><name><surname>Wodarz</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effect of cellular quiescence on the success of targeted CML therapy</article-title><source>PLOS ONE</source><volume>2</volume><elocation-id>e990</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000990</pub-id><pub-id pub-id-type="pmid">17912367</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koschmieder</surname><given-names>S</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Iwasaki-Arai</surname><given-names>J</given-names></name><name><surname>Akashi</surname><given-names>K</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Dayaram</surname><given-names>T</given-names></name><name><surname>Geary</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Huettner</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of Bcr-Abl leukemogenesis</article-title><source>Blood</source><volume>105</volume><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-12-4369</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Fulzele</surname><given-names>K</given-names></name><name><surname>Catic</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>CC</given-names></name><name><surname>Dombkowski</surname><given-names>D</given-names></name><name><surname>Hurley</surname><given-names>MP</given-names></name><name><surname>Lezeau</surname><given-names>S</given-names></name><name><surname>Attar</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Divieti-Pajevic</surname><given-names>P</given-names></name><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Schipani</surname><given-names>E</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential regulation of myeloid leukemias by the bone marrow microenvironment</article-title><source>Nature Medicine</source><volume>19</volume><fpage>1513</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1038/nm.3364</pub-id><pub-id pub-id-type="pmid">24162813</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krinner</surname><given-names>A</given-names></name><name><surname>Roeder</surname><given-names>I</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Scholz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Merging concepts-coupling an agent-based model of hematopoietic stem cells with an Ode model of granulopoiesis</article-title><source>BMC Systems Biology</source><volume>7</volume><elocation-id>117</elocation-id><pub-id pub-id-type="doi">10.1186/1752-0509-7-117</pub-id><pub-id pub-id-type="pmid">24180697</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname><given-names>M</given-names></name><name><surname>Clairambault</surname><given-names>J</given-names></name><name><surname>Volpert</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Improving cancer treatments via dynamical biophysical models</article-title><source>Physics of Life Reviews</source><volume>39</volume><fpage>1</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.plrev.2021.10.001</pub-id><pub-id pub-id-type="pmid">34688561</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanism of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Revealed by a Computational Model of CML Evolution</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.05.20.492875</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lander</surname><given-names>AD</given-names></name><name><surname>Gokoffski</surname><given-names>KK</given-names></name><name><surname>Wan</surname><given-names>FYM</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>Calof</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cell lineages and the logic of proliferative control</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e15</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000015</pub-id><pub-id pub-id-type="pmid">19166268</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>ID</given-names></name><name><surname>McDiarmid</surname><given-names>LA</given-names></name><name><surname>Samels</surname><given-names>LM</given-names></name><name><surname>To</surname><given-names>LB</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells</article-title><source>Blood</source><volume>91</volume><fpage>630</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">9427719</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liggett</surname><given-names>LA</given-names></name><name><surname>Sankaran</surname><given-names>VG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Unraveling hematopoiesis through the lens of genomics</article-title><source>Cell</source><volume>182</volume><fpage>1384</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.030</pub-id><pub-id pub-id-type="pmid">32946781</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomeli</surname><given-names>LM</given-names></name><name><surname>Iniguez</surname><given-names>A</given-names></name><name><surname>Tata</surname><given-names>P</given-names></name><name><surname>Jena</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Z-Y</given-names></name><name><surname>Van Etten</surname><given-names>R</given-names></name><name><surname>Lander</surname><given-names>AD</given-names></name><name><surname>Shahbaba</surname><given-names>B</given-names></name><name><surname>Lowengrub</surname><given-names>JS</given-names></name><name><surname>Minin</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Optimal experimental design for mathematical models of haematopoiesis</article-title><source>Journal of the Royal Society, Interface</source><volume>18</volume><elocation-id>20200729</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2020.0729</pub-id><pub-id pub-id-type="pmid">33499768</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomnitz</surname><given-names>JG</given-names></name><name><surname>Savageau</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phenotypic deconstruction of gene circuitry</article-title><source>Chaos</source><volume>23</volume><elocation-id>025108</elocation-id><pub-id pub-id-type="doi">10.1063/1.4809776</pub-id><pub-id pub-id-type="pmid">23822506</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomnitz</surname><given-names>JG</given-names></name><name><surname>Savageau</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid discrimination among putative mechanistic models of biochemical systems</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>32375</elocation-id><pub-id pub-id-type="doi">10.1038/srep32375</pub-id><pub-id pub-id-type="pmid">27578053</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>AL</given-names></name><name><surname>Filippi</surname><given-names>S</given-names></name><name><surname>Stumpf</surname><given-names>MPH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia</article-title><source>PNAS</source><volume>111</volume><fpage>3883</fpage><lpage>3888</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317072111</pub-id><pub-id pub-id-type="pmid">24567385</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahadik</surname><given-names>B</given-names></name><name><surname>Hannon</surname><given-names>B</given-names></name><name><surname>Harley</surname><given-names>BAC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A computational model of feedback-mediated hematopoietic stem cell differentiation in vitro</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0212502</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0212502</pub-id><pub-id pub-id-type="pmid">30822334</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Jamieson</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>WW</given-names></name><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Leeper</surname><given-names>NJ</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Clonal expansion of stem/progenitor cells in cancer, fibrotic diseases, and atherosclerosis, and CD47 protection of pathogenic cells</article-title><source>Annual Review of Medicine</source><volume>73</volume><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-042420-104436</pub-id><pub-id pub-id-type="pmid">35084991</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manesso</surname><given-names>E</given-names></name><name><surname>Teles</surname><given-names>J</given-names></name><name><surname>Bryder</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamical modelling of haematopoiesis: an integrated view over the system in homeostasis and under perturbation</article-title><source>Journal of The Royal Society Interface</source><volume>10</volume><elocation-id>20120817</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2012.0817</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Jäger</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Modeling of asymmetric cell division in hematopoietic stem cells -- regulation of self-renewal is essential for efficient repopulation</article-title><source>Stem Cells and Development</source><volume>18</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1089/scd.2008.0143</pub-id><pub-id pub-id-type="pmid">18752377</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Hedgley</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>RE</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Foroni</surname><given-names>L</given-names></name><name><surname>Milojkovic</surname><given-names>D</given-names></name><name><surname>Pocock</surname><given-names>C</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>O’Brien</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib</article-title><source>Blood</source><volume>120</volume><fpage>291</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-01-407486</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marum</surname><given-names>JE</given-names></name><name><surname>Yeung</surname><given-names>DT</given-names></name><name><surname>Purins</surname><given-names>L</given-names></name><name><surname>Reynolds</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>WT</given-names></name><name><surname>Stangl</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>PPS</given-names></name><name><surname>Price</surname><given-names>DJ</given-names></name><name><surname>Tuke</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>AW</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Asxl1 and Bim germ line variants predict response and identify CML patients with the greatest risk of imatinib failure</article-title><source>Blood Advances</source><volume>1</volume><fpage>1369</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017006825</pub-id><pub-id pub-id-type="pmid">29296778</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Iwasa</surname><given-names>Y</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamics of chronic myeloid leukaemia</article-title><source>Nature</source><volume>435</volume><fpage>1267</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1038/nature03669</pub-id><pub-id pub-id-type="pmid">15988530</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mon Père</surname><given-names>NV</given-names></name><name><surname>Lenaerts</surname><given-names>T</given-names></name><name><surname>Pacheco</surname><given-names>JMDS</given-names></name><name><surname>Dingli</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multistage feedback-driven compartmental dynamics of hematopoiesis</article-title><source>IScience</source><volume>24</volume><elocation-id>102326</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102326</pub-id><pub-id pub-id-type="pmid">33889822</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naka</surname><given-names>K</given-names></name><name><surname>Hoshii</surname><given-names>T</given-names></name><name><surname>Muraguchi</surname><given-names>T</given-names></name><name><surname>Tadokoro</surname><given-names>Y</given-names></name><name><surname>Ooshio</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Nakao</surname><given-names>S</given-names></name><name><surname>Motoyama</surname><given-names>N</given-names></name><name><surname>Hirao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia</article-title><source>Nature</source><volume>463</volume><fpage>676</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/nature08734</pub-id><pub-id pub-id-type="pmid">20130650</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naka</surname><given-names>K</given-names></name><name><surname>Hirao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of hematopoiesis and hematological disease by TGF-β family signaling molecules</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a027987</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a027987</pub-id><pub-id pub-id-type="pmid">28193723</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parekh</surname><given-names>C</given-names></name><name><surname>Crooks</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Critical differences in hematopoiesis and lymphoid development between humans and mice</article-title><source>Journal of Clinical Immunology</source><volume>33</volume><fpage>711</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1007/s10875-012-9844-3</pub-id><pub-id pub-id-type="pmid">23274800</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Akuffo</surname><given-names>AA</given-names></name><name><surname>Muench</surname><given-names>DE</given-names></name><name><surname>Grimes</surname><given-names>HL</given-names></name><name><surname>Epling-Burnette</surname><given-names>PK</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Anderson</surname><given-names>ARA</given-names></name><name><surname>Bonsall</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006913</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006913</pub-id><pub-id pub-id-type="pmid">31026273</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>RK</given-names></name><name><surname>Andersen</surname><given-names>M</given-names></name><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Ottesen</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mathematical modelling of the hematopoietic stem cell-niche system: clonal dominance based on stem cell fitness</article-title><source>Journal of Theoretical Biology</source><volume>518</volume><elocation-id>110620</elocation-id><pub-id pub-id-type="doi">10.1016/j.jtbi.2021.110620</pub-id><pub-id pub-id-type="pmid">33587928</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennisi</surname><given-names>MS</given-names></name><name><surname>Stella</surname><given-names>S</given-names></name><name><surname>Vitale</surname><given-names>SR</given-names></name><name><surname>Puma</surname><given-names>A</given-names></name><name><surname>Di Gregorio</surname><given-names>S</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name><name><surname>Tirrò</surname><given-names>E</given-names></name><name><surname>Massimino</surname><given-names>M</given-names></name><name><surname>Antolino</surname><given-names>A</given-names></name><name><surname>Siragusa</surname><given-names>S</given-names></name><name><surname>Mannina</surname><given-names>D</given-names></name><name><surname>Impera</surname><given-names>S</given-names></name><name><surname>Musolino</surname><given-names>C</given-names></name><name><surname>Mineo</surname><given-names>G</given-names></name><name><surname>Martino</surname><given-names>B</given-names></name><name><surname>Zammit</surname><given-names>V</given-names></name><name><surname>Di Raimondo</surname><given-names>F</given-names></name><name><surname>Manzella</surname><given-names>L</given-names></name><name><surname>Stagno</surname><given-names>F</given-names></name><name><surname>Vigneri</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bcr-Abl1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>764</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00764</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petzer</surname><given-names>AL</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Ponchio</surname><given-names>L</given-names></name><name><surname>Barnett</surname><given-names>MJ</given-names></name><name><surname>Eaves</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia</article-title><source>Blood</source><volume>88</volume><fpage>2162</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1182/blood.V88.6.2162.bloodjournal8862162</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietarinen</surname><given-names>P</given-names></name><name><surname>Koskenvesa</surname><given-names>P</given-names></name><name><surname>Klievink</surname><given-names>J</given-names></name><name><surname>Porkka</surname><given-names>K</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Mustjoki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cml patients with primary resistance or suboptimal response to TKI therapy have variants in genes affecting drug absorption and metabolism</article-title><source>Blood</source><volume>128</volume><elocation-id>3071</elocation-id><pub-id pub-id-type="doi">10.1182/blood.V128.22.3071.3071</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujo-Menjouet</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Blood cell Dynamics: half of a century of modeling</article-title><source>Mathematical Modelling of Natural Phenomena</source><volume>10</volume><fpage>182</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1051/mmnp/201611106</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintás-Cardama</surname><given-names>A</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular biology of bcr-abl1–positive chronic myeloid leukemia</article-title><source>Blood</source><volume>113</volume><fpage>1619</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-144790</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>MN</given-names></name><name><surname>Alden</surname><given-names>K</given-names></name><name><surname>Timmis</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Strategies for calibrating models of biology</article-title><source>Briefings in Bioinformatics</source><volume>21</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/bib/bby092</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynaud</surname><given-names>D</given-names></name><name><surname>Pietras</surname><given-names>E</given-names></name><name><surname>Barry-Holson</surname><given-names>K</given-names></name><name><surname>Mir</surname><given-names>A</given-names></name><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Jeanne</surname><given-names>M</given-names></name><name><surname>Sala-Torra</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Il-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development</article-title><source>Cancer Cell</source><volume>20</volume><fpage>661</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.10.012</pub-id><pub-id pub-id-type="pmid">22094259</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieger</surname><given-names>MA</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hematopoiesis</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a008250</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a008250</pub-id><pub-id pub-id-type="pmid">23209149</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Iniguez</surname><given-names>A</given-names></name><name><surname>Jena</surname><given-names>N</given-names></name><name><surname>Tata</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lander</surname><given-names>AD</given-names></name><name><surname>Lowengrub</surname><given-names>JS</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Predictive Nonlinear Modeling of Malignant Myelopoiesis and Tyrosine Kinase Inhibitor Therapy</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.10.11.511822</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeder</surname><given-names>I</given-names></name><name><surname>Horn</surname><given-names>M</given-names></name><name><surname>Glauche</surname><given-names>I</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>MC</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications</article-title><source>Nature Medicine</source><volume>12</volume><fpage>1181</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1038/nm1487</pub-id><pub-id pub-id-type="pmid">17013383</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeder</surname><given-names>I</given-names></name><name><surname>Glauche</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Overlooking the obvious? on the potential of treatment alterations to predict patient-specific therapy response</article-title><source>Experimental Hematology</source><volume>94</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2020.11.006</pub-id><pub-id pub-id-type="pmid">33246016</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>RK</given-names></name><name><surname>Johnsson</surname><given-names>K</given-names></name><name><surname>Hahnfeldt</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Hlatky</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A multicellular basis for the origination of blast crisis in chronic myeloid leukemia</article-title><source>Cancer Research</source><volume>71</volume><fpage>2838</fpage><lpage>2847</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4600</pub-id><pub-id pub-id-type="pmid">21487044</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savageau</surname><given-names>MA</given-names></name><name><surname>Coelho</surname><given-names>P</given-names></name><name><surname>Fasani</surname><given-names>RA</given-names></name><name><surname>Tolla</surname><given-names>DA</given-names></name><name><surname>Salvador</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phenotypes and tolerances in the design space of biochemical systems</article-title><source>PNAS</source><volume>106</volume><fpage>6435</fpage><lpage>6440</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809869106</pub-id><pub-id pub-id-type="pmid">19279208</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schemionek</surname><given-names>M</given-names></name><name><surname>Elling</surname><given-names>C</given-names></name><name><surname>Steidl</surname><given-names>U</given-names></name><name><surname>Bäumer</surname><given-names>N</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Spieker</surname><given-names>T</given-names></name><name><surname>Göthert</surname><given-names>JR</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Wagers</surname><given-names>A</given-names></name><name><surname>Huettner</surname><given-names>CS</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Tickenbrock</surname><given-names>L</given-names></name><name><surname>Berdel</surname><given-names>WE</given-names></name><name><surname>Serve</surname><given-names>H</given-names></name><name><surname>Holyoake</surname><given-names>TL</given-names></name><name><surname>Müller-Tidow</surname><given-names>C</given-names></name><name><surname>Koschmieder</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Bcr-Abl enhances differentiation of long-term repopulating hematopoietic stem cells</article-title><source>Blood</source><volume>115</volume><fpage>3185</fpage><lpage>3195</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-215376</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>JA</given-names></name><name><surname>Browning</surname><given-names>AP</given-names></name><name><surname>Mapder</surname><given-names>T</given-names></name><name><surname>Baker</surname><given-names>CM</given-names></name><name><surname>Burrage</surname><given-names>K</given-names></name><name><surname>Simpson</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Designing combination therapies using multiple optimal controls</article-title><source>Journal of Theoretical Biology</source><volume>497</volume><elocation-id>110277</elocation-id><pub-id pub-id-type="doi">10.1016/j.jtbi.2020.110277</pub-id><pub-id pub-id-type="pmid">32294472</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirard</surname><given-names>C</given-names></name><name><surname>Lapidot</surname><given-names>T</given-names></name><name><surname>Vormoor</surname><given-names>J</given-names></name><name><surname>Cashman</surname><given-names>JD</given-names></name><name><surname>Doedens</surname><given-names>M</given-names></name><name><surname>Murdoch</surname><given-names>B</given-names></name><name><surname>Jamal</surname><given-names>N</given-names></name><name><surname>Messner</surname><given-names>H</given-names></name><name><surname>Addey</surname><given-names>L</given-names></name><name><surname>Minden</surname><given-names>M</given-names></name><name><surname>Laraya</surname><given-names>P</given-names></name><name><surname>Keating</surname><given-names>A</given-names></name><name><surname>Eaves</surname><given-names>A</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Normal and leukemic SCID-repopulating cells (Src) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic Src are detected in blast crisis</article-title><source>Blood</source><volume>87</volume><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">8608245</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staversky</surname><given-names>RJ</given-names></name><name><surname>Byun</surname><given-names>DK</given-names></name><name><surname>Georger</surname><given-names>MA</given-names></name><name><surname>Zaffuto</surname><given-names>BJ</given-names></name><name><surname>Goodman</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>MW</given-names></name><name><surname>Calvi</surname><given-names>LM</given-names></name><name><surname>Frisch</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The chemokine CCL3 regulates myeloid differentiation and hematopoietic stem cell numbers</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>14691</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-32978-y</pub-id><pub-id pub-id-type="pmid">30279500</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steensma</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clinical consequences of clonal hematopoiesis of indeterminate potential</article-title><source>Blood Advances</source><volume>2</volume><fpage>3404</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018020222</pub-id><pub-id pub-id-type="pmid">30482770</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>FM</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Wuu</surname><given-names>J</given-names></name><name><surname>Hsieh</surname><given-names>C</given-names></name><name><surname>Nilsson</surname><given-names>SK</given-names></name><name><surname>Quesenberry</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Lymphohematopoietic engraftment in minimally myeloablated hosts</article-title><source>Blood</source><volume>91</volume><fpage>3681</fpage><lpage>3687</lpage><pub-id pub-id-type="pmid">9573004</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Baran</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse</article-title><source>Journal of the Royal Society, Interface</source><volume>11</volume><elocation-id>20140079</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2014.0079</pub-id><pub-id pub-id-type="pmid">24621818</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Baran</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival</article-title><source>Cancer Research</source><volume>75</volume><fpage>940</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2508</pub-id><pub-id pub-id-type="pmid">25614516</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>2809</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-21115-4</pub-id><pub-id pub-id-type="pmid">29434256</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lutz</surname><given-names>C</given-names></name><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mathematical modeling provides evidence for niche competition in human AML and serves as a tool to improve risk stratification</article-title><source>Cancer Research</source><volume>80</volume><fpage>3983</fpage><lpage>3992</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0283</pub-id><pub-id pub-id-type="pmid">32651258</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Field</surname><given-names>C</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells</article-title><source>Blood</source><volume>118</volume><fpage>1622</fpage><lpage>1631</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-02-339267</pub-id><pub-id pub-id-type="pmid">21653938</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielen</surname><given-names>N</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Baldauf</surname><given-names>M</given-names></name><name><surname>Barbany</surname><given-names>G</given-names></name><name><surname>Fioretos</surname><given-names>T</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Schuurhuis</surname><given-names>GJ</given-names></name><name><surname>Sopper</surname><given-names>S</given-names></name><name><surname>Stenke</surname><given-names>L</given-names></name><name><surname>Thunberg</surname><given-names>S</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Ossenkoppele</surname><given-names>G</given-names></name><name><surname>Porkka</surname><given-names>K</given-names></name><name><surname>Janssen</surname><given-names>J</given-names></name><name><surname>Mustjoki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy</article-title><source>Clinical Cancer Research</source><volume>22</volume><fpage>4030</fpage><lpage>4038</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2791</pub-id><pub-id pub-id-type="pmid">27006491</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udomsakdi</surname><given-names>C</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Swolin</surname><given-names>B</given-names></name><name><surname>Reid</surname><given-names>DS</given-names></name><name><surname>Barnett</surname><given-names>MJ</given-names></name><name><surname>Eaves</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level</article-title><source>PNAS</source><volume>89</volume><fpage>6192</fpage><lpage>6196</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.13.6192</pub-id><pub-id pub-id-type="pmid">1631107</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicente-Dueñas</surname><given-names>C</given-names></name><name><surname>Pérez-Caro</surname><given-names>M</given-names></name><name><surname>Abollo-Jiménez</surname><given-names>F</given-names></name><name><surname>Cobaleda</surname><given-names>C</given-names></name><name><surname>Sánchez-García</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Stem-Cell driven cancer: &quot;hands-off'' regulation of cancer development</article-title><source>Cell Cycle</source><volume>8</volume><fpage>1314</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.4161/cc.8.9.8217</pub-id><pub-id pub-id-type="pmid">19279406</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walenda</surname><given-names>T</given-names></name><name><surname>Stiehl</surname><given-names>T</given-names></name><name><surname>Braun</surname><given-names>H</given-names></name><name><surname>Fröbel</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Goecke</surname><given-names>TW</given-names></name><name><surname>Rath</surname><given-names>B</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis</article-title><source>PLOS Computational Biology</source><volume>10</volume><elocation-id>e1003599</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003599</pub-id><pub-id pub-id-type="pmid">24763223</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>Lapidot</surname><given-names>T</given-names></name><name><surname>Cashman</surname><given-names>JD</given-names></name><name><surname>Doedens</surname><given-names>M</given-names></name><name><surname>Addy</surname><given-names>L</given-names></name><name><surname>Sutherland</surname><given-names>DR</given-names></name><name><surname>Nayar</surname><given-names>R</given-names></name><name><surname>Laraya</surname><given-names>P</given-names></name><name><surname>Minden</surname><given-names>M</given-names></name><name><surname>Keating</surname><given-names>A</given-names></name><name><surname>Eaves</surname><given-names>AC</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase</article-title><source>Blood</source><volume>91</volume><fpage>2406</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">9516140</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wark</surname><given-names>G</given-names></name><name><surname>Heyworth</surname><given-names>CM</given-names></name><name><surname>Spooncer</surname><given-names>E</given-names></name><name><surname>Czaplewski</surname><given-names>L</given-names></name><name><surname>Francis</surname><given-names>JM</given-names></name><name><surname>Dexter</surname><given-names>TM</given-names></name><name><surname>Whetton</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha</article-title><source>Oncogene</source><volume>16</volume><fpage>1319</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201914</pub-id><pub-id pub-id-type="pmid">9546433</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welner</surname><given-names>RS</given-names></name><name><surname>Amabile</surname><given-names>G</given-names></name><name><surname>Bararia</surname><given-names>D</given-names></name><name><surname>Czibere</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pontes</surname><given-names>LLDF</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Levantini</surname><given-names>E</given-names></name><name><surname>Di Ruscio</surname><given-names>A</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells</article-title><source>Cancer Cell</source><volume>27</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.04.004</pub-id><pub-id pub-id-type="pmid">25965572</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whichard</surname><given-names>ZL</given-names></name><name><surname>Sarkar</surname><given-names>CA</given-names></name><name><surname>Kimmel</surname><given-names>M</given-names></name><name><surname>Corey</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hematopoiesis and its disorders: a systems biology approach</article-title><source>Blood</source><volume>115</volume><fpage>2339</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-08-215798</pub-id><pub-id pub-id-type="pmid">20103779</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodarz</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: implications for the outcome of imatinib treatment and discontinuation</article-title><source>Medical Hypotheses</source><volume>70</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2007.03.040</pub-id><pub-id pub-id-type="pmid">17566666</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woywod</surname><given-names>C</given-names></name><name><surname>Gruber</surname><given-names>FX</given-names></name><name><surname>Engh</surname><given-names>RA</given-names></name><name><surname>Flå</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: response to dasatinib or nilotinib therapy</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0179700</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0179700</pub-id><pub-id pub-id-type="pmid">28678800</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>DE</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Gulati</surname><given-names>AP</given-names></name><name><surname>Johnson</surname><given-names>FL</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Physiological migration of hematopoietic stem and progenitor cells</article-title><source>Science</source><volume>294</volume><fpage>1933</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1126/science.1064081</pub-id><pub-id pub-id-type="pmid">11729320</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>DT</given-names></name><name><surname>Osborn</surname><given-names>MP</given-names></name><name><surname>White</surname><given-names>DL</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Kornhauser</surname><given-names>M</given-names></name><name><surname>Slader</surname><given-names>C</given-names></name><name><surname>Issa</surname><given-names>S</given-names></name><name><surname>Hiwase</surname><given-names>DK</given-names></name><name><surname>Hertzberg</surname><given-names>MS</given-names></name><name><surname>Schwarer</surname><given-names>AP</given-names></name><name><surname>Filshie</surname><given-names>R</given-names></name><name><surname>Arthur</surname><given-names>CK</given-names></name><name><surname>Kwan</surname><given-names>YL</given-names></name><name><surname>Forsyth</surname><given-names>CJ</given-names></name><name><surname>Ross</surname><given-names>D</given-names></name><name><surname>Mills</surname><given-names>AK</given-names></name><name><surname>Grigg</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><collab>on Behalf Of ALLG</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial</article-title><source>Blood</source><volume>120</volume><elocation-id>3771</elocation-id><pub-id pub-id-type="doi">10.1182/blood.V120.21.3771.3771</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>DT</given-names></name><name><surname>Osborn</surname><given-names>MP</given-names></name><name><surname>White</surname><given-names>DL</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Braley</surname><given-names>J</given-names></name><name><surname>Herschtal</surname><given-names>A</given-names></name><name><surname>Kornhauser</surname><given-names>M</given-names></name><name><surname>Issa</surname><given-names>S</given-names></name><name><surname>Hiwase</surname><given-names>DK</given-names></name><name><surname>Hertzberg</surname><given-names>M</given-names></name><name><surname>Schwarer</surname><given-names>AP</given-names></name><name><surname>Filshie</surname><given-names>R</given-names></name><name><surname>Arthur</surname><given-names>CK</given-names></name><name><surname>Kwan</surname><given-names>YL</given-names></name><name><surname>Trotman</surname><given-names>J</given-names></name><name><surname>Forsyth</surname><given-names>CJ</given-names></name><name><surname>Taper</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>DM</given-names></name><name><surname>Beresford</surname><given-names>J</given-names></name><name><surname>Tam</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>AK</given-names></name><name><surname>Grigg</surname><given-names>AP</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><collab>Australasian Leukaemia and Lymphoma Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>TIDEL-II: First-line use of Imatinib in CML with early switch to Nilotinib for failure to achieve time-dependent molecular targets</article-title><source>Blood</source><volume>125</volume><fpage>915</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-07-590315</pub-id><pub-id pub-id-type="pmid">25519749</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Zenati</surname><given-names>A</given-names></name><name><surname>Chakir</surname><given-names>M</given-names></name><name><surname>Tadjine</surname><given-names>M</given-names></name><name><surname>Chrifi-Alaoui</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global Stability Analysis of Strictly Positive Steady State for a Surviving Hematopoietic Stem Cells Models</article-title><conf-name>2018 Annual American Control Conference (ACC</conf-name><conf-loc>Milwaukee, WI</conf-loc><pub-id pub-id-type="doi">10.23919/ACC.2018.8430856</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WW</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Reddy</surname><given-names>NG</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance</article-title><source>Journal of Clinical Oncology</source><volume>27</volume><fpage>3642</fpage><lpage>3649</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.19.4076</pub-id><pub-id pub-id-type="pmid">19506164</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>YW</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Hair</surname><given-names>A</given-names></name><name><surname>Holyoake</surname><given-names>TL</given-names></name><name><surname>Huettner</surname><given-names>C</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia</article-title><source>Cancer Cell</source><volume>21</volume><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.018</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>O’Connell</surname><given-names>RM</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>DiLoreto</surname><given-names>R</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis</article-title><source>Cell Stem Cell</source><volume>14</volume><fpage>445</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.01.007</pub-id><pub-id pub-id-type="pmid">24561084</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>JM</given-names></name><name><surname>Marshall</surname><given-names>H</given-names></name><name><surname>Venkatraman</surname><given-names>A</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>XC</given-names></name><name><surname>Ahamed</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1321</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1038/nm.3706</pub-id><pub-id pub-id-type="pmid">25326798</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>1 Design space analysis</title><sec sec-type="appendix" id="s8-2"><title>1.1 Introduction</title><p>In this section, we provide details on the application of design space analysis (DSA), developed in <xref ref-type="bibr" rid="bib89">Savageau et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>; <xref ref-type="bibr" rid="bib61">Lomnitz and Savageau, 2013</xref>; <xref ref-type="bibr" rid="bib62">Lomnitz and Savageau, 2016</xref> for chemical reaction networks, to a simplified version of the cell lineage model considered in the main text (see <xref ref-type="fig" rid="fig1">Figure 1</xref>). This enables us to analyze nonlinear dynamical systems near steady state to identify the regions in parameter space where common qualitative behaviors occur. Applying this analysis allows us to (1) ignore specific parameter values, (2) obtain analytical steady states, (3) reduce the search area in parameter space by searching boundaries separating regions of common behaviors, and (4) easily automate this process. In this section, we review how one can construct a design space given an ODE model. We then apply this analysis to an ODE model of cell lineages and show how this model can be used to define regions of stability in parameter space.</p></sec><sec sec-type="appendix" id="s8-3"><title>1.2 Boundaries of design space for general models</title><p>In order to apply DSA, the ODE must be a generalized mass action system, shown below in <xref ref-type="disp-formula" rid="equ2 equ3">Equations 1 and 2</xref>,<disp-formula id="equ2"><label>(1)</label><mml:math id="m2"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mspace width="1em"/></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ3"><label>(2)</label><mml:math id="m3"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>for  <inline-formula><mml:math id="inf75"><mml:mi>i</mml:mi></mml:math></inline-formula> = 1, <inline-formula><mml:math id="inf76"><mml:mi>n</mml:mi></mml:math></inline-formula>. Here, <inline-formula><mml:math id="inf77"><mml:mi>n</mml:mi></mml:math></inline-formula> corresponds to the number of dependent variables and <inline-formula><mml:math id="inf78"><mml:mi>m</mml:mi></mml:math></inline-formula> corresponds to the number of independent variables. The <inline-formula><mml:math id="inf79"><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf80"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> parameters correspond to rate constants of the differential equation and <inline-formula><mml:math id="inf81"><mml:mi>r</mml:mi></mml:math></inline-formula> corresponds to the number of associated rate constants.</p><p>DSA takes advantage of the above form by creating a system of deconstructed ODEs where one source term and one sink term in the differential equation dominate, known as a subsystem (S-system). The following is the generalized form of an S-system:<disp-formula id="equ4"><label>(3)</label><mml:math id="m4"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ5"><label>(4)</label><mml:math id="m5"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf82"><mml:mi>p</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf83"><mml:mi>q</mml:mi></mml:math></inline-formula> correspond to the number of positive and negative terms of the differential equation, respectively. We are interested in solving these solutions at steady state, and therefore solve the system by setting the time derivative to zero. We take advantage of the form shown in <xref ref-type="disp-formula" rid="equ4">Equation 3</xref> and take the log of the system:<disp-formula id="equ6"><label>(5)</label><mml:math id="m6"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>thus, making this a linear solve in log space. In defining the S-systems, we must make assumptions about the model and its parameters. To satisfy the S-systems, we impose inequality constraints to satisfy the dominating source and sink terms of the S-systems by the following:<disp-formula id="equ7"><label>(6)</label><mml:math id="m7"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mtext>for i = 1,..,n;</mml:mtext><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mtext>=1,...,p-1,p+1,...,r</mml:mtext></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ8"><label>(7)</label><mml:math id="m8"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mover><mml:mi>q</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mover><mml:mi>q</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mtext>for i = 1,..,n;</mml:mtext><mml:mrow><mml:mover><mml:mi>q</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mtext>=1,...,q-1,q+1,...,r</mml:mtext></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>We can then log transform these inequalities to obtain<disp-formula id="equ9"><label>(8)</label><mml:math id="m9"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>&gt;</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ10"><label>(9)</label><mml:math id="m10"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>q</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>&gt;</mml:mo><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mover><mml:mi>q</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mover><mml:mi>q</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>These inequalities become our boundaries in parameter space in which qualitative behavior is shared once the <inline-formula><mml:math id="inf84"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> ’s are evaluated at steady state, where the steady states are obtained from solving the log-linear S-system. Not all S-systems will have a unique solution or satisfy the inequality constraints. The S-systems that do not satisfy these constraints will be discarded. The analysis is summarized in <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Flow chart for design space analysis (DSA).</title><p>Given an ordinary differential equation (ODE), we can obtain the design space by obtaining all S-systems, steady states, and evaluated dominance conditions. S-systems that do not satisfy the dominance condition are not included in the design space.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig1-v5.tif"/></fig><sec sec-type="appendix" id="s8-3-1"><title>1.3 Analysis of a four-cell lineage model</title><p>We next apply this analysis to a lineage model with four cell types (see <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). The model consists of two dividing cell types consisting of <inline-formula><mml:math id="inf85"><mml:mi>S</mml:mi></mml:math></inline-formula> (HSC) and <inline-formula><mml:math id="inf86"><mml:mi>P</mml:mi></mml:math></inline-formula> (MPP) cells with a division rate associated to the cells (<inline-formula><mml:math id="inf87"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf88"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, respectively). The <inline-formula><mml:math id="inf89"><mml:mi>S</mml:mi></mml:math></inline-formula> cells have the ability to self-renew with fraction (<inline-formula><mml:math id="inf90"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) or differentiate (<inline-formula><mml:math id="inf91"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>). The <inline-formula><mml:math id="inf92"><mml:mi>P</mml:mi></mml:math></inline-formula> cells have the ability to self-renew with fraction (<inline-formula><mml:math id="inf93"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) or differentiate into either <inline-formula><mml:math id="inf94"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (lymphoid) or <inline-formula><mml:math id="inf95"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (myeloid) cells (<inline-formula><mml:math id="inf96"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> or <inline-formula><mml:math id="inf97"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, respectively). <inline-formula><mml:math id="inf98"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf99"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> cells only have the ability to die at rates <inline-formula><mml:math id="inf100"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf101"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , respectively. We add negative feedback on the self-renewal fraction of the stem cells from the differentiated cells. <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref> shows a schematic of the lineage with the parameters. The corresponding differential equations are<disp-formula id="equ11"><label>(10)</label><mml:math id="m11"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ12"><label>(11)</label><mml:math id="m12"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ13"><label>(12)</label><mml:math id="m13"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ14"><label>(13)</label><mml:math id="m14"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf102"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf103"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> is defined as the maximum stem cell self-renewal fraction and <inline-formula><mml:math id="inf104"><mml:mi>γ</mml:mi></mml:math></inline-formula> is the feedback strength.</p><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Lineage schematic depicting a stem cell and terminally differentiated cell with negative feedback onto stem cell self-renewal probability <inline-formula><mml:math id="inf105"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> .</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig2-v5.tif"/></fig><p>We begin by rewriting the equations in the form shown in <xref ref-type="disp-formula" rid="equ2">Equation 1</xref>.<disp-formula id="equ15"><label>(14)</label><mml:math id="m15"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ16"><label>(15)</label><mml:math id="m16"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ17"><label>(16)</label><mml:math id="m17"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ18"><label>(17)</label><mml:math id="m18"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="equ19"><label>(18)</label><mml:math id="m19"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Note that we introduce a new variable <inline-formula><mml:math id="inf106"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , which is necessary to achieve the form of <xref ref-type="disp-formula" rid="equ2">Equation 1</xref>. We next find all combinations in which one source term and one sink term dominates the system of differential equations.</p><p>From <xref ref-type="disp-formula" rid="equ15 equ16 equ17 equ18 equ19">Equations 14–18</xref>, we obtain 24 S-system combinations, a subset of which is shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. We continue the analysis with S-system 2 from <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. Using S-system 2, we set the time derivatives to zero and rearrange the equations such that we obtain <inline-formula><mml:math id="inf107"><mml:mi>A</mml:mi><mml:mover accent="false"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mover accent="false"><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> :<disp-formula id="equ20"><mml:math id="m20"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mtable columnalign="center center center center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>1</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>0</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>such that <inline-formula><mml:math id="inf108"><mml:mover accent="false"><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> , <inline-formula><mml:math id="inf109"><mml:mover accent="false"><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> , <inline-formula><mml:math id="inf110"><mml:msub><mml:mrow><mml:mover accent="false"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> , and <inline-formula><mml:math id="inf111"><mml:msub><mml:mrow><mml:mover accent="false"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> are the steady-state solutions for the S-system and <inline-formula><mml:math id="inf112"><mml:msub><mml:mrow><mml:mover accent="false"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the solution of the newly defined variable at steady state. Solving the linear equation gives us<disp-formula id="equ21"><mml:math id="m21"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>γ</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mi>γ</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mn>4</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mn>4</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>We can now construct the boundaries for this S-system. We substitute our steady-state solutions obtained above into the logged inequality constraints from <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. Thus, the inequalities in log space become<disp-formula id="equ22"><label>(19)</label><mml:math id="m22"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>0</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ23"><label>(20)</label><mml:math id="m23"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&gt;</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>1</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ24"><label>(21)</label><mml:math id="m24"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&gt;</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mtext>1</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Out of the 24 possible S-systems, only S-system 2 has a unique steady state that satisfies the constraints. We can plot the design space by varying <inline-formula><mml:math id="inf113"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf114"><mml:mi>γ</mml:mi></mml:math></inline-formula> (see <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>). The design space shows one region where <inline-formula><mml:math id="inf115"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, a requirement for a positive steady state in the full system. The domain in parameter space corresponds to S-system 2 in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>A sample of S-systems from <xref ref-type="disp-formula" rid="equ15 equ16 equ17 equ18 equ19">Equations 14–18</xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">S-system 1</th><th align="left" valign="bottom">S-system 2</th><th align="left" valign="bottom">S-system 3</th><th align="left" valign="bottom">S-system 4</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf116"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf117"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf118"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf119"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf120"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf121"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf122"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf123"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf124"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf125"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf126"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf127"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf128"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf129"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf130"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf131"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf132"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf133"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf134"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf135"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf136"><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf137"><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf138"><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf139"><mml:mi>γ</mml:mi><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">Boundary 1</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf140"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf141"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf142"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf143"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">Boundary 2</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf144"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf145"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf146"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf147"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr></tbody></table></table-wrap><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Design space for four-cell lineage model.</title><p>The design space is showing a slice of parameter space varying the max self-renewal probability (<inline-formula><mml:math id="inf148"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>) and feedback gain for stem cells (<inline-formula><mml:math id="inf149"><mml:mi>γ</mml:mi></mml:math></inline-formula>). If we are to sample parameters sets (shown by points), we observe oscillatory behavior in the full system, as shown by the time evolution plots.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig3-v5.tif"/></fig><p>It is possible to relate the S-system back to the true ODE system with classical techniques. For example, it was shown in <xref ref-type="bibr" rid="bib89">Savageau et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Fasani and Savageau, 2010</xref>; <xref ref-type="bibr" rid="bib61">Lomnitz and Savageau, 2013</xref>; <xref ref-type="bibr" rid="bib62">Lomnitz and Savageau, 2016</xref> that the S-system and full ODE system have the same linear stability behavior in the parameter regime appropriate for the S-system. Thus, parameter sensitivity analyses of the S-system provide insight on the behavior of the full system.</p><p>Performing a linear stability analysis on the S-system that corresponds to the region in parameter space shown in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>, we obtain the following eigenvalues:<disp-formula id="equ25"><label>(22)</label><mml:math id="m25"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>0.125</mml:mn><mml:mi>γ</mml:mi><mml:msqrt><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>64</mml:mn><mml:mo>+</mml:mo><mml:mn>16</mml:mn><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msqrt></mml:mrow><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac></mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ26"><label>(23)</label><mml:math id="m26"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true"/><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>0.125</mml:mn><mml:mi>γ</mml:mi><mml:msqrt><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>64</mml:mn><mml:mo>+</mml:mo><mml:mn>16</mml:mn><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msqrt></mml:mrow><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>which suggests a stable spiral or stable node depending on the value of <italic>d</italic>. We also perform the linear stability analysis on the full system and obtain the following eigenvalues:<disp-formula id="equ27"><label>(24)</label><mml:math id="m27"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.25</mml:mn><mml:mi>d</mml:mi><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>−</mml:mo><mml:mn>0.125</mml:mn><mml:msqrt><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>4</mml:mn><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>32</mml:mn><mml:mo>−</mml:mo><mml:mn>64</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:msqrt></mml:mrow><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ28"><label>(25)</label><mml:math id="m28"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true"/><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.25</mml:mn><mml:mi>d</mml:mi><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>+</mml:mo><mml:mn>0.125</mml:mn><mml:msqrt><mml:mi>d</mml:mi><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>4</mml:mn><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>32</mml:mn><mml:mo>−</mml:mo><mml:mn>64</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:msqrt></mml:mrow><mml:msup><mml:mrow><mml:mover><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac><mml:mo>]</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>and in the parameter space for the S-system, we obtain the same behavior. Using the full system, we can also plot the dynamics in the domain, which are shown as insets in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>. When plotting the full system in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>, we observe that the stem and progenitor populations oscillate before reaching steady state, characteristics of a stable spiral. The S-system and the true system eigenvalues are not identical, but using the same parameters in the appropriate S-system parameter space, the systems will have the same behavior. However, outside of the domain of validity of the S-system, we cannot conclude anything about the full system’s dynamics from the S-system. In fact, from <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>, we observe being outside of the domain of validity of S-system 2 (e.g., <inline-formula><mml:math id="inf150"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) yields to solutions that tend to the zero steady state.</p><p>We use DSA to select among all possible ODE models for normal hematopoiesis consistent with the lineage diagram shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref> in the main text in which each parameter <inline-formula><mml:math id="inf151"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf152"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf153"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf154"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , and <inline-formula><mml:math id="inf155"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is either unregulated (constant) or is subject to positive or negative regulation from most one cell type in the lineage. As described in the main text, there are 59,049 possible models, counting each combination as a model. We implement an automated implementation of DSA that enables an efficient exploration of this large space of models. Eliminating models with no valid S-systems and those with unstable equilibria, we eliminate all but the four model classes shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref> in the main text.</p></sec></sec></sec><sec sec-type="appendix" id="s9"><title>2 Mathematical model</title><p>The complete ODE model of normal hematopoiesis is composed of the following equations:<disp-formula id="equ29"><label>(26)</label><mml:math id="m29"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ30"><label>(27)</label><mml:math id="m30"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ31"><label>(28)</label><mml:math id="m31"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ32"><label>(29)</label><mml:math id="m32"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The ODE model for CML hematopoiesis tracks the dynamics of both the normal and CML cells (superscript <inline-formula><mml:math id="inf156"><mml:mi>L</mml:mi></mml:math></inline-formula>), and assumes that both cell types provide and respond to feedback signaling, although the CML stem cells are slightly less responsive to negative feedback regulation, which gives them a fitness advantage. The complete system is given by<disp-formula id="equ33"><label>(30)</label><mml:math id="m33"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ34"><label>(31)</label><mml:math id="m34"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ35"><label>(32)</label><mml:math id="m35"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ36"><label>(33)</label><mml:math id="m36"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ37"><label>(34)</label><mml:math id="m37"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ38"><label>(35)</label><mml:math id="m38"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ39"><label>(36)</label><mml:math id="m39"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ40"><label>(37)</label><mml:math id="m40"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:msubsup><mml:mi>q</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>When TKI therapy is applied, <xref ref-type="disp-formula" rid="equ37 equ38">Equations 34 and 35</xref> are replaced with<disp-formula id="equ41"><label>(38)</label><mml:math id="m41"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ42"><label>(39)</label><mml:math id="m42"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf157"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf158"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> denote TKI-induced death rates of the CML stem and MPP cells. With the introduction of differentiation therapy, <xref ref-type="disp-formula" rid="equ33 equ41">Equations 30 and 38</xref> instead become<disp-formula id="equ43"><label>(40)</label><mml:math id="m43"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ44"><label>(41)</label><mml:math id="m44"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p></sec><sec sec-type="appendix" id="s10"><title>3 Parameter estimation</title><p>The parameters for the model of normal hematopoiesis, and their descriptions, are listed in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>. The additional parameters needed to model the CML cell population, and the application of TKI therapy are given in <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>.</p><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Parameter values used to model the normal hematopoietic system.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Parameter</th><th align="left" valign="top">Description</th></tr></thead><tbody><tr><td align="left" valign="top"><inline-formula><mml:math id="inf159"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Maximal self-renewal fraction of HSC</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf160"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Maximal self-renewal fraction of MPP</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf161"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Maximum branching fraction from MPP to <inline-formula><mml:math id="inf162"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf163"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Maximum HSC proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf164"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Maximum MPP proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf165"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on HSC self-renewal fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf166"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on HSC proliferation rate (from HSC)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf167"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on MPP self-renewal fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf168"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on MPP branching fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf169"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Feedforward gain on MPP proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf170"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Death rate of <inline-formula><mml:math id="inf171"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf172"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Death rate of <inline-formula><mml:math id="inf173"><mml:mi>T</mml:mi><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td></tr></tbody></table><table-wrap-foot><fn><p>HSC: hematopoietic stem cell; MPP: multipotential progenitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table3" position="float"><label>Appendix 1—table 3.</label><caption><title>Additional parameter values used to model the chronic myeloid leukemia (CML) cell population dynamics and effect of tyrosine kinase inhibitor (TKI) therapy.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Parameter</th><th align="left" valign="top">Description</th></tr></thead><tbody><tr><td align="left" valign="top"><inline-formula><mml:math id="inf174"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Maximal self-renewal fraction of HSC <inline-formula><mml:math id="inf175"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf176"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Maximal self-renewal fraction of MPP <inline-formula><mml:math id="inf177"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf178"><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Maximum branching fraction from MPP <inline-formula><mml:math id="inf179"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> to <inline-formula><mml:math id="inf180"><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf181"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Maximum HSC <inline-formula><mml:math id="inf182"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf183"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Maximum MPP <inline-formula><mml:math id="inf184"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf185"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on HSC <inline-formula><mml:math id="inf186"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> self-renewal fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf187"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on HSC <inline-formula><mml:math id="inf188"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> proliferation rate (from HSC <inline-formula><mml:math id="inf189"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf190"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on MPP <inline-formula><mml:math id="inf191"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> self-renewal fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf192"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Feedback gain on MPP <inline-formula><mml:math id="inf193"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> branching fraction</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf194"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Feedforward gain on MPP <inline-formula><mml:math id="inf195"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> proliferation rate</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf196"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Death rate of <inline-formula><mml:math id="inf197"><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf198"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="top">Death rate of <inline-formula><mml:math id="inf199"><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf200"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Death rate of HSC <inline-formula><mml:math id="inf201"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> due to TKI therapy</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf202"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="left" valign="top">Death rate of MPP <inline-formula><mml:math id="inf203"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> due to TKI therapy</td></tr></tbody></table><table-wrap-foot><fn><p>HSC: hematopoietic stem cell; MPP: multipotential progenitor.</p></fn></table-wrap-foot></table-wrap><sec sec-type="appendix" id="s10-1"><title>3.1 Parameter distributions</title><p>A grid-search algorithm was used to find parameter values that demonstrate steady-state cell counts consistent with <xref ref-type="bibr" rid="bib66">Manesso et al., 2013</xref> and time of recovery to steady state from cellular perturbations consistent with <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>. The resulting distributions of the 1493 parameters are displayed along the diagonal of <xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>. In the distributions, the feedback gain of the feedforward regulation is skewed toward smaller values across all parameter sets. To investigate the observed feedforward loop, we selected only the parameter sets with sufficiently large feedforward gain <inline-formula><mml:math id="inf204"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. This resulted in a reduced distribution of 563 parameter sets and is shown in <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>. The parameter ranges for the gridsearch were found using the method shown in the following pseudo-Python.</p><p><code xml:space="preserve">for i in range(1e6):

param_gridsearch_dist = dict(p0max = np.random.uniform(0.5, 1.0),
p1max = np.random.uniform(0.0,0.5), q1max = np.abs(np.random.uniform(0.0,0.49)),
eta1max = np.random.uniform(0,0.5), eta2max = 10**np.random.uniform(–2,1.5),gam2=10**np.random.uniform(–6,0), gam3=10**np.random.uniform(–6,0),
gam4=10**np.random.uniform(–6,0), gam5=10**np.random.uniform(–6,0),dL = 10**np.random.uniform(–4,1), dM = 10**np.random.uniform(–4,1))
y=hematopoiesis(param_gridsearch_dist)

if y[0,–1]&gt;.01 and y[0,–1]&lt;y[1,-1]&lt;y[2,-1]&lt;y[3,-1]:master_params.append(param_gridsearch_dist)
</code></p><p>The specific parameters used to model the normal hematopoietic system in <xref ref-type="fig" rid="fig3">Figures 3</xref>—<xref ref-type="fig" rid="fig7">7</xref> in the main text are given in <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>. When CML cells are introduced, the additional parameters of a representative responder associated with the leukemic cell ODEs are given in <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>. A representative parameter set for a nonresponder is shown in <xref ref-type="table" rid="app1table6">Appendix 1—table 6</xref>.</p><fig id="app1fig4" position="float"><label>Appendix 1—figure 4.</label><caption><title>Pairwise parameter distributions for all 1493 parameter sets found from the gridsearch.</title><p>The overall distributions for each parameter are shown along the diagonal.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig4-v5.tif"/></fig><fig id="app1fig5" position="float"><label>Appendix 1—figure 5.</label><caption><title>Pairwise parameter distributions for the 563 parameter sets from <xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref> that have feedforward gain <inline-formula><mml:math id="inf205"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</title><p>The overall distributions for each parameter are shown along the diagonal.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig5-v5.tif"/></fig><fig id="app1fig6" position="float"><label>Appendix 1—figure 6.</label><caption><title>A spaghetti plot showing the dynamics of the effective proliferation, self-renewal, and branching parameters for 50 parameter sets under tyrosine kinase inhibitor (TKI) treatment started at early times.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig6-v5.tif"/></fig><table-wrap id="app1table4" position="float"><label>Appendix 1—table 4.</label><caption><title>Parameter values used to model the normal hematopoietic system in <xref ref-type="fig" rid="fig3">Figures 3</xref>—<xref ref-type="fig" rid="fig7">7</xref> in the main text.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Parameter</th><th align="left" valign="top">Value</th></tr></thead><tbody><tr><td align="left" valign="top"><inline-formula><mml:math id="inf206"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.756641</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf207"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.357913</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf208"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.032241</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf209"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.197639</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf210"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.47088</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf211"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.513281</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf212"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.197639</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf213"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.47088</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf214"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.513281</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf215"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.543987</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf216"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.000165</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf217"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.000428</td></tr></tbody></table></table-wrap><table-wrap id="app1table5" position="float"><label>Appendix 1—table 5.</label><caption><title>Additional parameter values used to model the chronic myeloid leukemia (CML) cell population dynamics in <xref ref-type="fig" rid="fig4">Figures 4A ,B</xref>—<xref ref-type="fig" rid="fig7">7</xref> in the main text.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Parameter</th><th align="left" valign="top">Value</th></tr></thead><tbody><tr><td align="left" valign="top"><inline-formula><mml:math id="inf218"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.756641</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf219"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.357913</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf220"><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.032241</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf221"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.197639</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf222"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.47088</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf223"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.2566405</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf224"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.197639</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf225"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.47088</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf226"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.2566405</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf227"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.543987</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf228"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.000165</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf229"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="top">0.000428</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf230"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.201311</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf231"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="top">0.024757</td></tr></tbody></table></table-wrap><table-wrap id="app1table6" position="float"><label>Appendix 1—table 6.</label><caption><title>Secondary parameter values used as a representative case to model nonresponsive chronic myeloid leukemia (CML) cell population dynamics in <xref ref-type="fig" rid="fig7">Figures 7C, D</xref>, <xref ref-type="fig" rid="fig8">8</xref> in the main text.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameter</th><th align="left" valign="bottom">Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf232"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.838481</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf233"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.009776</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf234"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.418627</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf235"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.226025</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf236"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.247591</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf237"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.676962</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf238"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.000219</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf239"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.000326</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf240"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.367564</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf241"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.168132</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf242"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.071273</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf243"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.155649</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf244"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.838481</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf245"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.009776</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf246"><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.418627</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf247"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.226025</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf248"><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.247591</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf249"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.338481</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf250"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.000219</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf251"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.000326</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf252"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.367564</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf253"><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.168132</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf254"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.071273</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf255"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.155649</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf256"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">0.25</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf257"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td align="char" char="." valign="bottom">30</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="appendix" id="s11"><title>4 Simulations of transplant experiment</title><p>As described in the main text, we simulated a transplant experiment in a transgenic mouse model of CML performed in <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref>. In this experiment, either leukemic stem HSC <inline-formula><mml:math id="inf258"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> or leukemic MPP <inline-formula><mml:math id="inf259"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> cells were implanted into sublethally irradiated mice. Transplantation of HSC <inline-formula><mml:math id="inf260"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> enables engraftment and myeloid cell production that leads to CML. On the other hand, transplanting MPP <inline-formula><mml:math id="inf261"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> cells does not allow for long-term engraftment but results in a larger fraction of donor-derived lymphoid cells after 35 d. We modeled this experiment by reducing the number of cells in equilibrium to mimic the effects of sublethal radiation (see ‘Methods’). Here, we present results of a range of possible reductions of HSC <inline-formula><mml:math id="inf262"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> and MPP <inline-formula><mml:math id="inf263"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> cells, and tracked the outcomes when 4000 HSC <inline-formula><mml:math id="inf264"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> or MPP <inline-formula><mml:math id="inf265"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> were introduced after the decrements from equilibrium. We then determine which of our parameter sets are consistent with the experimental outcomes found in <xref ref-type="bibr" rid="bib83">Reynaud et al., 2011</xref> using a simple majority of myeloid cells for HSC <inline-formula><mml:math id="inf266"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> transplant and a simple majority of lymphoid cells for MPP <inline-formula><mml:math id="inf267"><mml:msup><mml:mrow><mml:mi mathvariant="normal">​</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> transplant as consistency criteria. The results are summarized in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s2">2</xref>. The pairwise parameter distributions of the 478 remaining parameter sets are shown in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>.</p></sec><sec sec-type="appendix" id="s12"><title>5 Effective parameters</title><p>Here, we present the effective proliferation rates and self-renewal and branching factors—that is, the values of these parameters that takes the feedback regulation into account. That is, the effective stem cell proliferation rate <inline-formula><mml:math id="inf268"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> in normal hematopoiesis and <inline-formula><mml:math id="inf269"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> when CML stem cells are present. The other effective parameters are defined analogously.</p><p>In <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, the effective HSC and MPP proliferation rates (<inline-formula><mml:math id="inf270"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf271"><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>), the effective HSC and MPP self-renewal fractions (<inline-formula><mml:math id="inf272"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf273"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) and branching fraction <inline-formula><mml:math id="inf274"><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> are shown. The corresponding effective parameters are shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> when CML cells are introduced when the normal hematopoietic model system is at steady state and in response to treatment by TKIs (starts at the time labeled <inline-formula><mml:math id="inf275"><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, as indicated by the vertical line) for the cases shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> in the main text. In <xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>, we plot the effective proliferation, self-renewal, and branching parameters for 50 parameter sets under treatment at early times.</p></sec><sec sec-type="appendix" id="s13"><title>6 Distributions of model parameters grouped by response to TKI treatment using synthetic data (478 parameter sets)</title><p>In <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, we plot the distributions of all the unregulated proliferation, self-renewal, and branching parameters, as well as the feedback gains, grouped by response to TKI therapy. In particular, the blue color indicates achievement of MR3 by 50 mo (termed as responders) while orange indicates that MR3 is not achieved within 50 mo (termed as nonresponders). The only parameters that clearly delineate the responders from nonresponders are <inline-formula><mml:math id="inf276"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf277"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , with responders occurring at the lower values and nonresponders at the higher values.</p></sec><sec sec-type="appendix" id="s14"><title>7 Comparisons of prognostic criteria for predicting response to TKI therapy</title><sec sec-type="appendix" id="s14-1"><title>7.1 Performance of prognostic criteria using synthetic data (478 parameter sets)</title><p>Using data generated from our 478 parameter sets, we tested whether prognostic criteria could correctly identify patients who achieve MR3 within 18 mo after therapy starts. We tested the performance of our prognostic criterion (relative change of transcript levels) against two existing clinical prognostics: halving time (the time it takes for the BCR-ABL1 transcripts to reach one-half of their pretreatment value) and early molecular response (EMR) in which the fraction of BCR-ABL1 transcripts are 10% or less after 3 mo of treatment. We also tested a prognostic criterion based on the ratio of transcript levels. These different prognostic criteria were calculated for both the first and second 3 mo after the start of therapy (e.g., 0–3 mo and 3–6 mo). We calculated the corresponding receiving operating characteristic (ROC) curves and found the optimal threshold by maximizing the difference between true and false positive rates. The results are presented in <xref ref-type="fig" rid="app1fig7">Appendix 1—figure 7</xref> and reveal that generally the ratio and relative change prognostics offer similar performance, but that both demonstrate somewhat better performance compared to the traditional prognostics. In addition, all the prognostic criteria are more accurate when applied 3–6 mo after the start of therapy than when applied during the 0–3-month period. We did not calculate the ROC curves for EMR but rather we only plotted the point that corresponds to 10% transcript levels at 3 mo (black circle) and 1% at 6 mo (open black circle). The EMR prognostic criterion has fewer false positives but also fewer true positives than the other prognostics.</p><fig id="app1fig7" position="float"><label>Appendix 1—figure 7.</label><caption><title>Comparison between our prognostic and alternate prognostics, as labeled, at the first and second 3 mo after the start of therapy.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig7-v5.tif"/></fig></sec><sec sec-type="appendix" id="s14-2"><title>7.2 Performance of prognostic criteria using patient data</title><p>The prognostic criteria were tested on anonymized patient data obtained from Dr. Van Etten’s clinical practice, again asking whether MR3 at 18 mo after treatment could be correctly predicted. We used data in which patients were kept on the same therapy for 6 mo either from the start of therapy or after a change of therapy. For patients that achieved MR3 within 3 mo, we did not include their data at 6 mo. In <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref>, the first two columns correspond to results when the same therapy is applied for 6 mo after patient diagnoses. The last two columns correspond to patients who have had a change of therapy, but the new therapy is maintained for 6 mo. We do not use the EMR as a prognostic in the cases when therapy is changed. The figure demonstrates that the prognostics are more accurate for the 3–6-month period, as predicted from the synthetic data. Although the numbers of patients are small, the relative ratio prognostic criterion is at least as accurate as, or more accurate than, the other criteria. In <xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9</xref>, the predictions of the prognostic criteria are grouped by whether the patients achieve or do not achieve MR3 by 18 mo and by time period. In <xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10</xref>, the prognostic criteria data are aggregated into 3-month windows, where 0–3 mo contains both 0–3 mo after start of therapy and after a therapy change. The 3–6-month data is similarly aggregated. It is clear that the predictions using the 3–6-month data are more accurate than those using the 0–3-month window.</p><fig id="app1fig8" position="float"><label>Appendix 1—figure 8.</label><caption><title>The ability of prognostic criteria to predict MR3 by 18 mo is evaluated using anonymized patient data (n = 11) in which patients received the same therapy for 6 mo either from the start of therapy or after a change in therapy.</title><p>The first two columns correspond to results when the same therapy is applied for 6 mo after patient diagnoses. The last two columns correspond to patients who have had a change of therapy, but the new therapy is maintained for 6 mo. The Early molecular response (EMR) prognostic criterion is not used when the patients have had a therapy change.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig8-v5.tif"/></fig><fig id="app1fig9" position="float"><label>Appendix 1—figure 9.</label><caption><title>The predictive ability of each prognostic criterion from <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref> but grouped based upon patient (n = 11) outcome (blue, responder; and yellow, nonresponder) and the time frame for prediction.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig9-v5.tif"/></fig><fig id="app1fig10" position="float"><label>Appendix 1—figure 10.</label><caption><title>Aggregating the accuracy of prognostic criteria predictions with patient data (n = 11) from <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref> where a general time of 0–3 mo contains both 0–3 mo after start of therapy and after therapy change.</title><p>The 3–6-month data is aggregated similarly.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig10-v5.tif"/></fig></sec></sec><sec sec-type="appendix" id="s15"><title>8 Combination therapy parameter distributions by response</title><p>Finally, in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, we show how the distributions of model parameters from <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> change when TKI therapy is combined with a differentiation promoter. The blue hatching indicates a nonresponder that becomes a responder while the yellow hatching indicates that a responder becomes a nonresponder. Here, response is defined as achieving MR3 in 50 mo. We observe that differentiation therapy is very effective in driving nonresponders at large <inline-formula><mml:math id="inf278"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf279"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> to become responders, but also drives parameter sets that responded to TKI monotherapy at small values of <inline-formula><mml:math id="inf280"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf281"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> to no longer achieve MR3 at 50 mo (nonresponders).</p></sec><sec sec-type="appendix" id="s16"><title>9 Impact of intrinsic differences between normal and leukemic cells</title><p>In <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplements 2</xref>–<xref ref-type="fig" rid="fig4s4">4</xref>, we explored perturbations ranging from 90 to 110% of the original parameter values from <xref ref-type="table" rid="app1table4 app1table5">Appendix 1—tables 4 and 5</xref> to explore the effect of intrinsic differences between normal and leukemic cells. One exception is <inline-formula><mml:math id="inf282"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> , which is limited to a perturbation range of 90–100% due to biological constraints as described in the main text. For the single parameter set for normal cells from <xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref>, perturbations in most leukemic parameters yielded insignificant differences at the cellular and response dynamics levels. The three parameters that did see significant sensitivity to perturbation were the leukemic stem cell-specific parameters <inline-formula><mml:math id="inf283"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> , <inline-formula><mml:math id="inf284"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> , and <inline-formula><mml:math id="inf285"><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . To determine whether this sensitivity applies to the entire population of parameter sets, we explored sweeps of the newly added leukemic parameters and their associated feedback gain shown in the heat maps of <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref> and <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>. For a parameter combination to be considered useful, there must be a region of the left plots that is of a lower value, such that in a majority of cases leukemic cells can dominate the system. Along the bottom right plot, the region should be neither fully light or fully dark to give regions where there are both responsive parameter sets and nonresponsive parameter sets. Through these parameter combination studies, we find that even on the broader parameter set population <inline-formula><mml:math id="inf286"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf287"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> are the only cases with significant differences in overall qualitative outcomes. Additionally, we find that the domains of <inline-formula><mml:math id="inf288"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf289"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> are relatively restricted with the only viable values of <inline-formula><mml:math id="inf290"><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> being roughly equivalent with <inline-formula><mml:math id="inf291"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> with necessary decreases in <inline-formula><mml:math id="inf292"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> for lower <inline-formula><mml:math id="inf293"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> values to ensure parameter combination viability.</p><fig id="app1fig11" position="float"><label>Appendix 1—figure 11.</label><caption><title>Variations in <inline-formula><mml:math id="inf294"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> and <inline-formula><mml:math id="inf295"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> for the individual parameter set from <xref ref-type="fig" rid="fig6">Figure 6</xref> (top) and all eligible parameter sets (bottom).</title><p>Left heat maps display the proportion of parameter sets that maintain dominance of normal cells in the system in the lighter regions and the proportion that possess leukemic cell dominance in the darker regions. The right heat maps indicate proportion of cases where parameter sets achieve MR3 within 50 mo with lighter values associated with a higher proportion of response. Biologically relevant parameter combinations exist within darker regions on the bottom left and regions within orange to purple on the bottom-right plot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig11-v5.tif"/></fig></sec><sec sec-type="appendix" id="s17"><title>10 Effect of leukemic stem cell parameters on response to TKI therapy</title><p>By finding similar qualitative regions of the leukemic stem cell self-renewal heat map in <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref> (lower right), we examined the distributions of response for a few combinations of parameters shown in <xref ref-type="fig" rid="app1fig12">Appendix 1—figure 12</xref>. We found that it is possible to achieve similar distributions with different combinations of parameters. When <inline-formula><mml:math id="inf296"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf297"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> , in 33% of the cases the treatment is unsuccessful in achieving MR3 in 50 mo. When <inline-formula><mml:math id="inf298"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf299"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> , in 20% of the cases the treatment is unsuccessful in achieving MR3 in 50 mo. When <inline-formula><mml:math id="inf300"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf301"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> , in 30% of the cases the treatment is unsuccessful in achieving MR3 in 50 mo. When <inline-formula><mml:math id="inf302"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf303"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, in 39% of the cases the treatment is unsuccessful in achieving MR3 in 50 mo.</p><p>When we analyzed the role of the pretreatment leukemic stem cell proportion on response to TKI therapy (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), we find the results to agree qualitatively across the leukemic parameter combinations (<xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>). From this, to determine whether the <inline-formula><mml:math id="inf304"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> or <inline-formula><mml:math id="inf305"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the true predictor of response to TKI therapy <inline-formula><mml:math id="inf306"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, we first calculated a quantity we termed a characteristic effective self-renewal fraction to attempt to group these combinations by similarity. The characteristic self-renewal fractions for leukemic and normal stem cells are defined as <inline-formula><mml:math id="inf307"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mover><mml:mi>N</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf308"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mover><mml:mi>N</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> . We take <inline-formula><mml:math id="inf309"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>N</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> to be a characteristic value of the size of the MPP population. We then analyzed the behavior as a function of the maximal HSC self-renewal fraction <inline-formula><mml:math id="inf310"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf311"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> . The results are shown in <xref ref-type="fig" rid="app1fig14">Appendix 1—figure 14</xref> where all 478 parameter sets representing the states of the normal system are considered and the leukemic parameters <inline-formula><mml:math id="inf312"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf313"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are varied from 0.6 to 1.0 and 0.1–0.6, respectively, using blue and yellow colors to denote responders and nonresponders. We observe that when the fitness of the <inline-formula><mml:math id="inf314"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> (as measured by <inline-formula><mml:math id="inf315"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) is sufficiently low (e.g., <inline-formula><mml:math id="inf316"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0.65</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>), all the systems respond to TKI therapy. When the <inline-formula><mml:math id="inf317"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> increase in fitness, the number of nonresponders increases but nonresponders are only observed when <inline-formula><mml:math id="inf318"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is above a critical threshold, which depends on <inline-formula><mml:math id="inf319"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> through <inline-formula><mml:math id="inf320"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> . Note that the fitness of the HSC<sup>L</sup> can be increased either by increasing <inline-formula><mml:math id="inf321"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> or <inline-formula><mml:math id="inf322"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> or both.</p><fig id="app1fig12" position="float"><label>Appendix 1—figure 12.</label><caption><title>Combinations of leukemic values with similar overall response rates to tyrosine kinase inhibitor (TKI) therapy (see text) yield similar distributions of response.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig12-v5.tif"/></fig><fig id="app1fig13" position="float"><label>Appendix 1—figure 13.</label><caption><title>Simulated distributions of response to tyrosine kinase inhibitor (TKI) therapy as a function of initial proportion of leukemic stem cells is qualitatively similar across the parameter combinations from <xref ref-type="fig" rid="app1fig12">Appendix 1—figure 12</xref> (from left to right): <inline-formula><mml:math id="inf323"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="inf324"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="inf325"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="inf326"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="inf327"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="inf328"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.3</mml:mn></mml:math></inline-formula>, and <inline-formula><mml:math id="inf329"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="inf330"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:math></inline-formula>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig13-v5.tif"/></fig><fig id="app1fig14" position="float"><label>Appendix 1—figure 14.</label><caption><title>Comparison of trajectories of response as functions of <inline-formula><mml:math id="inf331"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf332"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> .</title><p>For each value of <inline-formula><mml:math id="inf333"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>, there is one tree starting from <inline-formula><mml:math id="inf334"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:math></inline-formula>, then for each <inline-formula><mml:math id="inf335"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> up to <inline-formula><mml:math id="inf336"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.6</mml:mn></mml:math></inline-formula> the tree splits into six branches. Dot color denotes whether a parameter set responds (blue) or does not respond (orange).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig14-v5.tif"/></fig><p>The overall fitness of the leukemic stem cells relative to that of the normal cells determines whether CML will develop and whether treatments will succeed or fail. This is shown in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>. The relative fitness of the CML cells is measured by the ratios of characteristic values of the <inline-formula><mml:math id="inf337"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf338"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> self-renewal fractions: <inline-formula><mml:math id="inf339"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> . Here, all 478 parameter sets representing the states of the normal system are considered and the leukemic parameters <inline-formula><mml:math id="inf340"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf341"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are varied from 0.6 to 1.0 and 0.1–0.6, respectively. The larger the relative fitness, the more likely that CML will develop and take</p><p>over the system (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and that the system will be refractory to TKI treatment (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>).</p><p>As we described in the main text, we estimated the relative fitness of <inline-formula><mml:math id="inf342"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> as <inline-formula><mml:math id="inf343"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mn>0.70</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> . In <xref ref-type="fig" rid="app1fig15">Appendix 1—figures 15</xref>–<xref ref-type="fig" rid="app1fig16">16</xref> and <xref ref-type="fig" rid="fig7">Figure 7B</xref>, we plot the bivariate histogram for response to TKI treatment for combinations of leukemic stem cell parameters such that <inline-formula><mml:math id="inf344"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0.50</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="app1fig15">Appendix 1—figure 15</xref>), <inline-formula><mml:math id="inf345"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0.60</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="app1fig16">Appendix 1—figure 16</xref>), and <inline-formula><mml:math id="inf346"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Through exploration of bivariate and marginal distributions, we find that <inline-formula><mml:math id="inf347"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is capable of separating response, while the fitness <inline-formula><mml:math id="inf348"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> does not have a clear delineation (<xref ref-type="fig" rid="app1fig15">Appendix 1—figures 15</xref>–<xref ref-type="fig" rid="app1fig16">16</xref> and <xref ref-type="fig" rid="fig7">Figure 7B</xref>). Additionally, in our virtual patient population we consider variations of <inline-formula><mml:math id="inf349"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> for individual biological variation with CML cells operating in a similar capacity across virtual patients to be more meaningful.</p><fig id="app1fig15" position="float"><label>Appendix 1—figure 15.</label><caption><title>Bivariate histogram for response to tyrosine kinase inhibitor (TKI) therapy where the relative fitness of <inline-formula><mml:math id="inf350"><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is <inline-formula><mml:math id="inf351"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0.50</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</title><p>Individual variable marginal distributions are shown along the sub-axes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig15-v5.tif"/></fig><fig id="app1fig16" position="float"><label>Appendix 1—figure 16.</label><caption><title>Bivariate histogram for response to tyrosine kinase inhibitor (TKI) therapy where the relative fitness of <inline-formula><mml:math id="inf352"><mml:mi>H</mml:mi><mml:mi>S</mml:mi><mml:msup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is <inline-formula><mml:math id="inf353"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0.60</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</title><p>Individual variable marginal distributions are shown along the sub-axes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig16-v5.tif"/></fig></sec><sec sec-type="appendix" id="s18"><title>11 The effect of leukemic stem cell parameters on combination therapy and prognostic criterion</title><p>We checked the combinations of <inline-formula><mml:math id="inf354"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf355"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> to ensure that the effectiveness of combination therapy and the accuracy of our prognostic criterion are largely unchanged by varying the leukemic stem cell parameters. In <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, we see combination therapy is still successful at improving the proportion of responders. We find that the optimal values from <xref ref-type="fig" rid="fig7">Figure 7E</xref>, where a single set of leukemic parameters was used, need to be modified when all the leukemic parameter combinations that have significant takeover proportions (<inline-formula><mml:math id="inf356"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>60</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) are considered. Nevertheless, using synthetic data we find that the 3–6-month time frame has a better predictivity of TKI response than does the 0–3-month time frame (<xref ref-type="fig" rid="app1fig17">Appendix 1—figure 17</xref>).</p><fig id="app1fig17" position="float"><label>Appendix 1—figure 17.</label><caption><title>Prognostic value sweep applied to combinations of <inline-formula><mml:math id="inf357"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> and <inline-formula><mml:math id="inf358"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> with leukemic predominance &gt; 60%.</title><p>Optimal values from <xref ref-type="fig" rid="fig7">Figure 7E</xref> are no longer the optimal across all combinations, but the 3–6-month time frame still outcompetes 0–3-month time frame.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84149-app1-fig17-v5.tif"/></fig></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84149.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Finley</surname><given-names>Stacey D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>University of Southern California</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.11.511822" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.11.511822"/></front-stub><body><p>This is an important study that investigates the impact of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia. Through a combination of preclinical in vivo measurements, clinical data, and computational modeling, the authors present solid evidence regarding the heterogeneous effects of TKIs in patients and how the response to treatment may be improved. This study is of interest to those working in the fields of mathematical oncology and cancer biology.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84149.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Finley</surname><given-names>Stacey D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>University of Southern California</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sharp</surname><given-names>Jesse A</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pnv4752</institution-id><institution>Queensland University of Technology</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.11.511822">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.10.11.511822v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Aleksandra Walczak as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Jesse A Sharp (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Account for intrinsic differences between leukemic and normal cells. This aspect of the manuscript is poorly justified and weakens the study.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>A) Several assumptions and hypotheses require a more detailed justification or a more careful discussion, e.g.,</p><p>– &quot;For simplicity, we assumed the only difference between the two lineages is a decrease in the feedback strength for leukemic HSC (HSC L ; S L ), as indicated by p 0L in the schematic in Figure 4A.&quot; This choice requires a more detailed justification. Why are potential differences in other parameters not considered?</p><p>– &quot;TKI treatment was initiated at three different times to achieve varying leukemic stem cell load (6, 18, and 36 months) and was simulated by introducing a death rate of HSC L and MPP L proportional to their proliferation rates, with the HSC L proliferation rate lower than that of normal HSC (Jørgensen et al., 2006)&quot; Several researchers in the field held the strong opinion that TKI do not affect the CML stem cell population in humans (Corbin et al., cited by the authors). Also, the work of Reynaud (cited by the authors) discusses this issue. Please provide a more detailed discussion of the assumption that TKI kills leukemic stem cells.</p><p>– Along the lines of point (2) above: &quot;The model further suggests that a key predictor of refractory response to TKI treatment is an increased probability of self-renewal of normal hematopoietic stem cells.&quot; and related statements: Please rephrase the statements more carefully pointing out the meaning of the parameter p_{0,max} and the model assumptions underlying this conclusion.</p><p>– Along the lines of point (2) above: To support the conclusion that normal and not leukemic stem cell self-renewal matters for TKI response, please consider analyzing a version of the model allowing for different p_{0,max} values for HSC and HSCL. In such a model: What is the predictor of poor TKI response, the p_{0,max} for HSC or the p_{0,max} for HSCL?</p><p>– &quot;This is consistent with clinical data that suggest that CML patients with pre-existing mutations in genes such as TET2 and ASXL1, which are known to increase stem cell self-renewal (Steensma, 2018), tend to have inferior outcomes under TKI therapy (Kim et al., 2017; Marum et al., 2017).&quot; In my opinion, the provided references argue for the concept that a simultaneous increase of self-renewal in both leukemic and normal stem cells leads to a low TKI efficacy. The CHIP mutations analyzed in the cited studies most probably affect normal AND leukemic stem cells. Marum et al. study germ-line mutations that naturally affect normal and leukemic cells at the same time.</p><p>– &quot;Although our data were derived from mice, we hypothesize that similar cell-cell</p><p>signaling occurs in humans.&quot; This hypothesis should be discussed in more detail. What are the potential differences between mice and humans that could lead to problems when applying the proposed model to patients?</p><p>– &quot;only those with sufficiently large feedforward gains on the MPP division rate (γ 5 &gt;0.01)&quot; Please justify the cutoff of 0.01, how sensitive are the presented results with respect to this choice?</p><p>– &quot;We used one eligible parameter set (see Supplemental Tables S4, S5), which is capable of characterizing the normal state of our simplified model of the hematopoietic system.&quot; Do other parameter sets lead to comparable results?</p><p>B) Several passages of the main text are difficult to follow since important arguments have been moved to the Methods Section at the very end or to the Supplement. Some conclusions merit a more detailed explanation. E.g.</p><p>– &quot;Taking all these results into consideration, we arrive at the feedback-feedforward model shown in Figure 2F.&quot; This statement should be explained in more detail in the main text. Have the authors performed a systematic search of the literature to search for evidence of such mechanisms, can they name potential factors mediating them?</p><p>– &quot;These time points and the number of mice analyzed at each time point were informed by a Bayesian hierarchical framework for optimal experimental design of mathematical models of hematopoiesis (Lomeli et al., 2021)&quot;</p><p>Please provide details.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Very nicely done work and I appreciate the efforts to validate the model and parameter estimates using sophisticated computational techniques as well as animal data.</p><p>A well-written manuscript and the right amount of detail.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>I commend the authors on a well-written manuscript with important results and clear methodology.</p><p>Here are some recommendations which I hope may improve the manuscript. I will preface these recommendations by noting that I have limited experience in a laboratory setting and as such do not have the expertise required to make any comments about the experimental component of this work.</p><p>– The authors could provide a brief justification for a grid search as the mechanism for identifying biologically relevant parameters.</p><p>– In modelling CML development, there is an assumption that the only difference between normal and leukemic cell lineages is the feedback strength for leukemic HSC self-renewal. Could the validity of this assumption be explored, perhaps via supporting evidence in the literature, or through briefly considering the sensitivity of the model predictions to this assumption?</p><p>– In Figure 1, concerning the process of identifying candidate model classes, I am not sure whether it is not present or simply hard to make out in the figure, but it appears to me that the downregulation of q_1 by TD_m marked in blue in Figure 1C is not a possible a factor in any of the four candidate model classes identified through design space analysis (Figure 1B). This is in contrast to the bottom left model of Figure 1B, where the downregulation of p_0 by p (also marked with blue in Figure 1C) is visible as a possibility.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84149.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Account for intrinsic differences between leukemic and normal cells. This aspect of the manuscript is poorly justified and weakens the study.</p></disp-quote><p>We have now performed a more thorough investigation of the leukemic parameters and their effect on CML hematopoiesis and response to TKI therapy. We describe the results below in our detailed responses to the Reviewers. We have also modified the paper to reflect this investigation in both the main manuscript (see modifications in the Results, Discussion and Methods sections) and in Appendix 1, where we introduce new sections 9-11, describing the effect of the leukemic parameters on the results (see revised Figures 4C,D and Figure 7B in the main manuscript, Figure 4—figure supplement 6, Figure 6—figure supplements 2-4, Figure 7—figure supplement 2, Figure 8—figure supplement 2, and Appendix 1–figures 11-17).</p><p>Our results can be summarized as follows. We found that only the leukemic cell parameters for the leukemic stem cells (HSC<sup>L</sup>)—the maximal HSC<sup>L</sup> self-renewal fraction <inline-formula><mml:math id="sa2m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, the feedback gain <inline-formula><mml:math id="sa2m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> on the HSC<sup>L</sup> self-renewal fraction , and the TKI-induced HSC<sup>L</sup> death rate <inline-formula><mml:math id="sa2m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>TK</mml:mtext><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>HSCL</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>—have the potential to significantly influence the results. The results are insensitive to changes in the other leukemic cell parameters (see Appendix 1–table 3 for a list of the parameters, Appendix 1–table 3 for the parameters used in Figures 4-7, Appendix 1 Sec. 9 for sensitivity studies of the CML parameters, Figure 6—figure supplements 2-4, and Appendix 1–figure 11). A careful investigation indicates that these leukemic stem cell parameters influence the fitness of the leukemic cells and this can also be used to predict outcomes of CML hematopoeisis and TKI therapy. Nevertheless we find that for sufficiently fit leukemic cells, which we define more precisely and estimate below (see Figure 4, Figure 7—figure supplement 2, Figure 7B and Appendix 1-figure 14 and the associated text), the main conclusions of the paper still hold. In particular, the maximum probability of self-renewal of the normal hematopoetic cells is a key predictor of refactory response to TKI treatment, the new clinical prognostic criterion is still predictive of outcomes, and differentiation therapy can significantly improve treatment outcomes.</p><p>The biological reason for this is as follows. If the CML stem cells are not sufficiently fit relative to the normal stem cells, these <italic>BCR-ABL1</italic>-expressing stem cells may not be able to produce clinical disease (e.g., come to predominate in the bone marrow and blood). Further, even if the CML stem cells are fit enough to drive the development of leukemia, since TKI therapy decreases their effective fitness, an even higher level of fitness of the CML stem cells is required for the disease to be refractory to therapy. Otherwise, the CML will always respond to therapy. See Appendix 1-figure 11, Figure 4 and Figure 7—figure supplement 2. On the other hand, if the CML cells are sufficiently fit relative to the normal stem cells, then increasing the self-renewal fraction of the normal stem cells has the effect of also increasing the fitness of the CML stem cells. Thus, we find that the self-renewal fraction of the normal stem cells is still predictive of outcomes to TKI therapy.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>A) Several assumptions and hypotheses require a more detailed justification or a more careful discussion, e.g.,</p><p>1. &quot;For simplicity, we assumed the only difference between the two lineages is a decrease in the feedback strength for leukemic HSC (HSC L ; S L ), as indicated by p 0L in the schematic in Figure 4A.&quot; This choice requires a more detailed justification. Why are potential differences in other parameters not considered?</p></disp-quote><p>We thank the reviewer for making this point. We have now performed a more thorough investigation of the leukemic parameters and their effect on CML hematopoiesis and response to TKI therapy. We have carefully investigated the effect of changes in the other leukemic cell parameters on the results. We describe these in detail below. We have incorporated these results into the main text, supplemental figures, and Appendix 1.</p><p>a). Only the leukemic stem cell (HSC<sup>L</sup>) parameters are found to have a significant impact on the results. All other leukemic cell parameters have a negligible effect. To illustrate this, we present a sensitivity analysis of the simulation in Figure 6A (early time) where we perturbed each of the leukemic parameters within 10% of the values used in that figure. However, we constrained the maximal HSC<sup>L</sup> self-renewal fraction <inline-formula><mml:math id="sa2m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> to be less than or equal to <inline-formula><mml:math id="sa2m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, the maximal self-renewal fraction of the normal stem cells (HSC). Although leukemic stem cells predominate the BM in most patients diagnosed with CML (<italic>Thielen et al., 2016</italic>), there is little evidence that <inline-formula><mml:math id="sa2m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> could be larger than <inline-formula><mml:math id="sa2m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. On the contrary, in vitro and in vivo studies suggest the opposite. For example, CML long-term culture initiating cells (LTC-IC; thought to be biologically similar to stem cells) decrease significantly in in vitro cultures while the number of normal LTC-IC is unchanged, consistent with a relative decrease in self-renewal probability of the CML cells (<italic>Udomsakdi et al., 1992</italic>). in vivo evidence for a lower intrinsic self-renewal comes from studies that attempted to engraft NOD-SCID mice with human CML bone marrow (BM). These mice can be efficiently engrafted with normal human BM, and also engraft with human AML samples, which leads to AML-like disease, morbidity and death. By contrast, attempts to engraft NOD-SCID mice with CML BM samples led to preferential engraftment by normal HSC. Although PH<sup>+</sup> cells did engraft, engraftment was highly variable and none of the mice developed a CML-like syndrome (<italic>Wang et al., 1998</italic>). We have revised the text in section “Extension of the hematopoiesis model to CML” to include this discussion and created a new section Appendix 1 Sec. 9 to describe these results.</p><p>The results for the HSC<sup>L</sup> parameters—the maximal self-renewal fraction <inline-formula><mml:math id="sa2m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, the feedback gain <inline-formula><mml:math id="sa2m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, and TKI-induced HSC<sup>L</sup> death rate <inline-formula><mml:math id="sa2m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>TK</mml:mtext><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>HSCL</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> -- are shown in Figure 6—figure supplement 2. To illustrate the insensitivity of the results to the other parameters, we present results for the maximal self-renewal fraction of the leukemic multipotent progenitor cells (MPP<sup>L</sup>) <inline-formula><mml:math id="sa2m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> in Figure 6—figure supplement 2. The effect of 10% variations in all of the leukemic cell parameters are shown in the revised Figure 6—figure supplement 2-4 and details in Appendix 1 Sec. 9. These results are characteristic of even larger changes in the base parameters. In Figure 6—figure supplement 2, the stem and progenitor cell numbers are in the first column, the terminally differentiated cells are in the second and the third column shows the simulated molecular responses to TKI treatment. The shaded regions denote the range of the dynamics while the while the curves denote the original dynamics of the base case.</p><p>As seen in Figure 6—figure supplement 2, perturbations in <inline-formula><mml:math id="sa2m12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> have the largest influence on the results, although in this case the leukemic stem and progenitor cells are decreased and the system responds better to therapy because only values of <inline-formula><mml:math id="sa2m13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> that are less than or equal to <inline-formula><mml:math id="sa2m14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are considered. When <inline-formula><mml:math id="sa2m15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="sa2m16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>TK</mml:mtext><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>HSCL</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are perturbed, the variation is smaller but the leukemic cell populations can increase or decrease and the treatment outcomes can be improved or worsened.</p><p>As indicated by the very narrow shaded region in Figure 6—figure supplement 2, the results are insensitive to perturbations to <inline-formula><mml:math id="sa2m17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>b). In order for CML hematopoiesis to dominate the system and cause therapy to fail, the CML stem cells should have <inline-formula><mml:math id="sa2m18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> sufficiently close to <inline-formula><mml:math id="sa2m19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> should be sufficiently small. We considered the influence of a wider range of leukemic stem cell parameters and normal stem cell parameters and investigate the fitness of the leukemic stem cells, relative to the normal stem cells, and the response of the system to therapy, focusing on the effects of <inline-formula><mml:math id="sa2m21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>. The results are presented in Appendix 1-figure 11. We have also placed Appendix 1-figure 11(C) in the main text as a new Figure 4(C) and appropriately modified the text in section “Extension of the hematopoiesis model to CML” to describe the new figure.</p><p>The heat maps in Appendix 1-figure 11(A,C) show the outcomes after CML stem cells are introduced and how the system responds to TKI therapy (B,D) as functions of the ratios <inline-formula><mml:math id="sa2m23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Panels A and B show results where all the other parameters correspond to those used in the base case from Figure 6—figure supplement 2. We observe that CML cells predominate hematopoiesis when <inline-formula><mml:math id="sa2m26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is close to 1 (dark regions in A). Here, “predominate” is defined as greater than 50% of the terminal cells being leukemic. As the ratio <inline-formula><mml:math id="sa2m28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> decreases from 1, takeover by CML cells requires smaller feedback gains <inline-formula><mml:math id="sa2m30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> to compensate. Further, there are threshold values of the parameters required for takeover. Namely, the system is dominated by normal cells (CML cells do not take over) when <inline-formula><mml:math id="sa2m31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is sufficiently large or when <inline-formula><mml:math id="sa2m33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is sufficiently small.</p><p>In Appendix 1-figure 11C-D we consider the behavior of the system when all 478 parameter sets are considered. In panel C, the heat map shows the proportion of the cases in which the system is dominated by normal cells after CML is introduced. The results are similar to that obtained for the base case. In order for the CML cells to take over a large proportion of the cases, the ratio <inline-formula><mml:math id="sa2m34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> should be close to 1 and if this ratio decreased, takeover by CML cells requires a smaller relative feedback gain ratio <inline-formula><mml:math id="sa2m36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> (i.e., a smaller effect of negative feedback on leukemic stem cells relative to normal stem cells) to compensate. Since experimental evidence (clinical and from mouse models) suggests that CML cells generally dominate the hematopoietic system, this places biologically-relevant constraints on the values of <inline-formula><mml:math id="sa2m37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>. (see our response to Reviewer 1 point 2 for estimates).</p><p>In panel D, the heat map shows the proportion of cases in which the system achieves MR3 under TKI therapy within 50 months (successful therapy). In the range of the biologically-relevant self-renewal ratios and feedback strengths, we observe that a proportion of the cases do not achieve MR3 after TKI treatment (darker regions). The proportion of unsuccessful treatments increases when the ratio <inline-formula><mml:math id="sa2m39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> increases and/or <inline-formula><mml:math id="sa2m41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> decreases. The region of unsuccessful TKI treatments is a subset of the takeover region because TKI-induced cell death decreases the fitness of HSC<sup>L</sup>, and thus to survive treatment, the HSC<sup>L</sup> must be fitter than would be required to dominate hematopoiesis in the absence of treatment.</p><p>c). When there is a significant proportion of cases in which MR3 is not achieved, the self-renewal fraction of the normal stem cells <inline-formula><mml:math id="sa2m42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> still predicts refractory response to TKI treatment. This is illustrated in Appendix 1-figure 12 using the combinations (A) <inline-formula><mml:math id="sa2m43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> where in 33% of the cases the treatment is unsuccessful; (B) <inline-formula><mml:math id="sa2m46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> where in 20% of the cases the treatment is unsuccessful; (C) <inline-formula><mml:math id="sa2m49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> where 33% of treatments are unsuccessful and (D) <inline-formula><mml:math id="sa2m52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> where 39% of treatments are unsuccessful (note that D is the original parameter set shown in the manuscript).</p><p>Summarizing, the only parameters that have a significant effect on CML hematopoiesis and response to TKI treatment are <inline-formula><mml:math id="sa2m55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="sa2m57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="sa2m58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>TK</mml:mtext><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>HSCL</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Further, in order for CML to dominate the hematopoietic system and be refractory to treatment, <inline-formula><mml:math id="sa2m59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> should be sufficiently close to 1 and <inline-formula><mml:math id="sa2m61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> should be sufficiently small. The value of <inline-formula><mml:math id="sa2m62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>TK</mml:mtext><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>HSCL</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> determines the level of potency at which therapy will fail to achieve MR3. For choices of leukemic stem cell parameters for which there is a significant proportion of non-responders, <inline-formula><mml:math id="sa2m63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> still predicts refractory response to TKI treatment as presented in the original manuscript.</p><disp-quote content-type="editor-comment"><p>2. &quot;TKI treatment was initiated at three different times to achieve varying leukemic stem cell load (6, 18, and 36 months) and was simulated by introducing a death rate of HSC L and MPP L proportional to their proliferation rates, with the HSC L proliferation rate lower than that of normal HSC (Jørgensen et al., 2006)&quot; Several researchers in the field held the strong opinion that TKI do not affect the CML stem cell population in humans (Corbin et al., cited by the authors). Also, the work of Reynaud (cited by the authors) discusses this issue. Please provide a more detailed discussion of the assumption that TKI kills leukemic stem cells.</p></disp-quote><p>We recognize that several publications have concluded, based on in vitro studies, that CML stem cells are refractory to TKI killing. Originally, Graham et al. (Blood 2002; 99:319-325), which we also cite, demonstrated that a quiescent CD34+CD38– CML progenitor population was resistant to imatinib in vitro. Subsequently, Corbin et al. showed that primitive CML cells were resistant to short-term (72h) TKI treatment despite substantial inhibition of BCR-ABL1 kinase activity. Reynaud et al. cited Corbin as a source for the statement that CML stem cells are TKI-resistant but did not carry out any experiments directly addressing this. However, clinical studies argue that long-term TKI treatment can decrement the CML stem cell population, at least in some patients. The only consistent factor that predicts whether a patient can remain in deep molecular remission (<italic>BCR-ABL1</italic> transcripts undetectable) following TKI withdrawal is the length of time spent in deep remission while on TKI therapy (<italic>Etienne et al., 2017</italic>).; Chen et al., Front Oncol 2019;9:372, suggesting that TKI treatment can gradually decrease CML stem cell frequency or function over time. This hypothesis is further supported by mathematical modeling of patient <italic>BCR-ABL1</italic> transcript data (Tang et al., Blood 2011; 118:1622-1631).</p><p>This remains an unsettled question in the CML field, but we have added a brief mention of these studies to the text in section “Leukemic stem cell load influences TKI therapy outcomes.”</p><disp-quote content-type="editor-comment"><p>3. Along the lines of point (2) above: &quot;The model further suggests that a key predictor of refractory response to TKI treatment is an increased probability of self-renewal of normal hematopoietic stem cells.&quot; and related statements: Please rephrase the statements more carefully pointing out the meaning of the parameter p_{0,max} and the model assumptions underlying this conclusion.</p></disp-quote><p>The reviewer raises an excellent point. The reviewer is correct that it is the overall fitness of the leukemic stem cells relative to that of the normal cells that determines whether CML hematopoiesis will predominate and whether TKI treatment will succeed or fail. This is shown Fig 4 where the relative fitness of the CML cells is measured by the ratios of characteristic effective values of the HSC<sup>L</sup> and HSC self-renewal fractions: <inline-formula><mml:math id="sa2m64"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Here, all 478 parameter sets representing the states of the normal system are considered and the leukemic parameters <inline-formula><mml:math id="sa2m66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m67"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m68"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> are varied from 0.6-1.0 and 0.1-0.6, respectively. The characteristic effective self-renewal fractions for leukemic and normal cells are defined as <inline-formula><mml:math id="sa2m69"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m70"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mover><mml:mi>N</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="sa2m71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mover><mml:mi>N</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>, a characteristic value of the size of the MPP population based on MPP steady state values (<italic>Manesso et al., 2013</italic>). The larger the relative fitness, the more likely that leukemic hematopoiesis will predominate the system Figure 4(D) and that the system will be refractory to TKI treatment Figure 7—figure supplement 2.</p><p>We have added accompanying text in section “Extension of the hematpoiesis model to CML”. Further analysis of the leukemic parameter combinations for CML hematopoiesis and under treatment has been added in Appendix 1 Secs. 9 and 10 in addition to Figure 4—figure supplement 6.</p><p>However, we have shown in Appendix 1-figure 12, using 3 examples where the leukemic parameters are varied and there is a significant proportion of non-responders (e.g., systems that do not achieve MR3), the normal stem cell self-renewal fraction <inline-formula><mml:math id="sa2m72"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> does predict refractory response to TKI treatment.</p><p>We next considered all the combinations of <inline-formula><mml:math id="sa2m73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m74"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m75"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> described above for each of the 478 data sets and plotted the outcomes of TKI therapy as a function of <inline-formula><mml:math id="sa2m76"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> in Appendix 1-figure 14 using blue and orange colors to denote responders and non-responders, respectively. We observe that when the fitness of the HSC<sup>L</sup> (as defined by <inline-formula><mml:math id="sa2m78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>) is sufficiently low (e.g., <inline-formula><mml:math id="sa2m79"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>0.65</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>), all the systems respond to therapy. When the HSC<sup>L</sup> increase in fitness the number of non-responders increases but non-responders are only observed when <inline-formula><mml:math id="sa2m80"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is above a critical threshold, which depends on <inline-formula><mml:math id="sa2m81"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> through <inline-formula><mml:math id="sa2m82"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>. Note that the fitness of the HSC<sup>L</sup> can be increased either by increasing <inline-formula><mml:math id="sa2m83"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> or decreasing <inline-formula><mml:math id="sa2m84"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> or both.</p><p>We expect the HSC<sup>L</sup> to be sufficiently fit for the following reasons. First, there is a significant proportion of patients (10-15%) who do not respond adequately to initial TKI treatment (Hanfstein et al., 2012; Marin et al., 2012) and BCR-ABL1 mutations are generally not present in this group of patients (Zhang et al., 2009; Pietarinen et al., 2016). From Appendix 1-figure 11(C)-(D) this suggests that the maximal self-renewal fraction <inline-formula><mml:math id="sa2m85"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> of the CML stem cells should be close to that of the normal stem cells <inline-formula><mml:math id="sa2m86"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Second, several studies suggest that CML stem cells are at least 5-10 times less sensitive to MIP-1a/CCL3-regulated self-renewal inhibition (Eaves et al., 1993; Chasty et al., 1995; Wark et al., 1998; Durig et al., 1999). That is, we expect <inline-formula><mml:math id="sa2m87"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> should be at less than 0.2 or 0.1. Our results in Appendix 1-figure 12(D) suggest that to be consistent with all this data, we should expect <inline-formula><mml:math id="sa2m88"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m89"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. As shown in Appendix 1-figure 12(A) and (C) the combination of <inline-formula><mml:math id="sa2m90"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m91"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m92"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> can be qualitatively reconstructed with the values used in the main text. As a result of the expected values, we expect <inline-formula><mml:math id="sa2m93"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> should be greater than 0.67, corresponding to <inline-formula><mml:math id="sa2m94"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m95"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m96"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> , or greater than 0.73, corresponding to <inline-formula><mml:math id="sa2m97"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>/<inline-formula><mml:math id="sa2m98"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m99"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mtext> </mml:mtext></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. Therefore, taking <inline-formula><mml:math id="sa2m100"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> as an example, we can replot the results in Appendix 1-figure 14 using a heat map, as seen in Figure 7(B), which shows the proportion of responders and non-responders as a joint distribution of the parameters <inline-formula><mml:math id="sa2m101"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m102"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. Summing the results over <inline-formula><mml:math id="sa2m103"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> results in the marginal distribution of <inline-formula><mml:math id="sa2m104"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> shown at the top of the plot, which indicates that the fitness parameter <inline-formula><mml:math id="sa2m105"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> does not distinguish between responders and non-responders. However, summing the results over <inline-formula><mml:math id="sa2m106"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> gives the marginal distribution of <inline-formula><mml:math id="sa2m107"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> on the right hand side of the plot and confirms that <inline-formula><mml:math id="sa2m108"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> can be used to predict refractory response for a wide range of HSC<sup>L</sup> parameters, as suggested by Appendix 1-figure 12. The biological reason for this is as follows. If the CML cells are sufficiently fit relative to the normal stem cells, then increasing the self-renewal fraction of the normal stem cells has the effect of also increasing the fitness of the CML stem cells, thereby making refractory outcomes to treatment more likely.</p><p>These figures, and associated text, have been incorporated in Appendix 1 Sec. 10 in the (see Appendix 1–figures 13, 15-16) where we also present heatmaps corresponding to different minimum fitness thresholds of <inline-formula><mml:math id="sa2m109"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>. As seen in Appendix 1, when the minimum threshold is decreased, the trend remains: larger <inline-formula><mml:math id="sa2m110"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> correlates with non-response although the correlation becomes weaker because the fitness of the HSC<sup>L</sup> decreases. For example, as seen from Appendix 1-figure 14 for <inline-formula><mml:math id="sa2m111"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msubsup><mml:mrow><mml:mover><mml:mi>p</mml:mi><mml:mo accent="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> &lt; 0.65, all the systems respond to TKI therapy regardless of the value of <inline-formula><mml:math id="sa2m112"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>We also modified the “Discussion” section summarizing our findings for the leukemic parameters, the efficacy of maximum stem cell self-renewal as a predictor, and that our prognostic criterion and theoretical combination therapy are robust to modifications of the leukemic stem cell parameters within the fitness thresholds identified above.</p><disp-quote content-type="editor-comment"><p>4. Along the lines of point (2) above: To support the conclusion that normal and not leukemic stem cell self-renewal matters for TKI response, please consider analyzing a version of the model allowing for different p_{0,max} values for HSC and HSCL. In such a model: What is the predictor of poor TKI response, the p_{0,max} for HSC or the p_{0,max} for HSCL?</p></disp-quote><p>We agree with the reviewer that it is important to distinguish whether the self-renewal fractions of the HSC<sup>L</sup> and HSC matter for TKI response. While the reviewer is correct that the overall fitness of the HSC<sup>L</sup> relative to the normal HSC is key for predicting refractory response, when the HSCL are sufficiently fit (see our response to Reviewer 1 point 2), the maximal self-renewal probability of normal stem cells p_[0,max] is still predictive of refractory response to TKI treatment. Please see our response to Reviewer 1 point 2 for a detailed explanation.</p><disp-quote content-type="editor-comment"><p>5. &quot;This is consistent with clinical data that suggest that CML patients with pre-existing mutations in genes such as TET2 and ASXL1, which are known to increase stem cell self-renewal (Steensma, 2018), tend to have inferior outcomes under TKI therapy (Kim et al., 2017; Marum et al., 2017).&quot; In my opinion, the provided references argue for the concept that a simultaneous increase of self-renewal in both leukemic and normal stem cells leads to a low TKI efficacy. The CHIP mutations analyzed in the cited studies most probably affect normal AND leukemic stem cells. Marum et al. study germ-line mutations that naturally affect normal and leukemic cells at the same time.</p></disp-quote><p>We agree with the reviewer, which is why we used the term “pre-existing mutations”. In the study by Kim et al., some of the patients with suboptimal response to TKI therapy had mutations in <italic>TET2</italic> or <italic>ASXL1</italic> that were present in both T cells and myeloid cells at diagnosis, indeed suggesting the existence of a pre-leukemic mutant clone, such as occurs in CHIP. Other refractory patients had these mutations only in the myeloid cells after TKI therapy (average treatment duration 12 months), suggesting they were selected for during TKI treatment. In our model, the self-renewal frequencies of normal and leukemic stem cells, while not required to be identical (see response to previous comments), are linked, so that the presence of a <italic>TET2</italic> or <italic>ASXL1</italic> mutation in both normal and leukemic stem cells that led to a proportional increase in self-renewal in both populations would tend to cause resistance to TKI therapy, provided that the HSC<sup>L</sup> are sufficiently fit in the presence of the mutations, which we would expect. We have reworded this section in the Results and Discussion to better clarify the discussion of this issue.</p><disp-quote content-type="editor-comment"><p>6. &quot;Although our data were derived from mice, we hypothesize that similar cell-cell</p><p>signaling occurs in humans.&quot; This hypothesis should be discussed in more detail. What are the potential differences between mice and humans that could lead to problems when applying the proposed model to patients?</p></disp-quote><p>While there are some documented differences between mouse and human hematopoiesis (reviewed in (<italic>Parekh and Crooks, 2013</italic>)), many of the proposed cell-cell signaling pathways have already been validated in both mice and humans. For example, CCL3 was shown to selectively inhibit normal HSC over CML HSC (<italic>Eaves et al., 1993</italic>), and this has been reproduced in a mouse CML model (<italic>Baba et al., 2013</italic>), while IL-6 has been shown to regulate lymphoid differentiation in both mice and humans. It remains important, however, to validate results from mice in human studies, whenever possible. We have added this information to the Discussion.</p><disp-quote content-type="editor-comment"><p>7. &quot;only those with sufficiently large feedforward gains on the MPP division rate (γ 5 &gt;0.01)&quot; Please justify the cutoff of 0.01, how sensitive are the presented results with respect to this choice?</p></disp-quote><p>This cutoff was selected to further explore the novel feedforward loop we identified; however, the other parameter sets still yielded consistent results as they obeyed the same criteria. The corresponding sentence is updated to, “We further restricted the candidate parameter sets by considering only those with sufficiently large feedforward gains on the MPP division rate (γ<sub>5</sub>&gt;0.01) in order to focus on the novel feedforward dynamics.” We added this comment in the section “Parameter estimation for feedback-feedforward model of hematopoiesis”.</p><disp-quote content-type="editor-comment"><p>8. &quot;We used one eligible parameter set (see Supplemental Tables S4, S5), which is capable of characterizing the normal state of our simplified model of the hematopoietic system.&quot; Do other parameter sets lead to comparable results?</p></disp-quote><p>The answer is yes. The other parameter sets were selected based on qualitative and quantitative similarities, so for normal dynamics they are very comparable. Under the development of CML all systems exhibit the takeover by leukemic cells but differ in the timescale that the takeover occurs. This is shown in Figure 7A for one choice of leukemic stem cell parameters and in Appendix 1–figure 13 for several additional choices of leukemic stem cell parameters. The text in section “Leukemic stem cell load influences TKI therapy outcomes” has been updated and a new section Appendix 1 Sec. 10 has been added.</p><disp-quote content-type="editor-comment"><p>B) Several passages of the main text are difficult to follow since important arguments have been moved to the Methods Section at the very end or to the Supplement. Some conclusions merit a more detailed explanation. E.g.</p><p>1. &quot;Taking all these results into consideration, we arrive at the feedback-feedforward model shown in Figure 2F.&quot; This statement should be explained in more detail in the main text. Have the authors performed a systematic search of the literature to search for evidence of such mechanisms, can they name potential factors mediating them?</p></disp-quote><p>We thank the reviewer for this comment. In the section “Model of Normal Hematopoiesis”, we discussed IL-6 and CCL3 as candidate factors mediating negative feedback of differentiated myeloid cells on lymphoid differentiation and of myeloid progenitors on stem cell self-renewal, respectively. In the discussion, we now also mention TGF-β as a candidate factor mediating negative feedback of HSC onto their own division rate and that of the MPPs (<italic>Naka and Hirao, 2017</italic>), and IL-6 as a candidate factor inhibiting MPP self-renewal (<italic>Zhao et al., 2014</italic>).</p><disp-quote content-type="editor-comment"><p>2. &quot;These time points and the number of mice analyzed at each time point were informed by a Bayesian hierarchical framework for optimal experimental design of mathematical models of hematopoiesis (Lomeli et al., 2021)&quot;</p><p>Please provide details.</p></disp-quote><p>We agree with the Reviewer that more detail would be helpful. We have modified the text in the section “Model of normal hematopoiesis” to read: These time points and the number of mice analyzed at each time point were informed by a Bayesian hierarchical framework for optimal experimental design of mathematical models of hematopoiesis. In particular, the Bayesian framework suggests combining early time points (soon after radiation was applied) with late time points because the early time points provide more information about division rates, while the late time points provide more information about the feedback parameters.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>I commend the authors on a well-written manuscript with important results and clear methodology.</p><p>Here are some recommendations which I hope may improve the manuscript. I will preface these recommendations by noting that I have limited experience in a laboratory setting and as such do not have the expertise required to make any comments about the experimental component of this work.</p><p>1. The authors could provide a brief justification for a grid search as the mechanism for identifying biologically relevant parameters.</p></disp-quote><p>While we could have used other approaches (<italic>Read et al., 2018</italic>), such as the Latin hypercube algorithm, to sample our multidimensional parameter space we chose to perform a grid search because of the ease of implementation and the fact that our goal was not to exhaustively search the full parameter space but rather obtain a set of biologically relevant parameter values consistent with normal homeostasis. This enabled us to create a cohort of virtual patients to investigate the variable dynamics of CML hematopoiesis and response to TKI treatment. We have updated the text in the Discussion to make this point.</p><disp-quote content-type="editor-comment"><p>2. In modelling CML development, there is an assumption that the only difference between normal and leukemic cell lineages is the feedback strength for leukemic HSC self-renewal. Could the validity of this assumption be explored, perhaps via supporting evidence in the literature, or through briefly considering the sensitivity of the model predictions to this assumption?</p></disp-quote><p>We agree with the Reviewer that this requires further investigation. Please see our responses to Reviewer 1 point (1) and (3), which address this point.</p><disp-quote content-type="editor-comment"><p>3. In Figure 1, concerning the process of identifying candidate model classes, I am not sure whether it is not present or simply hard to make out in the figure, but it appears to me that the downregulation of q_1 by TD_m marked in blue in Figure 1C is not a possible a factor in any of the four candidate model classes identified through design space analysis (Figure 1B). This is in contrast to the bottom left model of Figure 1B, where the downregulation of p_0 by p (also marked with blue in Figure 1C) is visible as a possibility.</p></disp-quote><p>We are sorry for the confusion. While this possibility is shown in both 1A and 1B as the dotted line from TD<sub>m</sub> to q<sub>1</sub> (see Figure 1A), but it is more difficult to see in Figure 1B. We have modified the figure to make this potential regulation more apparent.</p><p>References</p><p>Agathocleous M, Meacham CE, Burgess RJ, Piskounova E, Zhao Z, Crane GM, Cowin BL, Bruner E, Murphy MM, Chen W, Spangrude GJ, Hu Z, DeBerardinis RJ, Morrison SJ. 2017. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. <italic>Nature</italic> 549(7673):476-481. doi: 10.1038/nature23876, PMID: PMC5910063</p><p>Baba T, Naka K, Morishita S, Komatsu N, Hirao A, Mukaida N. 2013. MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia. <italic>J. Exp. Med.</italic> 210(12):2661-2673. doi: 10.1084/jem.20130112, PMID: PMC3832924</p><p>Chasty RC, Lucas GS, Owen-Lynch PJ, Pierce A, Whetton AD. 1995. Macrophage inflammatory protein-1 α receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia. <italic>Blood</italic> 86(11):4270-4277. doi: PMID:</p><p>Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M, Grillo I, Bakogianni S, Ndiaye-Lobry D, Martín MT, Guillamot M, Banh RS, Xu M, Figueroa ME, Dickins RA, Abdel-Wahab O, Park CY, Tsirigos A, Neel BG, Aifantis I. 2017. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. <italic>Cell</italic> 170(6):1079-1095.e1020. doi: 10.1016/j.cell.2017.07.032, PMID: PMC5755977</p><p>Durig J, Testa NG, Lord BI, Kasper C, Chang J, Telford N, Dexter TM, Heyworth CM. 1999. Characterisation of the differential response of normal and CML haemopoietic progenitor cells to macrophage inflammatory protein-1alpha. <italic>Leukemia</italic> 13(12):2012-2022. doi: 10.1038/sj.leu.2401610, PMID:</p><p>Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. 1993. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 α, an inhibitor of primitive normal hematopoietic cells. <italic>Proc. Nat.l Acad. Sci. USA</italic> 90(24):12015-12019. doi: PMID: Pmc48116</p><p>Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. 1993. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 α, an inhibitor of primitive normal hematopoietic cells. <italic>Proc Natl Acad Sci U S A</italic> 90(24):12015-12019. doi: 10.1073/pnas.90.24.12015, PMID: PMC48116</p><p>Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carre M, Guilhot F, Rousselot P, Mahon FX. 2017. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. <italic>J Clin Oncol</italic> 35(3):298-305. doi: 10.1200/JCO.2016.68.2914, PMID:</p><p>Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A. 2012. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). <italic>Leukemia</italic> 26(9):2096-2102. doi: 10.1038/leu.2012.85, PMID:</p><p>Manesso E, Teles J, Bryder D, Peterson C. 2013. Dynamical modelling of haematopoiesis: an integrated view over the system in homeostasis and under perturbation. <italic>J. R. Soc. Interface</italic> 10(80):20120817. doi: 10.1098/rsif.2012.0817, PMID: Pmc3565732</p><p>Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S. 2012. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. <italic>Blood</italic> 120(2):291-294. doi: 10.1182/blood-2012-01-407486, PMID:</p><p>Naka K, Hirao A. 2017. Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules. <italic>Cold Spring Harb Perspect Biol</italic> 9(9). doi: 10.1101/cshperspect.a027987, PMID: PMC5585852</p><p>Parekh C, Crooks GM. 2013. Critical differences in hematopoiesis and lymphoid development between humans and mice. <italic>J. Clin. Immunol.</italic> 33(4):711-715. doi: 10.1007/s10875-012-9844-3, PMID: PMC3633618</p><p>Pietarinen P, Koskenvesa P, Klievink J, Porkka K, Niemi M, Mustjoki S. 2016. CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism. <italic>Blood</italic> 128(22):a3017. doi: PMID:</p><p>Read MN, Alden K, Timmis J, Andrews PS. 2018. Strategies for calibrating models of biology. <italic>Briefings in Bioinformatics</italic> 21(1):24-35. doi: PMID:</p><p>Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP, Passegue E. 2011. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. <italic>Cancer Cell</italic> 20(5):661-673. doi: 10.1016/j.ccr.2011.10.012, PMID: Pmc3220886</p><p>Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S. 2016. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <italic>Clin. Cancer Res.</italic> 22(16):4030-4038. doi: 10.1158/1078-0432.Ccr-15-2791, PMID:</p><p>Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. 1992. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. <italic>Proc Natl Acad Sci U S A</italic> 89(13):6192-6196. doi: 10.1073/pnas.89.13.6192, PMID: PMC402148</p><p>Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE. 1998. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. <italic>Blood</italic> 91(7):2406-2414. doi: PMID:</p><p>Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD. 1998. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 α. <italic>Oncogene</italic> 16(10):1319-1324. doi: 10.1038/sj.onc.1201914, PMID:</p><p>Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. 2009. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. <italic>J. Clin. Oncol.</italic> 27(22):3642-3649. doi: 10.1200/jco.2008.19.4076, PMID: PMC2799062 are found at the end of this article.</p><p>Zhao JL, Ma C, O'Connell RM, Mehta A, DiLoreto R, Heath JR, Baltimore D. 2014. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. <italic>Cell Stem Cell</italic> 14(4):445-459. doi: 10.1016/j.stem.2014.01.007, PMID: PMC4119790</p></body></sub-article></article>